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2 Abbreviations 





AF  Atrial fibrillation 
A14  Adherence scale 14 
BMQ  Beliefs about medicines questionnaire 
DM  Diabetes mellitus 
DOAC  Direct oral anticoagulants 
DVT   Deep vein thrombosis 
DPPR   Daily patient possession ratio  
EHRA   European heart rhythm association 
HCP   Health care professionals 
HoloTc  Holotranscobalamine  
Hcy   Homocysteine  
INR   International normalized ratio 
i.m.   Intramuscular 
i.v.    Intravenous  
iPACT   International pharmacists for anticoagulation care taskforce  
KODOA  Knowledge of direct oral anticoagulants  
MEMS   Medication event monitoring system 
Met   Metformin 
MMA   Methylmalonic acid  
MMAS   Morisky medication adherence scale  
MPR   Medication possession ratio 
MUR   Medicines use review  
NOAC   Non vitamin K oral anticoagulants 
OAC   Oral anticoagulation therapy  
PE  Pulmonary embolism 
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P-gp  P-glycoprotein 
PPI  Proton pump inhibitors 
POEMS  Polypharmacy electronic monitoring system 
PMC   Polymedication check 
s.c   Subcutaneous 
SDM   Shared decision-making 
SPCs   Swiss summaries of product characteristics   
SF‐12  Short form 12 
S-THOFLA  Test of functional health literacy in adults 
T2DM  Type 2 diabetes  
VB12  Vitamin B12 
VKA   Vitamin K antagonists 
WHO   World Health Organization 
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Adherence is defined as “the extent to which a person's behavior - taking medication, following a 
diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health 
care provider”. Level of adherence to medication varies greatly and is related to treatment, patient 
and /or health care provider. The WHO stated in 2003 that adherence to long-term therapies in 
the general population is around 50% in developed countries. Non-adherence to medication is a 
complex, common healthcare problem and can be distinguished in unintentional and intentional 
non-adherence. It has been shown that poor medication adherence may cause toxicity or lack of 
efficacy, disease progression, lower quality of life, drug resistance, medication waste and hospital 
admission what results in costs of approximately 100 billion a year in the United States. Therefore, 
detection of non-adherence and interventions aiming at improving adherence are critically 
important. Adherence assessment methods can be broken down into direct and indirect methods. 
Each method has advantages and disadvantages. Within this thesis, different adherence 
assessment methods were applied including subjective self-reported measures (questionnaires) 
and objective measures such as electronic monitoring, rates of prescription refills and 
measurement of biomarker levels. 
In general, interventions to improve adherence can be divided into behavioural, technical, 
educational, and multifaceted methods. Behavioural interventions usually provide feedback, 
reminders or rewards to patients. Reduction of regimen complexity and use of fixed-dose regimen 
are examples for technical interventions. Educational interventions include patient education, 
provided to individuals or in group sessions using verbal, audio-visual or written material. 
Effectiveness of multifaceted approaches using combinations of different intervention types has 
been demonstrated in long-term situations. However, current methods of improving medication 
adherence for general chronic diseases are mostly complex and evidence of their effects remains 
low. 
 
Patients have to make important health decisions that affect health outcomes. Furthermore, 
patients can play an important role in protecting their own health and taking appropriate action in 
acute episodes of ill health, as well as managing chronic illness. In particular, the management of 
chronic diseases, such as atrial fibrillation, require a high level of self-care skills that are 
determined by patients’ health literacy. Overall, health literacy can be described as the people’s 
capacity to manage their health. Patient knowledge about medical conditions and treatment 
regimen is an important aspect of health literacy. Patient medication knowledge or shortly named 
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in this thesis “patient knowledge” refers to patient health knowledge related to medications 
including what is being used, why it is being used as well as instructions and precautions about 
certain medication. Lack of knowledge about medication and difficulties in understanding 
medication information may be related to misapprehension of instructions and/or symptoms, 
medication errors, low self-care behavior, poor health outcomes, and frequent visits to the 
emergency department. Therefore, detection of knowledge gaps and educational counselling 
about medication should be integrated in daily practice. Up to now, however, counselling practice 
in general practitioners’ practices and community pharmacies tend to concur on the relative 
poverty of such medication discussions. Therefore, it is not surprising that outpatients lack 
knowledge about their medication.  
For some therapies such as oral anticoagulation therapy (OAC), there is still insufficient evidence 
to draw definitive conclusion regarding the impact of educational interventions on therapeutic 
outcomes in patients, mostly due to the inhomogeneity of the study designs. Thus, educational 
contents need to be prioritized, educational domains should be standardized and validated 
instruments for the assessment of deficit knowledge are needed to demonstrate the impact of 
educational counselling on outcomes in clinical trials. Further, detection of knowledge gaps and 
individualized educational counselling enable patients to develop preferences and take 
appropriate health decisions. 
 
Patient preferences result from unique values (i.e. potential benefits, convenience) and concerns 
(i.e. potential harms, costs) that are formed by patient knowledge, experiences, and reflection. 
Having preference for a treatment mirrors the patients evaluation of these values and concerns in 
comparison with an alternative treatment option. For a given disease, different patients may have 
different preferences. Patients bring their preferences to a clinical encounter that should be 
integrated in decision making whenever they are to serve the patient. It has been shown that 
knowledge about patient preferences for a certain disease might lead to better-informed decisions 
in practice and in health policy. A better understanding of patient preferences is pivotal for shared 
decisions and important for increased adherence and ultimately patient health outcomes. Patient 
preferences in treatment-related decisions should be elicited and taken into account, because 
patients who felt less empowered with regard to treatment decisions reported lower rates of 
adherence. Assessment of patient preferences and Shared Decision Making is particularly 
recommended for situations with two or more equivalent available treatment options and similar 
treatment consequences for a patient’s daily life. The substitution of vitamin B12 (VB12) in deficient 
outpatients is one example where the evidence for equivalent efficacy between oral and 
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intramuscular application offers to patients both treatment opportunities with similar clinical 
outcome.  
  
The goal of this thesis was to assess patient knowledge of anticoagulation and patient preferences 
for VB12 therapy and to develop an educational program on adherence for outpatients with 
rivaroxaban therapy. We approached this goal with four individual projects: 
Project A: 
 Investigation of patient knowledge of OAC in Swiss community pharmacies in an 
observational study.  
 Development and validation of a self-assessment questionnaire for patient knowledge on 
direct oral anticoagulants (DOAC).  
Project B: 
 Assessment of the impact of type 2 diabetes and metformin use on VB12 associated 
biomarkers and their suitability to reflect VB12 supply. 
 Exploration of patient preferences for and biomarker levels after oral and intramuscular 
vitamin B12 substitution. 
 Investigation of patient preferences for oral and parenteral treatment in various diseases 
through literature review. 
Project C: 
 Translation and validation of the 8-item Morisky Medication Adherence Scale in German.  
 Comparison of one subjective with one objective adherence score in a pilot study.  
Project D: 
 Development of a study protocol for a stepwise educational program on adherence for 
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Overview of the projects: 
Project A 
Study A-1 aimed at screening for knowledge gaps about OAC in outpatients. We therefore 
amended the basic Polymedication Check (PMC) with specific open-ended questions on OAC and 
assessed its impact on knowledge in an observational study. Patients treated with vitamin K 
antagonists (VKA) or direct oral anticoagulants (DOACs) received an amended PMC. The study 
demonstrated that the majority of patients had knowledge gaps concerning OAC and that half of 
the patients did not know how to proceed in case of a missed dose. Identification of knowledge 
gaps led pharmacists to provide education spontaneously. Although verbally unstructured, the 
provision of this targeted and tailored education increased patient knowledge about OAC. We 
further found a trend that patients with DOAC therapy were more likely to have knowledge gaps 
compared to patients on VKAs. These observations served as a rationale for further studies on 
knowledge of DOAC, in particular the development and validation of a specific questionnaire to 
self-assess knowledge of DOAC (Study A-2).  
In Study A-2, we followed an evidence-based approach to select relevant items for patient 
knowledge of DOAC. After literature review, completeness of retrieved items were exhaustively 
verified and supplemented with Swiss summaries of Product Characteristics (SPCs), the Update 
EHRA Practical Guide on the use of non-vitamin K antagonist anticoagulants, and the patient 
guide for taking DOAC from the cardiology patient page. Twelve anticoagulation experts across 
different professions participated in the questionnaire development process to ensure content 
validity and selection of relevant items. The developed Knowledge Of Direct Oral Anticoagulants 
(KODOA) test was validated in patients on DOAC and pharmacists. The KODOA-test confirmed 
to be feasible, comprehensive, reliable and valid to self-assess patient knowledge of DOAC. 
Construct validity was supported by significant differences in scores between patients and 
pharmacists. Finally, the KODOA-test was responsive to educational counselling about DOAC 
supporting construct validity. 
Project B 
Several cross sectional studies and case reports have presented an increased frequency of VB12 
deficiency among patients with type 2 diabetes (T2DM). Because VB12 deficiency is a reversible 
cause of demyelinating nervous system disease and bone marrow failure, its early detection is 
important. Literature suggests that clinical biochemistry of VB12 is influenced by diabetes and its 
treatment. Therefore, Study B-1 aimed to assess the impact of T2DM and metformin use on VB12 
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associated biomarkers and their suitability to reflect VB12 supply. Differences of VB12, 
holotranscobalamine (HoloTc), the biologically active fraction %AB12=HoloTc/VB12*100 and 
homocystein (Hcy) were analysed i) among diabetic outpatients with and without metformin use 
and ii) compared to an external non-diabetic reference group with low level of VB12 (<200pmol/L). 
We found that metformin treatment alone did not explain the altered VB12 metabolism as reflected 
by VB12 and HoloTc serum levels in all T2DM patients. Further analysis focused on VB12-
deficient subgroups and included non-diabetic patients. In this sample, a significant difference of 
the %AB12 was observed and confirmed by multiple regression analysis. However, the model 
explained only 9.2% of the variance observed. These results suggest that VB12 metabolism is 
affected by diabetes itself as well as by other factors, which were not included in the model. 
Further, stepwise multiple regression analysis included HoloTc as independent variable to explain 
variance in Hcy levels and not VB12. Thus, HoloTc seems favorable compared to VB12 to predict 
hyperhomocysteinemia caused by VB12 deficiency in T2DM patients. 
Study B-2 was a prospective randomized unblinded parallel group trial. Patients were recruited 
by their general practitioner and randomly assigned to oral or intramuscular (i.m.)VB12 treatment. 
Group O-oral received oral daily 1000µg cyanocobalamine for 28 days and group I-i.m. received 
4 weekly injections of 1000µg hydroxocobalamine. Blood samples were analyzed for VB12, 
HoloTc, Hcy and methylmalonic acid (MMA). Before and after treatment, patients were asked to 
fill in a questionnaire about their preferences. After 28 days of treatment with high-dose VB12 
administered either by oral or i.m. route, median levels of VB12-associated biomarkers were 
normalized in both groups. Contrary to prior studies, we observed an exaggerated response after 
i.m. administration and therefore the hypothesis for non-inferiority of oral in comparison to i.m. 
treatment had to be rejected. Because we used electronic punch cards and monitored an almost 
perfect intake of tablets (99.6% taking adherence), non-adherence was ruled out as a contributor 
to the less pronounced biomarker response. We found that initial rating in favor of either i.m. or 
oral therapy changed over time. However, the majority of patients preferred oral treatment before 
and after the study. The literature review (Study B-3) across different diseases yielded similar 
results: A majority of patients prefer oral treatment. 
In order to investigate patient preferences for oral and parenteral treatment in various diseases, 
we conducted a literature research in the databases PubMed, EMBASE and Web of Science using 
the terms “patient preference” OR “patients’ preference” OR “patient perspective” AND “oral 
treatment” AND “inject*” (Study B-3). Our search was limited to original research articles that have 
been published after 1980, were accessible online and included intravenous, intramuscular or 
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subcutaneous parenteral therapy options. Our search strategy delivered 74 articles of which 62 
were excluded. One article was included by cross-referencing. Eleven out of 13 articles reported 
preference for the oral administration (84.6%). Out of the 13 articles retrieved, five concerned 
cancer therapy, three antibiotic therapies, two vitamin deficiency and three other indications. Oral 
or parenteral therapy was preferred according to the disease. Associated factors for the preferred 
route of administration varied between the studies. Most articles reported convenience as an 
important factor to influence preference, either in favour of the oral or the parenteral therapy. 
Project C 
Study C-1 aimed to translate and validate the 8-item Morisky Medication Adherence Scale 
(MMAS-8) in German against objective and subjective measures of adherence in cardiovascular 
patients with polypharmacy. Validation took place on a convenient sample of ambulatory patients 
on chronic antiplatelet therapy. Objective adherence was obtained from electronically monitored 
multidrug punch cards. Internal consistency was assessed using Cronbach’s alpha coefficient, 
construct validity using exploratory factor analyses and correlations between MMAS-8D and 
related measures. Convergent validity was assessed with a subjective questionnaire about beliefs 
about medicines (BMQ Specific, 2 subscales). A total of 70 patients were included in the study 
(mean score of MMAS-8D was 7.5 (SD 0.8; range 4.5-8)). Moderate internal consistency (alpha = 
0.31) was observed, due to multidimensionality of the scale. Factor analysis yielded four 
components that accounted for 71.7% of the total variance. Convergent validity was supported by 
significant correlations with BMQ Necessity (r= 0.31; p<0.01), BMQ Concerns (r= -0.16, p<0.05) 
and with electronic adherence reports (U-values 44 and 471, p<0.05). Platelet aggregation values 
were within therapeutic range for 80% of the patients. Antiplatelet blood values within therapeutic 
range were associated with a higher MMAS-8D score (U-value 125, p<0.05). 
Study C-2 aimed to assess whether the affirmative answer to the PMC question “Do you 
sometimes forget to take your medication?” coincides with a Medication possession ratio (MPR) 
<90% (non-adherence) in DOAC treated patients. For the pilot study, fifth-year pharmacy students 
recorded one PMC with an anticoagulated patient during internship in community pharmacies. 
Patient’s refills of the past 12 months were used to calculate a MPR if at least two refills were 
available. A total of 25 documented cases were included for analysis, of which all concerned 
patients treated with rivaroxaban. Refills (mean of 2.9±0.8 per patient) were available for a mean 
of 128±62 days. MPR ranged from 50.2 - 182.7%. MPR below 90% was observed in 4 patients 
(16%), out of them two self-reported to sometimes forget to take the DOAC. Two further patients 
reported non-adherence but showed a MPR >90%. Oversupply up to 110% was observed for 7 
3 Summary 
    
14 
 
patients, and excessive oversupply for 6 patients (MPR: 114-183%). Consideration of composite 
adherence measures to get a more detailed picture of adherence and experiences with 
educational counselling about OAC have further been implemented in Project D. 
Project D 
Study D aimed to develop a study proposal to demonstrate the impact of a tailored and stepwise 
educational program to rivaroxaban on adherence. Otherwise than in the previous project on 
knowledge about OAC (Project A), educational counselling was foreseen to be offered in a 
repetitive manner according to patient needs. Additionally, visualizing of intake pattern obtained 
with the electronic monitoring should be employed for providing feedback based on the individual 
patient profile and stressing the need of time adherence, or adapting the treatment plan in 
collaboration with the physician. This study will be executed beyond this thesis.  
The following conclusions could be drawn:  
Project A: Patient knowledge about oral anticoagulation therapy 
 A majority of outpatients show knowledge gaps concerning their therapy with OAC.  
 Specific screening questions allow community pharmacists to detect deficient knowledge 
in short time and to provide spontaneous verbally unstructured education besides the 
detection of deficient knowledge when needed.  
 The newly developed and validated KODOA-test showed good psychometric properties in 
Swiss elderly outpatients taking DOAC. The KODOA-test is a reliable and valid 
questionnaire to assess patient knowledge about DOAC. 
 To our knowledge, the KODOA-test is the first validated questionnaire specific for patients 
taking DOAC and sensitive to change. Therefore, the KODOA-test could be used in clinical 
trials where associations between knowledge of DOAC and adherence or clinical 
outcomes are of interest. 
 Patient knowledge increases after having received educational counseling either provided 
spontaneously and in an unstructured manner with the help of the amended PMC or in a 
structured manner after testing with the KODOA-test. 
 Patients show high acceptance and state to be more confident about how to take their 
anticoagulant agent either after having received educational counselling in an unstructured 
manner with the help of the amended PMC or in a structured manner after testing with the 
KODOA-test. More outpatients could be approached for educational counselling about 
OAC. 
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Project B: Patient preferences and vitamin B12 deficiency 
 The clinical biochemistry of VB12 in T2DM patients with scarce VB12 supply is modified in 
comparison to nondiabetic patients. This results in higher %AB12 due to reduced VB12 
levels. It needs to be clarified whether this effect is due to diabetes itself, metformin 
treatment and/ or a combination of other heath related situations.  
 Assessment of HoloTc seems favorable compared to VB12 to predict 
hyperhomocysteinemia caused by VB12 deficiency in T2DM patients. This may be a direct 
consequence of the modified %AB12 in T2DM patients, which strengthens the 
recommendation to assess VB12 supply in clinical practice by measuring HoloTc.  
 After oral and i.m. substitution with VB12, differences in VB12, HoloTc and Hcy levels 
between groups were higher than expected. Therefore, the hypothesis of non-inferiority of 
oral treatment had to be rejected. Normalization of HoloTc and MMA was reached by all 
patients and normalization of VB12 and Hcy by the majority of patients within group O-oral 
after a one-month treatment. The clinical benefit of exaggerated biomarker response after 
i.m. treatment within a typical primary care population is questionable. Therapeutic 
schemes should be chosen with the consideration of mid-term biomarker effects and 
patient preferences. 
 Initial rating in favor of either i.m. or oral therapy can change over time. The majority of 
patients preferred oral treatment before and after the study, pointing out the need for a 
high dose oral VB12 preparation in Switzerland.  
 
Project C: Adherence assessment methods 
 The German MMAS-8D appears to be a reliable instrument to catch medication adherence 
in cardiovascular patients. Further, the MMAS-8D is endowed with simplicity and 
quickness of administration and scoring, which facilitates its use in several pathologies. It 
may be useful in patients with chronic therapy for detecting non-adherence. 
 Combination of subjective and objective adherence measures may help to establish a 
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According to the conclusions and findings of this thesis, recommendations for future research and 
practice are: 
Project A: Patient knowledge about oral anticoagulation therapy 
 The best way to counsel patients about OAC and association of increased patient 
knowledge about OAC with adherence and clinical outcomes should be assessed in further 
studies. Project D provides future researcher with a study proposal to investigate 
associations of increased patient knowledge about OAC and adherence. 
 Patient opinions on counselling about OAC and acquisition of knowledge about barriers 
and facilitators for patient-centred counselling should be of interest in further studies in 
order to ameliorate educational counselling in primary care setting. 
 Health care professionals (HCP) in primary care should screen for deficient knowledge 
and provide educational counselling about OAC actively. A patients whole therapy and 
daily experiences have to be included in counselling in order to achieve patient-centred 
counselling. 
 In order to ensure continuous care in OAC patients, it may be helpful to provide different 
HCP with standardized screening questions and educational manuals about OAC 
counselling. Remuneration of counselling might increase implementation of such service 
in daily practise.  
 
Project B: Patient preferences and vitamin B12 deficiency 
 Assessment of HoloTc seems more favourable than VB12 to identify VB12 deficient 
patients. If these findings are restricted to T2DM patients, should be assessed in further 
studies. 
 The impact of T2DM, metformin use and other factors (e.g. age, duration of VB12 
deficiency) on VB12 associated biomarkers should be investigated in further studies. 
 Optimal injection interval for i.m. hydroxocobalamine is still to be defined. Weekly 
admisnistration to guidelines lead to exaggerated biomarker response in non-anemic 
patients. Consequently, lower injection frequency is very likely to be equivalent and thus 
make treatment for patients more convenient and thereby influencing patient preferences. 
 In practice, patient preferences should be assessed routinely before treatment initiation, 
across various diseases where equivalent treatment options exist. Repeated re-evaluation 
of patient preferences should be integrated in delivering continuous care because 
preferences might change over time.  
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Project C: Adherence assessment methods 
 
 In practice, community pharmacists should screen for non-adherence by combining 
different methods such as MPR from pharmacy refill data and subjective questions. 
 The collaboration with IT specialists to integrate non-adherence alerts from refill data within 
pharmacy software could support community pharmacists when screening for non-
adherence in daily practice. 
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Adherence is defined as “the extent to which a person's behavior - taking medication, following a 
diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health 
care provider” [1]. The terms “concordance” and “compliance” are often used as synonyms for 
adherence. Both are related to the intake of medicine, but they impose different views on the 
relationship between the patient and the health care professional [2]. “Concordance” describes 
the agreement between the prescriber and patient in which the beliefs and preferences of the 
patient have been taken into consideration on the purpose and use of the medication. The term 
“compliance” is the original term and refers to the extent to which the patient follows the 
recommendations of the prescriber [2]. Recently a new taxonomy for describing and defining 
adherence to medications has been published that further divides the process into three 
quantifiable phases: “initiation”, “implementation” and “discontinuation” [3]. “Initiation” describes 
the intake of the first dose of a prescribed medication, “implementation” the extent to which a 
patient’s actual dosing corresponds to the prescribed dosing regimen, from initiation until the last 
dose and “discontinuation” stopping the intake of the prescribed medication, for whatever 
reason(s). Additionally, the term “persistence” was introduced as length of time between initiation 
and the last dose, which immediately precedes discontinuation [2, 3]. Persistence to treatment is 
of particular interest in chronic diseases with long-term therapy such as oral anticoagulation 
therapy (OAC) or vitamin B12 (VB12) substitution.  
Level of adherence to medication varies greatly and is related to treatment, patient and /or health 
care provider [2]. The World Health Organisation (WHO) stated in 2003 that adherence to long-
term therapies in the general population is around 50% in developed countries [4]. A meta-analysis 
of 569 studies in various settings and conditions reported average non-adherence rate of 24.8% 
[5].  
 
Non-adherence to medication is a complex, common healthcare problem and can be distinguished 
in unintentional and intentional non-adherence [2]. Unintentional non-adherence can be 
considered as an accidental or passive process. The patient does not take the medication as 
prescribed for example due to forgetfulness or not knowing how to use the medicines or other 
factors, such as carelessness [2, 6]. Intentional non-adherence reflects the active decision of the 
patient not to take the medication as prescribed. This is a rational process where patient beliefs 
4 General introduction 
    
19 
 
and concerns are important factors influencing the motivation to take the medication [2]. Factors 
affecting intentional non-adherence are complex and can be related to adverse effects, cost, 
patient preferences, disagreement of patients with the need for treatment, or communication 
issues between patient and health care professionals (HCP) among others [7-14]. It has been 
shown that poor medication adherence may cause toxicity or lack of efficacy [15], disease 
progression, lower quality of life, drug resistance, medication waste and hospital admission what 
results in costs of approximately 100 billion a year in the United states [16-19]. Since 2003, the 
WHO has focused on improvement of medication adherence because of the above mentioned 
negative outcomes of non-adherence [4]. Therefore, detection of non-adherence and interventions 
aiming at improving adherence are critically important.  
 
4.1.1. Assessment of adherence 
 
Adherence assessment methods can be broken down into direct and indirect methods. Each 
method has advantages and disadvantages [18]. The quality of different adherence 
measurements was assessed in a recent review [20]. In brief, the authors concluded that 
composite measures are important to establish a detailed picture of adherence. The following 
subchapters look at a number of different adherence assessment methods that were used within 
this thesis.  
 
4.1.1.1 Morisky Medication Adherence Scale (MMAS) 
 
Patient self-reports or questionnaires are the most useful indirect methods in clinical settings to 
assess adherence. This method is simple and inexpensive. However, self-reported questionnaires 
are subjective and thus susceptible to errors with increases in time between visits. They can easily 
be distorted by the patient [18]. 
Among self-reported questionnaires, the Morisky, Green and Levine Medication Adherence Scale 
[21] is one of the most widely used scale to measure self-reported adherence [22], mainly because 
of the simplicity of its administration and scoring. It consists of 4 yes/no questions. Because of its 
poor psychometric properties and its limited value for identifying non-adherent patients to 
cardiovascular medication [23], the first scale was refined and expanded with 4 further items 
addressing the circumstances surrounding adherence behaviour. The new 8-item Morisky 
Medication Adherence Scale (MMAS-8) has demonstrated high internal consistency and good 
sensitivity and specificity, it is valid and reliable [24]. The questionnaire was shown to be an 
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effective screening tool in clinical practice to identify non-adherent patients at risk of uncontrolled 
blood pressure [25]. The MMAS-8 has been translated into more than 50 languages, e.g. French, 
Malay, Portuguese and Thai [26-29]. Parts of the MMAS-8 have been translated in German and 
used in specific investigations or larger trials, but the German scale was never validated. Because 
of the foreseeable use of the MMAS-8 as an adherence measurement and assessment tool in 
German speaking countries including Switzerland, this thesis focused on a German version of the 
MMAS-8, the MMAS-8D (Deutsch).  
 
4.1.1.2 Electronic monitoring 
 
From all available indirect adherence assessment methods, the electronic monitoring represents 
the most objective measure and is recommended as the method of choice in research on 
adherence [30]. Electronic monitoring allows tracking patterns of medication intake precisely and 
results are easily quantified. Electronic monitoring can be used to provide feedback based on 
recorded data. Elevated costs and the necessity of follow-up visits for the downloading of data from 
devices represent the major disadvantages of this method. Additionally, electronic monitoring 
systems do not document whether the patient actually ingested the correct drug or correct dose. 
Therefore, misuse of the device can lead to false positive or false negative results. Finally, a 
potential bias might occur by reinforcing medication intake through simple observation (Hawthorne 
effect). When bottles or punch cards are used, a device-specific limitation to certain dosage forms 
can occur [18, 31]. 
 
Up to now, electronic monitoring of one medication was feasible using devices such as the 
MEMS® caps (Medication Event Monitoring System). In several studies using these electronic 
caps, discussing the adherence profiles with the patients had a significant impact on patient 
outcome, mainly through a shared decision of the follow‐up strategy [32]. However, only one single 
medicine was monitored and the derived intervention focused on that specific medicine. Therefore, 
a new technology to monitor adherence of polypharmacy was developed. The Electronic 
Monitoring System (POEMS) technology can be used to assess adherence to multiple medication. 
In brief, POEMS consists of a polymer film with imprinted electronic components that measure the 
electrical resistance and record the time of its changes when a loop is broken i.e., when a cavity 
is emptied. The patient’s entire oral solid medication is filled in a disposable multidrug punch card 
with 7x4 cavities, equipped with the film on its backside [33].  
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4.1.1.3 Rates of prescription refills 
 
Rates of refilling prescriptions are objective, indirect and accurate adherence measures, provided 
that refills are measured at several points in time. Prescription refills are not equivalent to ingestion 
of medication and require a closed pharmacy system [18]. Measures reported from secondary 
database calculate the highest possible level of medication consumption over a particular period. 
Numerous measures for calculating adherence to one medication from dispensing data records 
exist, but the nomenclature is inconsistent and computations may vary for similar terms. Recently, 
a new measure for calculating adherence to polypharmacy has been introduced as Daily Patient 
Possession Ratio (DPPR) [34].  
Within this thesis, the Medication Possession Ratio (MPR) was applied. The MPR is the most 
commonly used measure for calculating adherence to one medication from dispensing data 
records. It is calculated by dividing the days’ supply of a medication dispensed by the number of 




Measurement of a biological marker in blood is a direct, objective method to assess adherence 
and is often used in clinical trials. Measurement of biomarkers is expensive, burdensome to the 
HCP and patients, might be influenced by other biological parameters and patient behaviors. It 
requires expensive quantitative assays [18, 31]. 
 
4.1.2 The Polymedication Check – Pharmacy led adherence counselling in Swiss primary care  
 
The Polymedication Check (PMC) was introduced in Switzerland in 2010 as an intermediate 
medication review for primary care [36]. Comparable pharmacy-led services are available in other 
countries such as Australia, Canada, the United States of America, the United Kingdom, and New 
Zealand [37-40]. The PMC allows the community pharmacist to address adherence issues, drug-
related problems and to provide direct interventions such as implementation of weekly pill 
organizer for better medicines management [36]. The PMC is a reimbursed cognitive service and 
it is based on the Medicines Use Review (MUR) from the United Kingdom [41]. Community 
pharmacists routinely deliver this service independently from the prescriber for patients taking ≥ 4 
prescribed drugs over ≥ 3 months [36]. The PMC takes place in a separated consultation area 
ensuring privacy in the community pharmacy and lasts about 30 minutes [36]. It can be performed 
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ad hoc or upon appointment. A recent evaluation of the PMC showed a consistent trend for 
improved adherence rates in patients treated with antiplatelet drugs after receiving a PMC, 
however without reaching a significant level [36]. 
 
4.1.3 Interventions to improve adherence 
 
To counteract intentional non-adherence, the exploration of the associated factors and patient 
counselling appear to be important. Interventions should address patients concerns, include 
motivational interviewing and patient education to increase knowledge about disease and its 
treatment. To reduce unintentional non-adherence, strategies such as reminder systems, the 
implementation of medication intake in daily routine or the simplification of medication regimes 
might be helpful. Thus, there is a need of patient tailored interventions to improve adherence [2]. 
In general, interventions to improve adherence can be divided into behavioural, technical, 
educational, and multi-faceted methods [42]. Behavioural interventions usually provide feedback, 
reminders or rewards to patients. Reduction of regimen complexity and use of fixed-dose regimen 
are examples for technical interventions. Educational interventions include patient education, 
provided to individuals or in group sessions using verbal, audio-visual or written material. 
Effectiveness of multi-faceted approaches using combinations of different intervention types has 
been demonstrated in long-term situations [43].  
 
A recent Cochrane review on interventions to enhance adherence [44] found that current methods 
of improving medication adherence for general chronic diseases are mostly complex and evidence 
of their effects remains low. A supplementary analysis of the Cochrane database assessed 
congruence between adherence-related patient characteristics and the adherence interventions. 
The authors concluded that including non-adherent patients was associated with effective 
adherence interventions which in turn were associated with improved clinical outcomes [45]. 
 
In conclusion, evidence for the effectiveness of single adherence interventions is weak, while 
combined interventions seem to improve adherence. Empowering the patient to participate in 
shared decisions when it comes to the choice of treatment, to take responsibility for self-care, and 
to seek social support have been reported to show the strongest effects for therapeutic success 
[46]. First, patient knowledge and preferences about medication need to be assessed and 
individualized counselling should be offered in order to empower patients to actively participate in 
treatment decisions. Second, improvement of adherence and in turn clinical outcomes needs the 
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development of meaningful combined long‐term interventions and follow-ups. Finally, validated 
instruments for subjective and objective adherence measures are needed that enable the 
detection of improvements in adherence and clinical outcomes.  
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4.2. Patient knowledge 
 
Patients have to make important health decisions that affect health outcomes. Furthermore, 
patients can play an important role in protecting their own health and taking appropriate action in 
acute episodes of ill health, as well as managing chronic illness. In particular, the management of 
chronic diseases, such as atrial fibrillation, require a high level of self-care skills that are 
determined by patient health literacy. 
 
Health is strongly associated with health literacy and other influencing factors such as age, 
education level, income, race, and employment status [47]. Although importance of health literacy 
is increasingly recognised, there is no consensus about its definition [48] and different definitions 
in the context of pharmacy and medications have been recently described, such as “medication 
literacy” [49]. Overall, health literacy can be described as the people capacity to manage their 
health [50]. The WHO has adopted a definition of health literacy that reflects a health promotion 
orientation [51]: 
 
“Health literacy represents the cognitive and social skills which determine the motivation and ability 
of individuals to gain access to, understand and use information in ways which promote and 
maintain good health.” 
 
Patient knowledge about medical conditions and treatment regimens is an important aspect of 
health or medication literacy [52, 53]. In general, the term knowledge can be described as 
awareness or understanding of facts, information, or skills, that have been acquired through 
education or experience. Knowledge has been defined as beliefs that are correct and are justified. 
In addition, a person needs to be certain to be able to know something [54]. Patient medication 
knowledge - or shortly named in this thesis “patient knowledge” - refers to patient health 
knowledge related to medications including what is being used, why it is being used as well as 
instructions and precautions of use of certain medication. Patients with low knowledge about how 
to manage their illness were found to have low health literacy [55-57]. Therefore, patient 
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4.2.1 Patient education and counselling 
 
Patient education has been defined as “a planned learning experience using a combination of 
methods such as teaching, counselling, and behavior modification techniques which influence 
patients’ knowledge and health behavior” [59]. Patient education attempts to improve health – or 
medication literacy - and attitudes that are necessary to change patient behavior [60] and ultimately 
improves health outcomes [61]. Behavior change depends on different factors, such as patients 
perceptions of health and illness, as well as effective communication with HCP [62]. It has been 
demonstrated that informing patients about medication can influence patient outcomes positively 
mainly when communication is empathic [63]. The patient centered type of communication 
encourages patients to express their perceptions on treatment, establishes patients and HCP as 
partners and takes patient emotional and social environments into account. Patient centered 
communication requires open-ended questions and mutual participation, in contrary to biomedical 
communication which uses closed-ended questions [63].  
 
Patient counselling can include different aspects in order to help the patient better manage health 
problems [59], such as adherence counselling or medical counselling. Patient counselling about 
medication should include a dialog of the advantages and disadvantages of each single drug of a 
therapy regimen. Information transfer between HCP and patient should include information on the 
effects of the drug, its dose and the timing of intake as well as an explanation of the meaning and 
probability of potential adverse effects and interactions [52]. Both, patient education and 
counselling, involve an interactive process which actively engages patients to participate in their 
own health [59]. 
 
Up to now, however, counselling practice about medication in general practitioners’ practices 
seems to be poorly implemented. Studies reported that between 17% and 30% of physicians give 
no verbal instructions when medications are prescribed [64] and for almost one third of the cases, 
the name of the drug – either new or changed - is not mentioned [65]. A more recent study 
concluded that in general, medical encounters lack depth and although communication skills are 
now part of most medical curriculums, the concept of patient medication knowledge-building over 
multiple clinician–patient encounters should be strengthened [66]. Community pharmacists have 
an important role in patient counselling about medication [67]. Studies investigating counselling 
practice in community pharmacies show that there is room for improvement. Patient counselling 
in community pharmacies appeared to be of little importance in daily practice [68-70]. Additionally, 
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community pharmacists provide little medication-related information at the counter, especially for 
repeated refills on long-term prescriptions [71] and about half of the patients do not receive any 
counselling [72]. Furthermore, patient-community pharmacist communication seemed 
predominantly nonmedical or product-centered, instead of patient-centered [73, 74]. Studies 
examining patient knowledge about medication from hospital also report significant deficits in 
patient knowledge of hospital medications [75] and a need for structured medication teaching 
programs [76]. Therefore, it is not surprising that outpatients lack knowledge about their 
medication [77]. Suboptimal patient knowledge about high-risk medication, such as OAC, was 
reported [78]. Lack of knowledge of medication and difficulties in understanding medication 
information may be related to misapprehension of instructions and/or symptoms, medication errors, 
low self-care behavior, poor health outcomes, and frequent visits to the emergency department 
[49]. 
 
4.2.2 Assessment of patient knowledge 
 
To determine whether a person possesses knowledge about a certain topic, i.e. medication, 
simple questions that are representative of the topic should be asked. Items of test instruments 
used to assess knowledge should not be biased, i.e. influenced by the test participants’ 
characteristics other than knowledge [54]. Patient knowledge can be retrieved orally using 
structured or semi-structured interviews or with written test forms. The following subchapter 
focuses on written test forms. 
 
4.2.2.1 Assessment of knowledge deficit with written test forms 
 
Written test forms are the most appropriate method used for the assessment of cognitive 
knowledge in medical education settings. Two major types of assessment forms can be 
distinguished: items with selected-response and items with constructed-response formats [79]. 
Selected-responses can have the forms true and false, or multiple choice. Multiple choice formats 
are the most appropriate and efficient forms to objectively assess cognitive knowledge [79]. 
Constructed-response forms require the examinee to produce responses to open-ended 
questions, or other stimuli such as short and long answer essays. Scoring objectively constructed-
response formats is more difficult as with the selected-response form. Nevertheless, some types 
of assessments such as the evaluation of writing skills require constructed-response forms [79]. 
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4.2.3 Patient knowledge and adherence   
 
While the influence of health literacy and medication knowledge is considered important during 
the process of health /disease management, adherence to treatment is another important factor. 
A recent Cochrane review concluded that interventions that provide information or education may 
improve adherence, clinical outcomes and knowledge when used in combination with other 
interventions (i.e. counselling as part of pharmacist-delivered packages of care, training of self-
management skills), but results are mixed [80].  
In the case of OAC, individual studies showed that enhancing patient knowledge about medication 
and the underlying disease was able to improve long‐term adherence [81, 82]. However, according 
to a recent Cochrane review, there is insufficient evidence to draw definitive conclusion regarding 
the impact of educational interventions on therapeutic outcomes in patients receiving OAC [60] 
mostly due to inhomogeneity of the study designs. Thus, educational contents need to be prioritized 
and educational domains should be standardized [61]. Simple screening tools could be useful for 
the detection of knowledge gaps in daily practice. Further, standardized validated instruments for 
the assessment of deficit knowledge are needed to demonstrate the impact of patient education on 
outcomes in clinical trials. Finally, patient counselling about medication and available therapy 
options represents the first step to promote shared decision-making and apply evidence-based 
medicine and patient preferences. 
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4.3 Patient preferences 
 
Nowadays, a variety of treatment options exist for a single disease. The aim of a specific treatment 
can be the reduction of mortality or morbidity, the reduction of symptoms, or the improvement of 
the quality of life. Besides differences in health outcomes (such as for example the duration of life 
prolongation, side effects), therapy options can differ in other characteristics such as the 
application form or the costs.  
Patient preferences result from unique values (i.e. potential benefits, convenience) and concerns 
(i.e. potential harms, costs) that are formed by patient experiences, knowledge and reflection. 
Having preference for a treatment mirrors the patient evaluation of these values and concerns in 
comparison with an alternative treatment option. For a given disease, different patients may have 
different preferences. Each patient brings their preference to a clinical encounter that should be 
integrated in decision making whenever they are to serve the patient [83-86].  
Decisions resulting from preferences are personal judgements and involve balancing possible 
benefits and possible risks of the optional treatments [87]. Patients must be able to understand 
information, recognize benefits and consequences of various alternatives, question information 
rationally, and communicate their preference, to have capacity for a particular decision [88]. 
Besides benefits, risks and costs of a given treatment, practical aspects such as the patient ability 
to open package of medication, impairments within daily life caused by the medication or access 
to medication need to be considered [89]. Even though the underlying disease may influence the 
amount of decision-making patients want [90, 91], patients recognize that they are the best judges 
of their values when reflecting different options for their health care problem [92]. A method to 
include patient preferences by HCP is the model of Shared Decision Making [93]. 
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4.3.1 Shared decision-making 
 
In a systematic review, an integrative model of Shared Decision Making (SDM) was proposed and 
nine essential elements based on 161 definitions were identified [94]: 
1. Define /explain the health problem  
2. Introduce (treatment) options 
3. Discuss pros and cons (benefits/risks/costs)  
4. Assess patient values and preferences 
5. Discuss patient ability and self-efficacy 
6. Present doctor knowledge and make recommendations  
7. Check /clarify the patients understanding 
8. Make or explicitly postpone decision    
9. Arrange follow-up 
 
Within the SDM model, the patient and the HCP share the responsibility to decide on a treatment 
[95, 96]. The HCP’s task is to provide patients with evidence-based medical knowledge, 
experiences and attitudes while patients disclose their individual values, treatment goals and 
expectations. Then, a subsequent decision can be made based on evidence-based medicine and 
patient preferences [97, 98]. Throughout the process, both parties should periodically check the 
patient ability to follow-up the chosen treatment plan and changes in understanding of facts and 
perspectives and if needed to provide further clarification [94]. 
 
It has been shown that knowledge about patient preferences for a certain disease might lead to 
better informed decisions in practice and in health policy [84]. A systematic review gave evidence 
that SDM can be an effective method of reaching a treatment agreement in particular in long-term 
decisions, in the context of a chronic illness or when the intervention contains follow-up sessions 
[99]. Few studies exist about concordance between patient preferences and initiated treatment. 
Standardized interventions might facilitate the exchange of views between patients and health 
care providers [89]. SDM is particularly recommended for situations with two or more equivalent 
available treatment options and similar treatment consequences for a patient daily life. The 
substitution of VB12 in outpatients with VB12 deficiency is one example where the equivalent 
efficacy of oral and intramuscular application offers for patients both treatment opportunities. 
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4.3.2 Assessment of patient preferences  
 
Patient preferences concern three areas: the specific health state, the treatment itself and the 
patient participation, i.e. if a patient wants to be involved in the decision making process [95]. In a 
rational world, preference for health state are linked to preference for treatment [100]. However, 
some patients might prefer to avoid for example a major surgery although surgery might be the 
most effective option to increase lifespan. Therefore, in addition to the preferences, the values on 
which preferences are based should be assessed. This may especially clarify wrong information 
and unjustified beliefs. It has been shown that a significant proportion of patients would like to play 
an active role in decisions concerning their health [101]. Furthermore, patient participation in the 
decision-making process may be associated with favorable health outcomes [102, 103], even 
when patients avoided to be part of the decision making [104, 105]. Thus, asking patients about 
their preferences and values seems advantageous for every patient. 
A review about patient preferences in cancer treatment showed that a variety of methods exist to 
assess patient preferences, such as standard gamble, time to trade off or discrete choice 
experiment. However, the easiest method to assess preferences is by ranking or rating [84] a 
given set of alternative treatment options on a scale (for example Likert). The strengths of this 
approach are its easiness and quickness. Most of the methods ask patients what they would do 
in a hypothetical situation rather than what they would chose in a real situation [84]. 
 
4.3.3 Patient preferences and adherence 
 
It has been recognized that one single guideline does not account for the differences in patient 
preferences for treatments and health outcomes, suggesting a need for flexible guidelines that 
might facilitate patient involvement in clinical decision making [106]. A better understanding of 
patient preferences is pivotal for shared decisions and important for increased adherence and 
ultimately patient health outcomes [100]. Patient preferences in treatment-related decisions 
should be elicited and taken into account because patients who felt less empowered with regard 
to treatment decisions reported lower rates of adherence [107]. 
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4.4 Oral anticoagulants 
 
OAC are used for the prevention and treatment of both venous and selected arterial thrombotic 
disorders, such as atrial fibrillation (AF) [108]. For many decades, vitamin K antagonists (VKAs) 
have been the only available OAC despite their many limitations. Therefore, direct oral 
anticoagulants (DOAC), also called non-vitamin K oral anticoagulants (NOAC) have been 
developed to overcome VKA limitations. However, therapy with VKA and DOAC entails a high 
potential for adverse events and strict adherence is needed. Furthermore, the main target 
population is aged, presents multiple comorbidities and uses polypharmacy. Adherence and 
persistence to medication regimen increase when patients understand the reasons for the 
prescription, know potential side effects and know how to handle risky situations. For these 
reasons, medication review, the identification of safety issues and patient education are important 
for anticoagulation therapy with VKA and the newer anticoagulants. The following chapters 
introduce VKA and DOACs that are approved in Switzerland. 
 
4.4.1 Vitamin K antagonists 
 
VKAs (coumarins) used in Switzerland are phenprocoumon (Marcoumar®) and acenocoumarol 
(Sintrom®). VKA’s interfere with the synthesis of proteins important for blood clotting like 
prothrombin (factor II), factor VII, factor IX and factor X in the liver. In more detail, VKAs interfere 
with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide), thereby 
modulating the g-carboxylation of glutamate residues on the N-terminal regions of these vitamin 
K-dependent proteins. Therefore, treatment with VKAs results in the hepatic production of partially 
carboxylated and decarboxylated proteins with reduced coagulant activity [109]. Phenprocoumon 
is a long-acting agent, with both the R- and S-isomers having elimination half-lives of 5.5 days. 
Both are metabolized by CYP2C9. Acenocoumarol also exists as isomer. R-acenocoumarol has 
an elimination half-life of 9 hours, is primarily metabolized by CYP2C9 and CYP2C19, and is more 
potent than S-acenocoumarol which has an elimination half-life of 0.5 h and is primarily 
metabolized by CYP2C9 [109].  
All VKA’s are highly susceptible to drug-drug interactions, have drug-food interactions and a 
narrow therapeutic window. Therefore, anticoagulation with VKAs has to be monitored regularly 
through the assessment of International Normalized Ratio (INR) [109]. The INR is a standardized 
method to monitor the extrinsic pathway of the coagulation cascade. Its value indicates how much 
longer the blood needs to coagulate compared to physiological situations. The therapeutic range 
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of the INR value is usually between 2 and 3.5. Regular monitoring with dose adjustment is needed 
to ensure effective and safe anticoagulation [110] . It was shown that best therapeutic effects are 
achieved if the INR is in the therapeutic range at least 70% of time [111]. The effect of the 
anticoagulation starts two to three days after therapy-initiation and the full effect is achieved after 
five to seven days. This implies that in case of a desired rapid anticoagulation effect the bridging 
with a low molecular heparin is necessary at the initiation of treatment [110] . 
 
4.4.2 Direct oral anticoagulants 
 
In Switzerland, so far (September 2017) four different DOACs have been approved: Rivaroxaban 
(Xarelto®), apixaban (Eliquis®), edoxaban (Lixiana®) and dabigatran (Pradaxa®). 
Rivaroxaban, apixaban and edoxaban are selective and competitive reversible factor Xa inhibitors. 
Factor Xa activity is highly dependent on the concentration of the drug and the onset of action is 
rapid. The activation of factor X to factor Xa via extrinsic and intrinsic coagulation pathways plays 
an important role in the coagulation cascade and leads to the activation of prothrombin to 
thrombin. The inhibition of factor Xa leads to the prevention of thrombin formation. Factor Xa 
inhibitors has no effects on platelet aggregation induced by collagen, adenosine diphosphate, or 
thrombin [109]. 
Dabigatran is a concentration dependent, competitive, highly selective and reversible direct 
thrombin inhibitor. Because the dabigatran molecule is highly polar and lipophobic, it is not 
absorbed and its oral availability required the synthesis of an absorbable prodrug, dabigatran 
etexilate. Dabigatran prevents the conversion of fibrinogen to fibrin and thereby prevents thrombin-
induced platelet aggregation but not platelet aggregation by arachidonic acid, collagen, or 
adenosine diphosphate [109]. 
DOACs are taken once or twice daily, they all have a short elimination half-life and have similar 
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Table 1: Pharmacokinetic properties and interactions of rivaroxaban, apixaban, edoxaban and dabigatran 
adapted from [108, 112, 113]. 
   
 Rivaroxaban Apixaban Edoxaban Dabigatran 
Dosing Once (or twice) daily Twice daily Once daily Twice daily 
Prodrug No No No Yes 
Bioavailability 66-100%* 52% 62% 3-7% 
Peak plasma 
concentration 
2-4 h 3-4 h 1-2 h 0.5-2 h 
Clearance non-
renal / renal 
66% / 33% 75% / 25% 50% / 50% 20% / 80% 
Liver metabolism 
via CYP 3A4 
Yes Yes Yes No 
Elimination half 
life 
5-9 h (young) 
11-13 h (elderly) 
12 h 10-14 h 12-17 h 





*Dependent on intake without or with food 
P-gp= P-glycoprotein 
PPI= Proton pump inhibitors 
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4.5 Vitamin B12  
 
VB12, is a water-soluble vitamin and 
essential for DNA-, fatty acid- and hem 
synthesis [114]. VB12 is also called 
cobalamin and refers to a variety of 
structurally related compounds. 
Cobalamins contain a central cobalt ion 
coordinated to four nitrogen atoms 
donated by the tetrapyrrolic corrin-ring 
system. The axial ligand on the lower 
surface of the corrinring is the nucleotide 
base dimethylbenzimidazole. The second 
axial ligand lies on the upper surface of the ring. Different ligands can coordinate to the cobalt ion. 
The ligand may be a cyano-, hydroxyl- alkyl group or 5- deoxyadenosyl [115] (Figure 1). VB12 is 
synthesized by some bacteria species and has to be ingested from food. Sources of VB12 include 
mainly animal products such as liver, meat, fish, eggs milk and cheese [116, 117]. A typical 
Western diet contributes 3–30 μg of cobalamin per day toward the estimated daily requirement of 
2,4 μg that is recommended by DACH Liga for adults [118, 119].  
 
After ingestion, pepsin and hydrochloric acid release VB12 in the stomach from animal proteins. 
A central role for the absorption of VB12 plays the Intrinsic Factor. The Intrinsic Factor is a 
glycoprotein that is synthesized in the parietal cells of the stomach. Within the small intestine, 
VB12 is bound by Intrinsic Factor leading to receptor-mediated endocytosis. It is supposed that 
around 1% of VB12 is absorbed by passive diffusion. Within the blood circulation, VB12 is bound 
to transcobalamine, called holotranscobalamine (HoloTc). HoloTc is the biologic active form 
available for cell [120, 121] . VB12 is stored mainly in the liver and in case of abstinence, storage 






 Figure 1: Vitamin B12 forms. Adapted from: Obeid R et 
al.  [117]. 
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4.5.1 Detection of vitamin B12 deficiency   
 
Biochemically, VB12 deficiency is characterized by subnormal to borderline VB12 values in serum 
(<148-221 pmol/l) [122]. HoloTc is the bioactive form of VB12 and makes up to 20% of the total 
VB12 concentration in the human body [123]. It has been discussed as a more specific and 
sensitive marker of VB12 deficiency [124-126]. Broad ranges of cut-off points for HoloTc have 
been described <20 – 50pmol/l [127]. Functional VB12 deficiency is characterized by elevated 
homocysteine (Hcy) and/or methylmalonic acid (MMA) [122]. However, it is known that clinical 
biochemistry of VB12 is influenced by different health states. One example of altered VB12 











Further laboratory findings are hematological abnormalities such as 
macrocytosis, pancytopenia and hypersegmented neutrophils 
(Figure 3). Hematological changes can be found in the more severe 
cases, while biochemical findings go in parallel with less specific 
clinical manifestations of VB12 deficiency. However, no clear-cut 
limits exist for the prediction of symptoms [130]. Subclinical VB12 
deficiency occurs and is found in up to 10-25% of the aged 
population. Treatment of these patients is common, even though the 





Figure 2: Relationship between Diabetes, Metformin 
treatment, health situation and VB12 status. 
Figure 3: Hypersegmented 
neutrophil. 
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4.5.2 Treatment of vitamin B12 deficiency 
 
The treatment of VB12 deficiency consists of VB12 supplementation, which can be performed 
either orally or by injections. In Switzerland, VB12 supplementation is predominantly performed 
with i.m. injections of VB12 [131], which are usually painful. In Switzerland, only combination 
preparations for oral substitution are available containing different doses of cyano- or 
hydroxocobalamine (Table 2). Oral treatment with VB12 may be superior to i.m. injections in terms 
of patient acceptance and cost-effectiveness [132]. Patient preferences in treatment-related 
decisions should be elicited and taken into account, because patients who feel less empowered 
with regard to treatment decisions reported lower rates of adherence [107]. 
 
Table 2: Examples for VB12 containing products in Switzerland. 
 Dose (mg) 
mono (M) / 
combination 
products (K) 
Rx/ OTC Application 
Products containing cyanocobalamine 
Supradyn Energy 0.003 K OTC oral 
Berocca ® 0.01  K OTC oral
Becozym forte ® 0.01 K OTC oral
Vitasprint ® 0.5 K OTC oral
Benexol ® 1 K Rx oral
Vitarubin superconc® 1 M Rx i.m, (s.c./i.v*) 
Products containing hydroxocobalamine 
Biovigor® 0.5 K OTC oral
BIO-LOGOS ® 0.5 K Rx oral
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5 Thesis overview 
 
The goal of this thesis was to assess knowledge of oral anticoagulation therapy and preferences 
for VB12 in outpatients, and to develop an educational program for outpatients on DOAC. The 
thesis approaches this goal in four parts:  
 
5.1 Project A: Patient knowledge of oral anticoagulation therapy  
 
Community pharmacists are one of the last HCP patients see before they take their medicines. 
Therefore, pharmacists play an important role in counselling about adherence and about 
medicines. Study A-1 aimed at assessing outpatients knowledge of OAC in Swiss community 
pharmacies. Within this study, the basic PMC was amended with specific open-ended questions 
on OAC. The impact of the amended PMC on basic knowledge of OAC was assessed in an 
observational study with patients treated with VKA or DOACs. Knowledge gaps regarding OAC 
therapy were frequently detected and resulted in pharmaceutical intervention improving patient 
knowledge. Patients on DOAC had more knowledge gaps compared to VKA patients. Up to now, 
no questionnaire assessing patient DOAC knowledge was psychometrically validated. Therefore, 
the aim of the second study was to develop and validate a questionnaire to self-assess knowledge 
of DOAC that can be used in clinical trials (Study A-2). An item pool to assess knowledge of 
DOACs was retrieved from a systematic literature review and reduction of items was achieved 
with a focus group discussion. The newly developed questionnaire was then validated in 
outpatients with a prescription for DOAC. 
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Table 3: Overview of the studies of Project A. 
Project A 
Study A-1 
Intermediate medication review focusing on oral anticoagulation therapy 
enhances patient’s medication literacy – an observational study in Swiss 
community pharmacies (research report) 
 To detect knowledge gaps about OAC in outpatients 
 To observe the counselling process of community pharmacists with the 
help of the basic PMC amended with specific questions on OAC  
 To assess the impact of the amended PMC on patient knowledge of OAC 
Study A-2 
Development and validation of a tool to assess knowledge of DOAC 
(published in: Drug Healthc Patient Saf. 2018 Jul 20;10:69-77. doi: 
10.2147/DHPS.S152954. eCollection 2018.[134]) 
 To develop a questionnaire to self-assess patient knowledge of DOAC  




Project B: Patient preferences and vitamin B12 deficiency 
 
VB12 deficiency is relatively common, especially in elderly. Recently, an increased frequency of 
VB12 deficiency among T2DM patients has been documented. The clinical biochemistry of VB12 
is influenced by diabetes and its treatment. Systematic observations in clinical trials as well as 
biochemical studies in animals raised questions on possible interactions between diabetes, 
metformin treatment and VB12 metabolism. Study B-1 aimed at assessing whether serum VB12 
or HoloTc is more suitable to detect VB12 deficiency in T2DM patients. Furthermore, differences 
in VB12 associated biomarkers were analysed i) among diabetic outpatients with and without 
metformin use and ii) in comparison to an external non-diabetic reference group with low VB12 
(<200pmol/L).Because VB12 deficiency is a reversible cause of demyelinating nervous system 
disease and bone marrow failure, its early detection and treatment of deficient patients are 
important. The treatment of VB12 deficiency consists of VB12 supplementation which can be 
performed either orally or by intramuscular (i.m.) injections. In Switzerland, VB12 supplementation 
is predominantly performed with i.m. injections of VB12, which are usually painful. No high-dose 
VB12 oral mono-preparation is currently available, despite evidence of its effectiveness. 
Moreover, when equally effective treatment options exist, patient preferences need to be            
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taken into account. Patients who felt less empowered with regard to treatment decisions reported 
lower rates of adherence. Finally, a better understanding of patient preferences and values for 
making choices is fundamental to achieve shared decision making and ultimately improve 
adherence. Therefore, Study B-2 aimed at assessing patient preferences to oral and i.m. VB12 
substitution. Furthermore, Study B-2 aimed to prove non-inferiority of oral treatment compared to 
i.m. VB12 substitution. Study B-3 aimed to assess patient preferences towards oral and 
parenteral treatment in various diseases. A literature review retrieved 13 research articles with 
focus on patient preferences. 
 
Table 4: Overview of the studies of Project B. 
Project B 
Study B-1 
Impact of type 2 diabetes and metformin use on Vitamin B12 associated 
biomarkers - an observational study ( published in Exp Clin Endocrinol 
Diabetes. 2018 Jun;126(6):394-400. doi: 10.1055/s-0043-120760. Epub 2018 
Feb 2. [135]) 
 To assess the effect of metformin treatment on VB12 status as reflected by 
total VB12 and HoloTc in T2DM patients. In particular, the the biologically 
active fraction %AB12 (=HoloTc/VB12*100) in T2DM patients with and 
without metformin treatment was compared. 
 To investigate the impact of diabetes itself on VB12 associated biomarkers 
at low VB12 levels in patients with diabetes, in comparison to an external 
reference group of non-diabetic patients.  
 To assess the suitability of VB12 and HoloTc to represent VB12 supply in 
T2DM patients 
Study B-2 
Early Biomarker Response and Patient Preferences to oral and 
intramuscular Vitamin B12 Substitution in Primary Care: A Randomized 
Parallel Group Trial (publication in Swiss Med Wkly. 2017 Apr 19;147:w14421. 
doi: smw.2017.14421. eCollection 2017 Apr 19. [136]) 
 To compare patient preferences for oral versus parenteral treatment before 
substitution with VB12 with preferences after a one-month therapy.  
 To assess early biomarker response to the supplementation with oral or 
i.m. VB12 treatment in outpatients. 
Study B-3 
B 3 Oral versus parenteral route of application: The patients’ perspective 
(research report [137]) 
 To assess patient preferences towards oral and parenteral treatment in 
various diseases. 
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Project C: Adherence assessment methods 
 
Considering that interventions aimed at optimizing adherence will be more effective if they are 
tailored to patient´s needs, HCPs will need tools to measure adherence. Among self-reported 
questionnaires, the Morisky Medication Adherence Scale is one of the most widely used. However, 
to date no German version is available. Therefore, Study C-1 aimed to translate the MMAS-8 and 
psychometrically validate it in cardiovascular patients. In Switzerland, the PMC, an intermediate 
medication review focusing on adherence issues, is available since 2010. The PMC contains one 
single adherence question from [138]: “Do you sometimes forget to take your medication?” to 
screen for non-adherence. It is known that subjective measures such as questionnaires are easily 
distorted by the patient. Therefore, a pilot study in DOAC treated patients aimed to evaluate 
whether the affirmative answer to the subjective PMC question coincides with an objective 
adherence measure. The MPR calculated from pharmacy refill data served as comparator (Study 
C-2). 
 
Table 5: Overview of the studies of Project C. 
Project C 
Study C-1 
The 8-item Morisky Medication Adherence Scale translated in German and 
validated against objective and subjective polypharmacy adherence 
measures in cardiovascular patients.                                   
(Second author, published in J Eval Clin Pract. 2015 Apr;21(2):271-7. doi: 
10.1111/jep.12303. Epub 2015 Jan 6. [139]) 
 To translate and validate the 8-item Morisky Medication Adherence Scale 
in German in cardiovascular patients. 
Study C-2 
Medication possession ratio may detect half of the self-declared non-
adherent patients to direct oral anticoagulation treatment – A pilot study 
(research report [140]) 
 To assess whether the affirmative answer to the PMC question “Do you 
sometimes forget to take your medication?” coincides with a MPR <90% 
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Finally, Study D aimed to develop a tailored and stepwise educational program on adherence to 
DOAC therapy in Switzerland. This study design allows to investigate the impact of the intervention 
on subjective (questionnaire based) and objective (electronically monitored) adherence and to 
assess patient satisfaction with an educational tailored and stepwise program. 
 
Table 6: Overview of Project D. 
Project D 
Study D 
Impact of a tailored and stepwise educational program on adherence to 
rivaroxaban therapy in Switzerland – adaptable to other European 
countries such as Germany or France (Research protocol) 
 To develop a stepwise educational program on adherence for patients on 
DOAC and especially on rivaroxaban using feedback from electronic 
monitoring.  
 To investigate the impact of the intervention on subjective (questionnaire 
based) and objective (electronically monitored) adherence. 
 To assess patient satisfaction with an educational tailored and stepwise 
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6.1 Intermediate medication review focusing on oral anticoagulation therapy enhances 
patient’s medication literacy – an observational study in Swiss community pharmacies 
[A-1] 
 
Corina Metaxas, Albert Valerie, Habegger Susanne, Markus Messerli, Kurt E. Hersberger, 
Isabelle Arnet 
Department of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of 
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Oral anticoagulation therapy (OAC) is often prescribed to elderly patients with polypharmacy (>3 
different medications).  High adherence to OAC is needed for optimal therapeutic outcomes. Since 
2010, Swiss community pharmacists can deliver an intermediate medication review, the 
Polymedication Check (PMC) that focuses on adherence and handling problems. The pertinence 
of the delivered information through the PMC and its impact on patient knowledge has never been 
investigated. We amended the basic PMC with open-ended questions on OAC and evaluated 




Based on previous studies, an amended PMC with focus on knowledge of OAC was developed. 
Fifth-year pharmacy students documented one amended PMC with OAC patients during their 
internship in community pharmacy. They documented knowledge gaps, pharmacists-led 
interventions and patients’ satisfaction with the amended PMC. 
 
Results  
A total of 81 patients (61.7% VKA, 38.3% DOAC) received an amended PMC. Half of the patients 
(50.6%) did not know how to proceed in case of a missed dose. Percentage of patients with at 
least one knowledge gap decreased from 65.4% to 23.8% after spontaneous educational 




The majority of OAC patients shows knowledge gaps that could be detected by community 
pharmacist through the amended PMC. Although spontaneous and unstructured, the provision of 
tailored education increased patients’ medication literacy. Thus, a simple screening with open-
ended questions enables community pharmacists to easily counsel OAC patients.  
 
Keywords: medication literacy, oral anticoagulants, patient knowledge, medication review 
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Oral anticoagulation therapy (OAC) is prescribed for the prevention and therapy of 
thromboembolic diseases [141-143] with either vitamin K antagonists (VKA) or direct oral 
anticoagulants (DOAC), also called non-vitamin K antagonist oral anticoagulants (NOAC). The 
chronic nature of anticoagulant treatment and the inherent bleeding risk increase the challenge of 
treatment for both types of OACs. DOACs were developed predominantly to overcome the 
practical difficulties associated with VKAs (i.e. frequent dosage-adjustments, drug-drug, drug-
food interactions)[144]. However, strict intake time i.e., a high adherence rate is needed to achieve 
optimal therapeutic outcome with VKA and DOAC [145]. Non-adherence may reach 32% in 
patients with the VKA warfarin [146] and similar adherence levels can be assumed with DOACs 
[147] since both agents have the same target population that is aged, presents multiple co-
morbidities and uses polypharmacy [148]. Non-adherence can be intentional or non-intentional 
[2]. Unintentional non-adherence can be considered as an accidental process. The patient does 
not take the medication as prescribed due to e.g., forgetfulness or not knowing how to use the 
medicines. Unintentional non-adherence can be decreased by the addition of a reminder system 
(i.e., weekly pill organizer) [149]. Intentional non-adherence reflects the active decision of the 
patient not to take the medication as prescribed. This is a beliefs-based process that influences 
the motivation to take the medication. Patient counseling and education about medicines may 
improve intentional adherence [2, 150]. Finally, interventions aimed to increase adherence are 
likely to succeed if the entire medication is taken into account. Therefore, the performance of a 
medication review represents an essential first step in any adherence counseling [36].  
 
1.1 Polymedication Check 
The Polymedication Check (PMC) was introduced in Switzerland in 2010 as an intermediate 
medication review for primary care [36]. Comparable pharmacy-led services are available in 
several other countries such as Australia, Canada, the United States of America, the United 
Kingdom, and New Zealand[37-40]. The PMC allows the community pharmacist to address 
adherence issues, drug-related problems and provide direct interventions i.e. implementation of 
weekly pill organizer independently from the prescriber [36]. The PMC is a reimbursed cognitive 
service and it is based on the Medicines Use Review (MUR) from the United Kingdom [41]. The 
pertinence of the delivered information through the PMC and its impact on patient knowledge has 
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1.2 Patient education  
Different definitions for health literacy in the context of pharmacy and medications have recently 
been described, such as “medication literacy” [49]. Patient education attempts to improve 
medication literacy and attitudes that are necessary to change patient behavior [60] and ultimately 
to improve health outcomes [61]. Difficulties in understanding medication information may be 
related to misapprehension of instructions and/or symptoms, medication errors, low self-care 
behavior, poor health outcomes, and frequent visits to the emergency department [49].  
It has been demonstrated that informing patients about medication can influence patient outcomes 
positively mainly when communication is empathic[63]. A patient-centered communication 
establishes patients and health care providers (HCP) as partners, takes patients’ emotional and 
social environments into account and requires open-ended questions to encourage patients to 
express their perceptions on treatment [63]. Few studies showed that enhancing patient 
knowledge about OACs and the underlying disease were able to improve long‐term adherence 
[81, 82]. However, according to a recent Cochrane review, there is insufficient evidence to draw 
definitive conclusion regarding the impact of educational interventions on therapeutic outcomes in 
patients receiving OAC [60] mostly due to inhomogeneity of study designs. Thus, educational 
contents need to be prioritized and educational domains should be standardized [61]. Therefore, 
simple screening tools could be useful for the detection of knowledge gaps. 
 
Usually, community pharmacists are the last HCP patients see before they take their medication. In 
Switzerland, physicians hand out prescriptions for chronic diseases that are valid for up to one year. 
Therefore, pharmacists are in a central position to assess a patient’s medication literacy, counsel and 
provide a follow-up beside the delivery of the medication. The ability of detecting knowledge gaps in 
patients with chronic treatments such as OAC could help pharmacists or other HCPs to enhance 
adherence. We amended the basic PMC with a semi-structured questionnaire containing open-
ended questions on OAC resulting in a new protocol for a specific MR with OAC patients.  
 
1.3 Aim of the study 
We aimed at assessing the impact of the amended PMC on OAC knowledge of outpatients taking 
VKAs or NOACs. 
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2.1 Trial design 
A cross-sectional study was initiated by the Pharmaceutical Care Research Group (PCRG) of the 
University of Basel. Swiss community pharmacies that employed pharmacy students in their final 
year (internship) served as recruiting places. The study was conducted in accordance with the 
Declaration of Helsinki and has been registered at ClinicalTrials.gov ID NCT02703727. The study 
was approved by the regional ethic committee (EKNZ 50/12). All patients gave written informed 
consent. 
 
2.2 Data collection 
Fifth year pharmacy students were trained on OAC and PMC during plenary lectures of the regular 
curriculum at the University of Basel. A descriptive manual and an online training including one 
video, which described the study procedure and provided instructions for the correct use of 
amended PMC and the follow-up interview, were available for the students   
Community pharmacists were instructed to perform a basic PMC (A) with an orally anticoagulated 
patient in the pharmacy and (B) to add the newly developed semi-structured interview immediately 
after the basic PMC. Students observed the patient-pharmacist-interaction and documented all 
the pharmacist-led interventions on provided standardized protocols. Two weeks later, students 
called the patients by phone and performed a follow-up interview (C).   
 
2.2.1 Basic PMC (A) 
The basic PMC contains several items to be checked for every single medication such as 
knowledge about the therapy: “know how to take the medication” (item 2) and “know why to take 
the medication” (item 3) (Table 1). Item 1 concerns the name and dosage of the product. It is rarely 
asked because name and dosage are mostly extracted in advance from the pharmacy software. 
The PMC does not specify how the questions should be asked. According to the patient’s response, 
the pharmacist ticks the appropriate box in the report. After gathering information the pharmacist 
delivers targeted information in an unstructured manner [72]. 
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2.2.2 Development of the amended PMC on OAC (B) 
Thirteen items from a French publication about the evaluation of a pharmaceutical interview in an 
anticoagulation clinic [151] were translated into German (CM). Readability and comprehension 
were approved by three German native speaking pharmacists (MM, SH, KH). Five items were not 
specific for OAC (n=2) or did not concern knowledge about OAC (n=3) and were therefore 
excluded. The remaining eight items delineating knowledge were formulated as open-ended 
questions (Table 1). Asking these eight questions in form of a semi-structured interview placed at 
the very end of a basic PMC was supposed to take about 10 minutes. 
 
Table 1: Questions asked in the basic PMC (A), the following semi-structured interview (B) and/or the follow-























Item  Content Asked in 
2  “knows how” A , B , C 
3   “knows why” A , B , C 
4   “What happens in case of underdosage” B , C 
5  “What happens in case of overdosage” B , C 
6   “What to do in case of a missed dose” B , C 
7 “How long to take the OAC” B, C 
8 
“Why to inform HCPs about having an OAC 
therapy” 
B , C 
9  
“I would recommend this service to other 
patients” 
C 
10   




“I am more confident about how to take my 
OAC” 
C 
12 “It is easier to take my OAC as prescribed” C 
13  
“I have less concerns about my therapy with 
OAC” 
C 
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2.2.3 Development of the follow-up interview (C) 
The same eight questions delineating knowledge were completed with five additional items about 
patient satisfaction using 5-point-Likert scales retrieved from a prior study [36] (see Table 1).   
 
2.2.4 Pilot study 
Comprehension of the amended PMC, usability of the standardized protocol for documentation of 
interventions by students and feasibility of the study design was tested with 91 fifth year pharmacy 
students of a prior study course (2014/2015). Adaptions were made. 
 
2.3 Inclusion criteria 
Patients were eligible if they fulfilled the official selection criteria for a basic PMC (age ≥ 18 years, 
≥4 prescribed medications for ≥3 months[36]) and if they were taking a VKA (Acenocoumarol, 
Phenprocoumon) or a DOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban) not for orthopedic 
indication. 
 
2.4 Outcome Variables 
Negative or incorrect answers were defined as “knowledge gaps” during the basic PMC (item 2, 
3), the semi-structured interview (Items 2-8) and the follow-up interview (items 2-8). Answers to 
patient’s satisfaction could be given on a 5-point-Likert scale with options ranging from 1 (= ‘I do 
not agree’) to 5 (= ‘I do agree’). The response category ‘no answer’ was also available. Number 
of pharmacist-led interventions aiming at increasing knowledge about OAC were retrieved from 
the standardized protocol the students had filled in. 
 
2.5 Statistical methods  
Where appropriate, mean and standard deviations, median and interquartile ranges are 
presented. Mann-Whitney U test was used to compare numerical data and Chi-Square-test to 
compare categorical data between groups. McNemar's test was used to compare paired 
proportions before and after the interviews. Comparison of data before and after interviews was 
restricted to subjects with full datasets. Data were entered and analyzed using SPSS statistical 




6 Project A: Patient knowledge about oral anticoagulation 
    
50 
 
3. Results        
3.1 Participants  
A total of 91 students collected data during their internship between November 2015 and June 
2016 (n=91 in community pharmacy. Two pharmacies declined participation and eight pharmacies 
failed to recruit a patient with OAC during the study period.  
Out of 81 recruited patients five (6.2%) were lost for follow-up (Table 2). Phenprocoumon was the 
most common VKA prescribed (Phenprocoumon: 94%, n=47; Acenocoumarol: 6%, n=3). Out of 
the 31 NOAC patients, 90.3% (n=28), 6.5% (n=2) and 3.2% (n=1) received rivaroxaban, 
dabigatran and apixaban, respectively. Age, gender, and number of prescribed medication were 
equally distributed between patients treated with VKAs or with NOACs (Table 2). Duration of 
treatment with VKA was significantly longer than the duration of treatment with NOAC ( p<0.001) 
(Table 2).  
 
3.2 Time 
Average time needed to perform an amended PMC and the follow-up interview was 36±15 minutes 
and 17±12 minutes, respectively, and did not differ between VKA and NOAC patients (data not 
shown). Average time until follow-up was 15±9 days. 
 
 
Table 2: Characteristics of patients with VKA or NOAC therapy.  
Characteristics Total  VKA  NOAC  
p-value 
between groups
Number of recruited 

































Duration of OAC Therapy, 
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3.3 Detected knowledge gaps 
 
3.3.1 PMC (A) 
Missing data represented 9.9% and 14.8% in item 2 and 3, respectively. The knowledge questions 
were answered negatively by 6 patients (7.4%; item 2 on “know how”) and 6 patients (7.4%; item 
3 “know why”) (Table 3).  This lack of knowledge triggered an immediate intervention in 100% and 
83.3% of the cases, respectively.  
 
3.3.2 Semi-structured interview (B) 
A total of 9 knowledge gaps were detected in item 2 and 3 during the semi-structured interviews, 
which triggered another immediate intervention in 28.3% and 42.9% of the cases, respectively. 
Compared to the basic PMC, the semi-structured interview allowed to detect 7 additional 
knowledge gaps in item 2 and 3.  
 
Items 4 (“underdosage”) and 5 (“overdosage”) were not known in 24.7% (n=20) and 25.9% (n=21) 
of the cases, respectively (Table 3). The majority of patients (50.6%, n=41) did not know how to 
proceed in case of a missed dose (item 6; Table 3). Items 7 (“treatment period”) and 8 (“HCP 
information”) were not known in 11.1% (n=9) and 22.2% (n=18). Identification of knowledge gaps 
in item 4-8 were followed by an immediate intervention in 28.6-90.0% of the cases.  
 
3.3.3 Follow-up interview (C) 
Missing data for the follow-up interview represented 0-1.5%. Percentage of patients with 
knowledge gaps during the semi-structured interview in items 4,5, 6 and 8 decreased significantly 
at follow-up (Table 3). Percentage of patients with knowledge gaps in item 7 during the semi-
structured interview increased slightly at follow-up. Percentage of patients with at least one 
knowledge gap during the semi-structured interview decreased significantly from 65.4% to 23.8% 
at follow-up (p<0.001; data not shown). 
 
3.3.4 Differences between VKA and DOAC patients 
Patients with NOAC did significantly more often not know how to take their medication (item 2, 
basic PMC, p<0.01) and the effects of overdose (item 5, semi-structured interview, p<0.05) 
compared to VKA patients. 
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Table 3: Number of knowledge gaps detected during the basic PMC (items 2, 3), the semi-structured interview (items 2-6) and the follow-up interview 
(items 2-6).  
*Chi-Square or fishers exact test; **= McNemar's test
 
 
[A] basic PMC [B]  semi-structured  interview [C]  follow-up interview before-after comparison  


























“knows how”  6 1 5 <0.05 2 1 1 ns 1 1 0 ns ns ns 
Item 3:   






    20 11 9 ns 4 2 2 ns 
 
<0.001 




    21 9 13 <0.05 9 3 6 ns  <0.001 
Item 6: 
 “What to do in 
case of a 
missed dose” 
    41 25 16 ns 13 11 2 ns  <0.001 
Item 7:      
“How long 
to take the 
OAC “ 
    9 6 3 ns 10 5 5 ns  ns 
Item 8:      




    18 8 10 ns 2 2 0 ns  <0.005 
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3.4 Patient satisfaction  
The majority of the patients would recommend the amended PMC to other people (92.0%), was 
satisfied with the answers by the pharmacists (98.6%) and stated to be more confident how to 
take the OAC (52.7%) after receiving an amended PMC. The amended PMC did not influence the 
easiness to take OAC as prescribed (31.6% neutral). More patients agreed that they had less 
concerns about their OAC after the amended PMC (42.1%) than were neutral (27.6%) or 
disagreed (30.3%) (Figure 1).                                   
 
 
Figure 1: Patients’ answers to questions on satisfaction with the amended PMC during the follow-up 
telephone interview. 
 





0 20 40 60 80 100
Item 13: I have less concerns that my
OAC does not work
Item 12: It is easier to take my OAC as
prescribed
Item 11: I am more confident about how
to take my OAC
Item 10: The Pharmacist was able to
answer all my questions




I do rather agree
neutral
I do rather not agree
I do not agree
no statement
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4. Discussion  
Our findings confirm that a semi-structured interview with specific open-ended questions on 
medication knowledge enable community pharmacists to detect gaps in patients’ comprehension 
and trigger immediate patient education. Even unstructured but targeted information enhances 
medication literacy after spontaneous pharmacist-led interventions. Thus, these questions could 
serve as screening tool.  
In our study, 65% of the patients had at least one knowledge gap concerning their therapy with 
OAC during a semi-structured interview. This is in agreement with other studies that observed that 
a majority of patients treated with OAC had poor or inadequate knowledge about treatment[152-
154]. The specific open-ended question format of the semi-structured interview might be the 
reason for the detection of additional knowledge gaps compared to the basic PMC, which was 
developed as a screening tool for any drug related problem linked to polypharmacy. It was shown 
that open-ended questions enable gathering of qualitative and accurate information [155] and 
further allow patient-centered communication[63].  
Surprisingly, the majority of patients showed knowledge gaps in item 6 (“What to do in case of a 
missed dose”) and around one quarter of patients did not know what happens in case of 
underdosage or overdosage. A study investigating patient knowledge about warfarin found also 
that only half of the patients or fewer knew what happens in case of a missed dose, overdosage 
or underdosage [156]. Beyond that, one study in elderly patients with polypharmacy showed that 
patients overestimate their knowledge about therapy [157]. These results highlight the necessity 
to assess patients’ medication literacy concerning OAC.  
We further found a trend that patients with DOAC therapy were more likely to have knowledge 
gaps compared to patients on VKAs. Knowledge gaps of patients with DOAC therapy concerned 
mostly the questions ‘How to take the medication?’ and ‘What happens in case of overdosage?’ 
Compared to patients with VKA therapy, the number of knowledge gaps concerning these two 
questions was higher. One reason might be the duration of therapy which was significantly shorter 
in DOAC patients compared to VKA patients, suggesting that contacts of DOAC patients with 
HCPs and possible education were limited to a few. Another reason may be that routine blood 
testing in VKA patients allows self-reflection on medication intake behavior and thereby increases 
awareness of VKA therapy.  
 
It has been shown in observational studies that community pharmacists provide little medication-
related information at the counter [71] and about half of the patients do not receive any counseling 
[72]. Contrary to these findings, we found that detection of poor knowledge through an amended 
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PMC triggered pharmacists to provide targeted patient education and thereby significantly 
reduced knowledge gaps. Duration of a counseling session with the amended PMC took a mean 
of 53±15 minutes, which is about 20 minutes longer than the duration of the basic PMC (29.8±16.5 
minutes [36]). Training of pharmacists might reduce the time needed to perform an amended PMC 
and intervention rate. Furthermore, training for pharmacists incorporating patient-centered type of 
communication might trigger successful medication intake behavior in patients [158]. However, 
the duration of the amended PMC might be a barrier for its implementation in practice, if not higher 
reimbursed as the basic PMC. Additionally, the length of a counselling session may be critical in 
practice, because advanced age of our population (70.7±12.3 years) which might go along with 
reduced cognitive capacity leading to loss of concentration. Therefore, it may be reasonable to 
amend the PMC with specific questions only for high-risk medication, such as OAC. We therefore 
suggest to further adapt the amended PMC to an “anticoagulation PMC”, similar to the medicines 
use review in UK, which was also adapted for specific target groups [159]. Within our study, we 
did not collect data on possible reasons for incorrect answers at follow-up. Assessment of barriers 
for learning might improve further development of screening questions. Long-term sustainability 
of the increased knowledge about OAC and subsequent influence on behavior e.g., adherence 
and save medicines use, need to be addressed in randomized controlled trials. 
 
We acknowledge some limitations. First, the presence of students as observer of a counseling 
with the amended PMC could have triggered community pharmacists to engage more in 
counseling practice than usual (also known as the Hawthorne effect [160]). Second, the semi-
structured interview consists of eight questions which do not cover all educational domains 
important for OAC according to Wofford [61]. However, because this study was not VKA specific, 
topics such as blood-testing and food-drug interactions were omitted on purpose. In further 
studies, different sets of questions for either DOAC or VKA might be adequate. Third, an increased 
knowledge might have occurred at follow-up because the study may have increased patients’ 
awareness of OAC therapy.  
 
4.1 Conclusions 
Our study demonstrated that the majority of chronic patients show knowledge gaps concerning 
their therapy with OAC. Detection of deficient knowledge through the amended PMC triggered 
pharmacists to provide spontaneous education, which in turn increased patients’ medication 
literacy. Patients stated to be more confident about how to take their anticoagulant agent after 
having received counseling through the community pharmacist. Further, patients showed high 
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acceptance of the service. However, adaptions regarding duration and structure of the counseling 
and specific screening questions for patients with VKA or NOAC might be helpful before 
implementing a new pharmacy service in practice.  
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Few studies have examined associations between patient knowledge of direct oral anticoagulants 
(DOAC) and clinical outcomes, mostly because of the lack of validated questionnaires for 
assessing knowledge. The aim of this study was to develop and validate a questionnaire to self-
assess knowledge of DOAC. 
 
Methods  
Twelve anticoagulation experts participated in the questionnaire development process to ensure 
content validity. The Knowledge Of Direct Oral Anticoagulants (KODOA-) test was submitted to 
patients on DOAC and to pharmacists to assess construct validity. Responsiveness was evaluated 
after educational counselling. Test-retest reliability was assessed to ensure stability over time and 
Cronbach’s alpha was calculated for internal reliability. Index of difficulty and item discrimination 
(D-value) were calculated to assess the performance of single items.  
 
Results  
The KODOA-test contains 15 items with multiple-choice answers. Each correct answer scores 1 
point (max. score of 15). The KODOA-test was administered to 32 patients on DOAC and 28 
pharmacists. Pharmacists scored significantly higher than patients at baseline (median score 13.3 
vs. 10.0; p<0.001), supporting construct validity. Patient scores increased significantly after 
educational counselling (median score 11 (IQR 2) vs. 14 (IQR 3); p<0.001). Test-retest and 
Cronbach’s alpha were acceptable with a Pearson’s correlation of 0.8 and an alpha of 0.67. The 
index of difficulty for most items was satisfactory (0.38-0.72) and the mean D-value was 42.5%. 
 
Conclusions  
The KODOA-test is a brief, valid and reliable knowledge self-assessment questionnaire that may 
be used in clinical trials to investigate associations between knowledge increase and patient 
related outcomes.  
 
Keywords: Patient knowledge, direct oral anticoagulants, questionnaire development, 
adherence, validation 
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After a 50 years use of vitamin K antagonists (VKAs) as oral anticoagulant agents (OACs), a new 
class of substances with different mechanism of action, the direct oral anticoagulants (DOAC) also 
called non-vitamin K oral anticoagulants (DOAC), has been developed. DOAC are recommended 
for the prevention and treatment of thromboembolic diseases such as the long-term prevention or 
treatment of thrombosis [161] and the prophylaxis of stroke and systemic embolism in non‐valvular 
atrial fibrillation (AF) [162]. Controlling of blood values is needed to maintain appropriate 
anticoagulation with VKAs due to the narrow therapeutic window, which makes the treatment 
challenging.In contrast to VKA, DOAC do not require routine monitoring, have a fixed dose 
regimen and no restriction on dietary consumption of vitamin K-containing food. Therefore, DOAC 
seem more convenient for patients than therapy with VKAs. In practice, use of DOAC to treat AF 
is increasing [163, 164]. However, due to their short half‐life, DOAC’s anticoagulant effect is likely 
to be rapidly reduced after the omission of one dose when no counterbalancing action is 
undertaken [165]. Thus, DOAC’s daily intake requires a strict timing adherence to ensure 
appropriate therapeutic coverage. Because DOAC do not require consultations for monitoring, the 
opportunity to discuss aspects of adherence with the patient during such encounters will be 
missing. Consequently, other ways of insuring adherence to DOAC are required. 
 
Improvement of knowledge and adherence among patients on OACs, in particular DOACs, is 
needed [154]. For VKAs, enhanced patient knowledge about OACs and the underlying disease 
was associated with improved long‐term adherence or better therapeutic outcomes [81, 82, 166]. 
To study associations between knowledge and adherence, validated questionnaires are needed 
to assess patient knowledge about DOACs. To date, various questionnaires exist that assess 
OAC knowledge. However, only a few have been psychometrically validated, such as the OAK 
[167], the AKA test [168] and the recently published AKT [169]. Only AKT can be used for VKAs 
and DOACs. To our knowledge, there is no specific knowledge assessment questionnaire for 
DOACs available. 
 
The objective of this study was to develop and validate a questionnaire to self-assess patient 
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2.1 Trial design 
The study was initiated by the Pharmaceutical Care Research Group (PCRG) of the University of 
Basel. The study was conducted in accordance with the Declaration of Helsinki and has been 
registered at ClinicalTrials.gov ID NCT03124654. The study was approved by the regional ethic 
committee (Ethikkommission Nordwest- und Zentralschweiz UBE15/126). All patients gave written 
informed consent. 
 
2.2 Development of the Knowledge Of Direct Oral Anticoagulants (KODOA)-test 
 
2.2.1 Literature search 
A systematic literature search in Medline and Embase was conducted in March 2015 to retrieve 
published questions assessing patient knowledge about anticoagulation treatment. The search 
strategy was performed with truncated terms: “Patient* education*” AND “Anticoagulant*” OR 
“Anticoagulation treatment*” OR “Knowledge” and the limits: English language, human, published 
from 2005 to march 2015. Abstracts were screened and full texts were retrieved. Two authors 
(CM, VA) extracted the items of interest. Items regarding VKAs were adapted to DOACs if 
applicable. Consensus was reached by discussion. Swiss summaries of Product Characteristics 
(SPCs), the Updated EHRA Practical Guide on the use of non-vitamin K antagonist anticoagulants 
[113] , the patient guide for taking DOACs from a cardiology patient page [170] and patient 
information leaflets of the 4 in Switzerland authorized DOACs were used to retrieve additional 
content. Items were grouped into the 9 educational topics adapted from [61]: 
1. Underlying disease 
2. Risk-Benefit of treatment 
3. Mode of action 
4. Application and treatment adherence 
5. Accessing health care providers 
6. Relevant blood tests 
7. Medication interactions 
8. Diet and lifestyle 
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2.2.2 Item reduction and content validity 
A panel of experts was created with 12 helath care proffesionals (HCP; 4 nurses, 4 pharmacists, 
4 physicians)  who had experience with DOAC patients.They selected the relevant items for 
patient knowledge of DOAC and determined the extent to which the items represent the construct 
of interest (content validity) [171].  
 
The item reduction occurred with an online survey (2 rounds) followed by a focus group discussion. 
The 9 educational topics (first round) and the single items (second round) were ranked in 
descending order (1st =most relevant, last =most irrelevant topic). The focus group discussion 
aimed at defining which items had to be included in the questionnaire by defining a threshold 
above which the items were perceived as relevant for patient knowledge. Discussion and setting 
threshold occurred by voting until a consensus was found (unanimity). The session was recorded 
and transcribed verbatim. 
 
2.2.3 Answer format 
Answers to the items were developed as multiple-choice format because this is the most 
appropriate and efficient form for assessing cognitive knowledge [79]. One correct and two 
incorrect response alternatives were adapted from the original article when available or newly 
created. Score was defined as 1 for a correct response and 0 for an incorrect or no response. 
Confidence about the given response was assessed with a single question with a yes/no answer 
option. 
 
2.2.4 Educational manual with correct answers as counseling guide 
A manual with referenced correct answers and background information about the reason for 
correctness was generated in order to standardize the education provided to patient. The manual 
is not supposed to be given to patients. The manual starts with an instruction section about how 
to dispense the educational counseling. The HCP is invited to discuss systematically each 
question with the patient. Whenever the patient gave a wrong answer or ticked to be uncertain 
about the question, HCPs are instructed to give the correct answer with background information 
according to the manual. Then HCPs should ask if the issue is clear or if patient needs further 
information. When every question of the KODOA-test has been discussed as described, HCPs 
should ask patient if there are any unanswered questions about their DOAC. Although not part of 
the questionnaire, information about intake time of DOAC was added to cover all instructions 
needed to counsel. The manual was used by two investigators (CM and VA) during counseling 
sessions.  
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2.2.5 Pilot testing 
Comprehension and readability of the finalized KODOA-test was presented to the experts who 
participated in the focus group discussion, and five patients who were not included in the validation 
study. They rated structure, content, comprehension and response alternatives by writing 
commentaries in free text. Adaptions were made accordingly.  
 
2.3 Validation of the KODOA-test 
 
2.3.1 Patient eligibility  
Patients were eligible if they filled a prescription for DOAC (rivaroxaban, edoxaban, dabigatran, or 
apixaban) in a community pharmacy or if a DOAC was present in their medical record, if they 
suffered from atrial fibrillation, deep vein thrombosis, or pulmonary embolism, if they were ≥18 
years old and if they were able to give written informed consent in German. Patients with an 
orthopedic indication for DOACs, with dementia, or lack of written and/or oral understanding in 
German were excluded from the study. 
 
2.3.2 Data collection 
A selection of community pharmacists engaged as experts for the state exams of the University 
of Basel were invited to participate in the research and asked to distribute this invitation to all 
community pharmacists with whom they were working. Three dedicated community pharmacies 
located in Basel and Münchenstein accepted to serve as recruiting places. Pharmacy staff asked 
patients with a prescription for DOACs to participate in the study and handed out the patient 
information and the informed consent forms. Patients who agreed to participate fixed two 
appointments within two weeks at the community pharmacy.  
 
Patients filled in the KODOA-test four times. During the first appointment at the community 
pharmacy (T1), feasibility and acceptability were also assessed. Immediately after patients filled 
in the KODOA-test, they rated on a 4-point Likert scale structure, readability and time to fill in the 
questionnaire, comprehensibility and ambiguity of the items and the available answer options.  
During the second appointment at the community pharmacy patients (T2), patients received 
educational counseling according to the wrong given answers. Immediately after, patients filled 
the KODOA-test a further time (T2+edu). Test-retest was assessed with answers from T1 and T2; 
responsiveness with answers from T2 and T2+edu. 
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Approximately two weeks after T2, patients received the KODOA-test by post mailing (with a paid 
reply envelope) and filled it at home (T3) to assess sustainability of the educational counseling. 
Patient follow-up by the treating physician (general practitioner or cardiologist) took place as usual.  
Patient characteristics were obtained through written survey at T1 and included demographic 
(age, gender, educational background, duration of DOAC therapy) and three health literacy 
questions: Difficulties to understand written information about medication (yes/neutral/no); 
Difficulties to understand verbal information about medication (yes/neutral/no); Confidence when 
filling out forms (yes/neutral/no). One question assessed self-estimated knowledge of DOAC with 
the answer options: bad, moderate, good or excellent. At T3, patients were asked to rate following 
statement on a five point Likert Scale: “After educational counseling I know more about my DOAC” 
(1=I do agree; 5=I do not agree). 
 
A personal letter was sent to 29 pharmacists asking them to answer the KODOA-test without 
consulting additional media and to return it using a pre-paid reply envelope.   
 
 2.4 Statistical methods  
Where appropriate, frequencies, mean and standard deviations or median and interquartile ranges 
are presented. Kruskal-Wallis test was used to compare numerical variables between four groups. 
All data were entered and analyzed using SPSS statistical package version 24.0 (SPSS Inc, 
Chicago, Illinois, USA) and p-values <0.05 were considered significant. 
 
2.4.1 Validation parameters 
Construct validity was tested with the method of contrasted groups [172]. Construct validity would 
be confirmed if the median test score of pharmacists was significantly higher than median test 
score of patients at T1. Mann-Whitney U Test was used to compare numerical data between 
groups. At T2 patients received educational counselling about DOACs and responsivness of the 
KODOA-test was tested. Median test scores before (T2) and after educational counselling 
(T2+edu) about DOACs were compared using Wilcoxon test. 
 
The test–retest method was used to demonstrate the stability of the questionnaire over time. 
Pearson’s correlation coefficient was calculated between the test scores from T1 to T2 and 
T2+edu to T3. Additionally, internal consistency or reliability was assessed using Cronbach’s 
alpha, which indicates whether each item of a scale is appropriate for assessing the underlying 
concept of its scale. Values for Cronbach’s alpha range between 0 and 1; the closer they are to 
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0, the less the items are related to one another. Values between 0.5-0.7 are the minimal 
requirement to indicate satisfactory internal consistency [173]. 
Index of difficulty and item discrimination (D-value) were calculated to assess performance of 
single items. The index of difficulty is defined as the proportion of patients answering the item 
correctly (=number of correct responses/total number of responses). An item with an index of 
difficulty >0.75 is deemed to be too frequently answered correctly [174]. Item discrimination (D-
value) tests how well an item discriminates between people who have a low and high knowledge 
score. A D-value is calculated by subtracting for each item the proportion of respondents 
answering correctly in the lowest quartile from those answering correctly in the highest quartile, 
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Out of 45 compiled items, the expert panel selected 15 to be important for knowledge about 
DOACs. The 15 items were derived from the educational topics “Application and treatment 
adherence” (5 items, nb. 3, 5-8), “Risk-benefit of treatment” (2 items, nb. 2, 4), “Accessing health 
care providers” (2 items, nb. 12, 13), “Self-care” (2 items, nb. 9, 15), “Relevant blood tests” (1 item 
nb. 14), “Medication interactions” (2 items, nb. 10, 11), and “Mode of action” (1 item, nb. 1). Two 
versions of the KODOA-test were developed, one for patients with atrial fibrillation and one for 
patients with deep vein thrombosis or pulmonary embolism. The two versions differed in the 
answer options in items 2, 3 and 4, depending on the underlying disease (Appendix). 
 
Out of 67 invited patients, 32 participated (Table 1). They were prescribed either rivaroxaban 
(84.4%) or apixaban (15.6%). Mean duration of DOAC use was 1.8 ± 1.7 years. Patients had 
mandatory education (n=3), technical/vocational education (n=11), a higher school certificate 
(n=11), University degree (n=4) or did not give any information (n=3). A majority of patients stated 
to have no difficulties to understand written and verbal information about medication and to be 
confident when filling out forms (Table 1). One patient (3.1%) was lost for follow-up (T3) and one 
patient did not fill in the knowledge question for follow-up evaluation. 
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Table 1: Patient and pharmacists characteristics at T1 (baseline) 




Age (years; mean ± SD) 
 
Indication (%) 
   Atrial fibrillation 
   Deep vein thrombosis/pulmonary 
embolism 
 
Duration of therapy (years, mean ± SD) 
 
Comprehension of written information 
about medication (%) 
   Without  difficulties 
   Neutral 
   With difficulties 
 
Comprehension of verbal information 
about medication (%) 
   Without difficulties 
   Neutral 
   With difficulties 
 
Confidence when filling out forms (%) 
   Confidence 
   No confidence  
    
65.5 
 























  6.2 
89.0 
 





Self-estimated knowledge (% of patients, 















KODOA-test scores (mean ± SD) 11.0±4.4 
 
 
8.2 ± 2.4  
 
10.9 ± 2.1 
 
10.5 ± 3.5 
 
Number of ticks “being certain about the  
correctness of the given answer” (mean ± 
SD) 
7.7 ±1.5 9.6 ± 3.4 10.9 ± 2.6 12.5 ± 2.1 
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Feasibility was confirmed. Mean time to fill in the KODOA-test was 7.8 ± 3.0 minutes and patients 





Figure: Patients' answers to questions regarding feasibility of the questionnaire (n=32). 
 
 
Twenty-eight pharmacists (34 ± 9 years, 89% women, 8 ± 9 years working experience) filled in 
the KODOA-test. Median test score of community pharmacists (13.0 (IQR 1)) was significantly 
higher compared to test score of patients (10 (IQR 4)) at T1 (U-Test: p<0.001). Median test score 
of patients at T2 was 11 (IQR 2) and increased significantly to 14 (IQR 3) after educational 
counseling (Wilcoxon: p<0.001). Educational counseling about DOAC lasted 14 ± 7 minutes. The 
median number of items whose answers were correct and ticked as confident was calculated. This 
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Reliability of the KODOA-test was demonstrated. Test-retest reliability between T1 and T2 
(r=0.800, p<0.001; 12 day mean duration between the tests) and between T2+edu and T3 was 
confirmed (r=0.644, p<0.001; 17 days mean duration between the tests) (Table 2). Internal 
consistency was acceptable (Cronbach’s alpha=0.67). Cronbach’s alpha increases slightly (0.673 
to 0.678) if items 3, 5, 6 or 11 are excluded (Table 3). The index of difficulty for most items was 
satisfactory (0.38-0.72) (Table 3). The mean D-value was 42.5%.   
 
 
Table 2: Mean test scores, i.e. correctly answered questions (± SD) at T1, T2, T2+edu (after educational 
counselling) and T3. 






10.03 ± 2.7 
10.06 ± 2.1  
 
13.9 ± 1.2 
13.1 ± 1.7  






NA= not applicable 
a mean duration between tests: 12 days 





There was no relationship between KODOA-test scores at T1 and patient self-estimated 
knowledge of DOAC (Table 1). Patients with higher self-estimated knowledge tended to answer 
with more confidence (Table 1). At T3, all patients agreed that they knew more about their DOAC 
after having received educational counseling. 
  
**
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Name of the DOAC 
Duration of therapy 
Dosing frequency 
Indication for DOAC 
What to do if uncertain whether last dose 
was ingested 
What to do in case of a missed dose 
What to do in case of double dosing 
Does the DOAC work when vomiting 
immediately after ingestion 
Most frequent side effect 
Safest OTC analgesic with DOAC 
Whom to ask about safe OTC 
When to inform others about DOAC therapy 
Recognition of emergencies 
How often to visit the doctor for lab 
monitoring 









































































OTC= Over the counter 
 
6 Project A: Patient knowledge about oral anticoagulation 




The KODOA-test was confirmed to be feasible, comprehensive, reliable and valid to self-assess 
patient knowledge of DOAC. Furthermore, the KODOA-test is responsive to change. Content 
validity was ensured by a developing process with experts of different professions taking care of 
patients undergoing anticoagulation therapy in their daily practice. Construct validity was 
supported by significant differences in scores between patients and pharmacists. Finally, the 
KODOA-test was responsive to educational counseling on DOAC, supporting construct validity. 
Patients were able to complete the test within 8 minutes and rated this time as acceptable. 
Compared to other assessment questionnaires for knowledge about oral anticoagulation therapy 
the KODOA-test is relatively brief. The AKT and AKA assessment questionnaires need 10-15 
minutes and 20 minutes to be filled in, respectively [168, 169].  
The index of difficulty of most items and mean D-value was satisfactory. Although six items 
showed a poor level of difficulty, they were retained because they are related to core information 
about DOAC therapy, such as name, treatment duration or whom to ask in case of pharmaceutical 
questions. The KODOA-test showed moderate internal consistency, with a Cronbach’s alpha of 
0.67. The obtained Cronbach’s alpha value is likely a result of the multifactorial nature of the 
KODOA-test, because it consists of items derived from several educational topics. Omission of 
single items had minimal effect on Cronbach’s alpha. The KODOA-test included very easy items 
and very difficult items. Despite the fact that such grade of difficulty tends to decrease the internal 
consistency of the scale [175], HCPs need basic questions on the medication used by the patient 
such as dosing frequency. Finally, a low Cronbach’s alpha might be explained by the shortness 
of KODOA-test with 15 questions, since internal consistency increases as test length increases 
[176]. Therefore, an alpha of 0.67 seems acceptable. 
 
Stability over time was confirmed by test-retest correlation above the threshold of 0.7, which 
indicates adequate reliability [177]. The mean time between test and re-test was 12 days. 
Recommendations for interval between two identical tests vary between two days [175] and three 
months [178]. Two studies investigating knowledge about anticoagulation with questionnaires had 
longer interval of two to three months for test re-test [167, 169] and two further studies on 
knowledge about nutrition had intervals of two weeks [179, 180]. We selected a short time interval 
based on ethical considerations, because patients with deficient knowledge should be corrected 
as soon as possible in order to avoid life threatening situations. Knowledge scores remained high 
after approximately two more weeks demonstrating the sustainability of the educational 
counselling. In addition, patients agreed uniformly that their knowledge had increased. 
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Nevertheless, further follow-ups could be useful to maintain a high level of knowledge. State of 
the art currently in Switzerland and in many other countries is silo interventions from several HCPs. 
It would be best practice to share information and questionnaire results between HCPs. 
 
The majority of patients rated their knowledge about DOACs at baseline as good or excellent. 
However, this self-estimation did not correspond to KODOA-test scores suggesting that patients 
both overestimate and underestimate their knowledge. Consequently, self-estimation of 
knowledge with a single question should be taken with caution. Further, asking confidence when 
answering the item is subject to the same under- and overestimation. However, because of the 
low number of patients in the bad and excellent self-estimated knowledge groups, this finding 
needs further investigation. 
 
Interestingly, patients’ scores after educational counselling were still below the maximum with an 
average of 1.9 erroneous answers. The items concerning safety issues (missed dose, double 
dosing, vomiting) seemed difficult to remember. HCPs should be aware that some 
pharmacological concepts are more demanding than others.  
Previous studies observed an increase of knowledge about oral anticoagulation therapy following 
education [181-184]. However, only one study included patients with DOACs, but knowledge 
assessment methods were not developed for patients on DOAC therapy [181]. In a recent study, 
the development of an oral anticoagulation knowledge questionnaire was reported [169]. The AKT 
contains 20 items applicable for DOAC patients and 8 additional items for VKA patients. Overall, 
the AKT seems to be a valid and reliable questionnaire to measure patient knowledge about oral 
anticoagulants. However, it is not reported whether the AKT is responsive to change and scoring 
seems more complicated as with the KODOA-test. In light of these inconveniences, KODOA-test 
is likely to be easier to use in patient studies.  
 
Our study has several strengths. First, we followed an evidence-based approach to select items. 
We coupled a literature search to educational theory to reduce the number of items to the minimum 
needed to assess knowledge. Second, we used the most recent publication such as the EHRA 
guidelines to cover exhaustively the characteristics of anticoagulation therapy. Third, we selected 
experts in all fields of the health care professions to determine the relevant items needed in a self-
assessment questionnaire. Fourthly, we tested pharmacists as representatives of health care 
professionals. We are confident that similar knowledge results would have been obtained with 
doctors and nurses. Finally, we developed a manual with answers to obtain standardization of 
6 Project A: Patient knowledge about oral anticoagulation 
    
72 
 
educational counseling. By doing so, we offer a fast and efficient way of counseling to all 
healthcare professionals who provide information for patients. 
 
We acknowledge some limitations. First, 52.3% of the patients refused to participate in the study. 
Time consumption (i.e. two visits at the community pharmacy) was likely the reason of this 
moderate acceptance rate, rather than a low acceptability to answer the KODOA-test. Secondly, 
the relatively small number of subjects may limit the ability to generalize results to all patients on 
DOAC. Importantly, sample size was adequate to show that the KODOA-test is responsive to 
change and that construct validity is given (data not shown). Thirdly, this study included elderly 
Swiss German speaking patients with an indication of AF or DVT/PE and taking rivaroxaban or 
apixaban that is, only two of the four commercially available DOACs in Switzerland. Because the 
KODOA-test targets DOAC knowledge in general that is, independently of the anticoagulant 
agent, we cannot think that patients on other anticoagulants (i.e. edoxaban or dabigatran) or in 
another setting (i.e. after surgery) would have answered differently. Applicability of the KODOA-
test in other settings should nevertheless be investigated in a further study. Finally, the multiple-
choice format permits guessing, which may have increased scores in patient and pharmacist 
group.   
 
Conclusions 
The KODOA-test showed to be valid and reliable in Swiss German speaking elderly outpatients 
taking DOAC. The application of the KODOA-test in other populations needs confirmation by 
further research. To our knowledge, the KODOA-test is the first validated questionnaire specific 
for patients taking DOAC that is responsive to educational counseling. Therefore, the KODOA-
test could be used in clinical trials where associations between knowledge of DOAC and 
adherence or clinical outcomes are of interest. 
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Assessment of the impact of type 2 diabetes (T2DM) and metformin use on vitamin B12 (VB12) 
associated biomarkers and their suitability to represent VB12 supply. 
 
Methods  
Differences of VB12, holotranscobalamine (HoloTc), the biologically active fraction 
%AB12=HoloTc/VB12*100 and homocystein (Hcy) were analysed i) among diabetic outpatients 
with (DMMet+) and without metformin use (DMMet-) and ii) in comparison to an external non-
diabetic reference group with low VB12 (<200pmol/L). 
 
Results  
VB12 associated biomarkers were distributed equally between T2DMMet+ (n=29, 58%) and 
T2DMMet- (n=21, 42%). Significant differences in %AB12 in diabetic patients with low VB12 
(n=19) compared to the non-diabetic reference group (n=31) were found. Higher %AB12 was 
associated with diabetes. Hcy levels were significantly associated with age, folic acid level, renal 
function and HoloTc but not with VB12. 
 
Conclusions  
In T2DM patients with low VB12, %AB12 was confirmed as being higher in comparison to 
nondiabetic patients. The effect was not clearly attributable to metformin use. HoloTc was 
unaffected by the lowering of VB12 and significantly associated with the functional marker Hcy. 
Both findings support the use of HoloTc for the assessment of VB12 supply in diabetic patients. 
 
Keywords: T2DM, metformin, vitamin B12 deficiency, vitamin B12, holotranscobalamine 
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Recently, an increased frequency of VB12 deficiency among T2DM patients has been 
documented by several cross sectional studies and case reports [185]. Clinically, VB12 deficiency 
in adults may result in nonspecific symptoms such as tiredness, loss of appetite, hematologic 
manifestations (megaloblastic anemia), neurologic symptoms (e.g. polyneuropathy, ataxia), as 
well as symptoms of a psychiatric nature (e.g. depression) [119, 130]. Additionally, cardiovascular 
manifestations associated with hyperhomocysteinemia were mentioned [186-189]. 
Clinical symptoms of VB12 deficiency in T2DM are comparable to those in the general population. 
Worsening of diabetic neuropathy has been described among patients with co-existing vitamin 
B12 deficiency. Furthermore, VB12 replacement has been shown to cause symptomatic 
improvement, reduction in pain, and paranesthesia among patients with severe diabetic 
neuropathy [185] , suggesting that functional VB12 deficiency in T2DM patients is clinically 
significant. Sensory polyneuropathy caused by VB12 deficiency mimics diabetic neuropathy [190]. 
Overlapping symptoms between T2DM and VB12 deficiency may complicate its clinical suspicion 
(or diagnosis). Biochemically, VB12 deficiency is characterized by subnormal to borderline VB12 
values in serum (<148-221 pmol/l) [122]. Holotranscobalamine (HoloTc) is the bioactive form of 
VB12 and makes up to 20% of the total vitamin B12 concentration in the human body [123]. It has 
been discussed as a more specific and sensitive marker of VB12 deficiency [124-126]. Broad 
ranges of cut-off points for HoloTc have been described as <20 – 50pmol/l [127]. Functional VB12 
deficiency is characterized by elevated homocysteine (Hcy) and/or methylmalonic acid (MMA) 
levels [122].  
Additionally, the clinical biochemistry of VB12 is influenced by diabetes and its treatment. 
Systematic observations in clinical trials as well as biochemical studies in animals raised questions 
on possible interactions between diabetes, metformin treatment, and VB12 metabolism. It has 
been proposed that the increased oxidative stress in diabetes is involved in the pathogenesis of 
functional VB12 deficiency [128]. Treatment of T2DM patients with metformin has been reported 
with reductions of 10-20% in plasma VB12 levels [191-195]. Metformin may impair VB12 
absorption and thereby induce VB12 deficiency [195, 196]. One study described the correlation of 
cumulative metformin dose, low VB12 levels and clinically more severe peripheral neuropathy 
[190]. Given the widespread use of metformin as first line treatment for patients with diabetes and 
normal kidney function, its effect on VB12 metabolism is remarkable [197]. Metformin is a 
biguanide. It’s mechanism of action primarily involves decreasing hepatic glucose production and 
increasing glucose uptake [198]. Because VB12 deficiency is a reversible cause of demyelinating 
nervous system disease and bone marrow failure, its early detection and treatment are important 
[130].  
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Therefore, the identification of metformin as a risk factor for the development of VB12 deficiency 
is important and the evaluation of VB12 status is recommended [199]. However, there is 
reasonable doubt whether the reductions of VB12 levels reflects a true decrease in VB12 supply. 
A recent study in patients with diabetes (> 65 years old) which were treated for 3 months with 
metformin showed that the inactive part of VB12 bound to haptocorrin is reduced in metformin-
treated patients but not in the control group (non significantly) [200]. Additionally, a study in rats 
found that metformin treatment increases liver accumulation of VB12 thereby resulting in 
decreased circulating VB12 and kidney accumulated VB12 [201]. The same authors found a 
significant reduction of serum VB12 but not HoloTc after 6 months of metformin treatment in 
women with polycystic ovarian syndrome (PCOS) [129]. These findings raise the question of 
whether low serum VB12 observed in patients treated with metformin actually reflects VB12 
deficiency and rather supports the hypothesis of altered metabolism of VB12 in metformin-treated 
patients.  
In this study, the effect of metformin treatment on VB12 status as reflected by total VB12 and 
HoloTc in T2DM patients is investigated. In particular, the %AB12 in T2DM patients with and 
without metformin treatment was compared and interactions between VB12, HoloTc and 
homocystein were analysed. Additionally, the impact of diabetes itself on VB12 associated 
biomarkers at low VB12 levels is investigated in a subgroup of patients with diabetes in 
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Materials and methods  
This was an observational cross-sectional trial approved by the ethics committee of northwestern 
Switzerland (EKNZ), and was registered at ClinicalTrials.gov NCT02111967. The study was 
conducted in accordance with the Declaration of Helsinki and correspondent to International 
Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines. All patients gave 
written informed consent. Patients for the external reference group were included from a previous 
study (ClinicalTrials.gov NCT01832129). The primary hypothesis was that VB12 would be lower 
in T2DM patients treated with metformin while HoloTc levels would not differ compared to T2DM 
patients without metformin treatment.    
  
Setting 
The study included adults with type 2 diabetes and an external reference group of nondiabetic and 
metformin-naïve patients. Patients with T2DM were classified as metformin users (DMMet+) if 
they were treated with metformin for at least 6 months or as metformin-naïve patients      (DMMet-
), when no prior use of metformin was reported (Figure 1; A). Participants with newly initiated 
metformin (< 6 months usage), concurrent intake of preparations containing VB12 (in the last 3 
months), diagnosis of transcobolamin transporter defect, diagnosis of vitamin B6 deficiency, 
diagnosis of liver disease with CHILD-PUGH scores B and C, acute hepatitis and diagnosis of 
alcohol abuses (defined as a diagnosed condition or by self-reported daily intake of alcohol), 
diagnosis of renal insufficiency stadium III, IV and V (KDOQI), acute renal diseases or renal 
function below 60ml/min according to the Cockroft Gault’ equation were excluded from the study. 
For the reference group data from patients from a previous study were used [136]. Out of 37 
patients 4 were excluded due to an alcohol use disorder (n=4).(Figure 1). 
 
Patient Recruiting 
Patients with diabetes with (DMMet+) and without metformin treatment (DMMet-) were recruited 
during a routine visit at their diabetes specialist (Figure 1; sample A). Patients with diabetes and 
serum VB12 levels below 200pmol/L were classified as VB12 deficient (LVB12-DM). The external 
reference group of non-diabetic patients with low VB12 levels (LVB12-Ref) was established from 
a previously published study that recruited outpatients during a routine visit to their general 
practitioner. If patients had a diagnosis of diabetes, they were not excluded but assigned to the 
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Questionnaires and physical examinations 
Patients were asked to fill in a questionnaire about their nutrition, co-medication and 
demographics. Patients with type 2 diabetes were screened for neuropathy signs using the 
Neuropathy Symptom Score (NSS) and the Neuropathy Disability Score (NDS) [202].  
 
Pharmacological biomarker 
All venous blood samples were analyzed for VB12 (Beckman Coulter® DxC 860i), HoloTc (Abbott 
Architect® i2000SR) and Hcy (Roche Cobas® 6000). The biologically active fraction %AB12 was 
calculated by dividing HoloTc/VB12*100. Blood cell count was determined on a Beckman Coulter 
DxH 800. Cut-off values defining VB12 deficiency were VB12: <200pmol/L, HoloTc: <37pmol/L 
and Hcy :> 15mol/L. Blood samples of patients with VB12 levels below <200pmol/L were re-




Based on published data, patients with diabetes were assumed to display VB12 levels of 
approximately 400 pmol/l, with an estimated standard deviation of 250 pmol/l (62.5%) [203]. In 
this study, 40.1% of patients had consumed VB12 supplements; therefore, we concluded that the 
standard deviation among patients without VB12 supplements was approximately half of the 
observed standard deviation (30%). A reduction in plasma VB12 levels of 20%-24% is described 
in the scientific literature [200]. Since we expected a reduction in levels, a one-tailed test was 
applicable. Based on a reduction of VB12 levels of 24%, a total of 50 samples had had to be 
analysed to ensure that the 80% confidence interval includes the true difference of means with a 
α-significance level of 5%. 
 
Statistical analysis 
Values are given as medians with quartiles and percentages where appropriate. Frequencies were 
analyzed using Chi‐square tests or Fishers test. The Mann‐Whitney test was used to compare 
numerical variables between two groups. Bivariate correlation was performed when association 
between two scaled variables was assessed. A p-value ≤0.05 was considered significant. Multiple 
linear regression analyses were conducted to calculate i) the relative impact of VB12 and HoloTc 
on Hcy in relation to age, renal function assessed as estimated Glomerular filtration rate (eGFR) 
according to the Cockroft-Gault’ equation, and folic acid levels and ii) the relative impact of 
diabetes, age, BMI, renal function and folic acid levels on VB12/HoloTc ratio using a stepwise 
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method to include the independent variables. The statistical procedures were performed with 
SPSS statistical software Version 24 (SPSS Inc., Chicago, Il, USA). 
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Between March 2014 and August 2014, 50 outpatients with diabetes were recruited within the 
endocrinology unit. Recruitment and patient characteristics of the external reference group have 
been described elsewhere [136]. Two of the 37 recruited subjects in this study had diabetes and 
were thus integrated in the respective subgroup for the analysis of VB12 associated biomarkers 
in diabetes (Figure 1). Patient characteristics of T2DM patients (29 DMMet+; 21 DMMet-) were 
equally distributed (Table 1). 
 
 
Figure 1. Sample A) Patients recruited by the diabetologist. Comparison of VB12, HoloTc and 
VB12/HoloTc-ratio between DMMet+ and DMMet- and assessment of associations between VB12, HoloTc, 
Hcy and severity of neuropathy. Sample B) Patients with low VB12 (<200pmol/L) recruited by diabetologist 
and general practitioners. Comparison of VB12, HoloTc and VB12/HoloTc-ratio between LVB12-DM and 
LVB12-Ref. 
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Table 1: Patient characteristics of sample A and potential risk factors for the development of VB12 
deficiency of DMMet+ group and DMMet- group. Parameters are given as median and 25/75 
percentiles if not otherwise indicated. 
 
DMMet+ (n=29) DMMet- (n=21) p-value 
Age (years) 60 (53/70) 64 (55/72) 0.42 
Women (%) 44.8 38.1 0.43 
BMI (kg/m2) 30.9 (24.9/40.6) 33.8 (30.2/37.8) 0.33 
Years with diabetes 7 (4/15) 12.5 (5.5/20) 0.10 
HbA1C (%) 7.7 (6.7/8.4) 8.7 (6.9/9.8) 0.17 
NSS+NDS 6.5 (2.8/11.3) 11 (5.3/14.8) 0.09 
eGFR (Cockroft Gault) 115 (78.4/160.4) 116 (74.7/157) 0.78 
Proton-pump inhibitors use 
(%) 
6.9 19.0 0.22 
Antacid and H2 Blocker use 
(%) 
0 0 - 
Vegetarians (%) 6.9 0.0 0.33 
Vegans (%) 0.0 0.0 - 
 
 
VB12 associated biomarker levels in diabetes patients (sample A) 
DMMet+ versus DMMet- 
Vitamin B12 serum levels and HoloTc levels were slightly lower in DMMet+ patients compared to 
DMMet-, but not significantly (VB12: -10.4%; HoloTc: -9.2% Table. 2). The %AB12, Hcy and blood 
count levels were equally distributed between the two groups (Table 2). Out of 50 patients, 17 
(34%) had a VB12 value below 200pmol/L (11 DMMet+ (39.3%) and 6 DMMet- (28.6%); Fishers-
test: 0.55), 3 (6%) had a HoloTc value below 37pmol/L (3 DMMet+ (10.3%) and 0 DMMet- (0%); 
Fishers-test: 0.25) and 16 (32%) had a Hcy level above 15µmol/L (10 DMMet+ (34.5%) and 6 
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Table 2: VB12 associated biomarker and blood count levels of DMMet+ and DMMet- groups. 
Parameters were given as median and 25/75 percentiles, respectively. 
 
DMMet+ (n=29) DMMet- (n=21) p-value 
VB12 (pmol/L), Beckman 224 (163/263) 250 (190/344) 0.19 
HoloTc (pmol/L) 79.9 (46/102) 88 (68/111) 0.09 
%AB12 30.1 (25.0/40.8) 35.4 (29.5/39.6) 0.32 
Hcy (µmol/L) 12.9 (11.3/17.5) 11.8 (10.5/19.3) 0.55 
Hb (g/L) 142 (133/154) 145 (139/152) 0.71 
MCV (fL) 90 (88/93)  93 (88/96) 0.12 
MCH (pg)  30 (29/31) 31 (30/32) 0.07 
 
Correlations of VB12 associated biomarkers 
Significant correlations (p<0.05) of VB12 levels with age (r=-0.42) and Hcy (r=-0.37) were found 
for the entire study population, as well as with metformin dose (-0.43) and renal function (r=-0.41) 
in DMMet+ patients. For HoloTc significant correlations were limited to Hcy (r=-0.44) and 
Metformin dose (r=-0.47) in DMMet+ patients. High Hcy levels were associated with high age 
(r=0.35), low renal function (r=-0.48) and low folic acid levels (r=-0.36) in the entire study 
population. Mean daily metformin dose in DMMet+ group was 1.9g ±0.6g (range: 1.0g - 3.0g). 
 
Prediction of Hcy levels 
In a multiple linear regression model, a significant association of Hcy with age (β=0.325; p=0.029), 
folic acid (β=-0.359; p=0.003), HoloTc levels (β=-0.300; p=0.01), and renal function expressed as 
eGFR by Cockroft-Gault (β=-0.343; p=0.014) was found in all DM patients (r2=0.539; p=0.022), 
while no significant association of VB12 with Hcy was observed.  
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VB12 associated biomarker levels according to the severity of neuropathy 
Neither VB12, HoloTc nor Hcy differed significantly between patients with mild, moderate, and 
severe symptoms of neuropathy (Figure 2). Age and diabetes duration were significantly higher in 
patients with severe neuropathy compared to patients with mild neuropathy. 
 
Figure 2: Median levels with 95% confidence intervals of VB12 (pmol/L), HoloTc (pmol/L), Hcy (µmol/L), 
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Analysis in patients with low VB12 levels (sample B) 
LVB12-DM versus LVB12-REF  
Diabetes patients with low VB12 (LVB-DM) were compared with a non-diabetic reference group 
(LVB-Ref). In the LVB-Ref group, a trend towards higher HoloTc level and significantly higher of 
%AB12 was found (Table 3). Patients in the reference group were younger and had a significantly 
lower mean BMI (Table 3).  
 
Table 3: VB12 associated biomarker and blood count levels of sample B. Parameters were given as 
median and 25/75 percentiles, respectively when not otherwise indicated. 
LVB-DM (n=19) LVB-Ref (n=31) P-value 
Women (%) 50 % 71% 0.22 
Age (years) 65 (57/74) 47 (30/60) 0.001 
BMI (kg/m2) 29.6 (24.4/34.2) 24.4 (22.6/29.0) 0.02 
VitB12 (pmol/L), Roche 162.0 (140/ 178) 164.0 (149/177) 0.75 
HoloTc (pmol/L) 53.2 (42.0/ 78.1) 43.0 (32.1/62.2) 0.08 
%AB12 32.1 (25.5/48.5) 27.7 (21.5/40.0) 0.04 
Hcy (µmol/L) 13.4 (11.0/17.3) 11.9 (9.8/15.3) 0.40 
HB (g/L) 134 (131/143) 136 (127/144) 0.98 
MCV (fL) 90 (87/93) 92 (90/96.0) 0.74 
       
Prediction of %AB12 in patients with low VB12 
A multiple linear regression showed a significant association of %AB12 with diabetes (β=-0.336; 
p=0.02; r2=0.092; p=0.023), whilst no significant associations of the %AB12 with age, BMI, renal 
function expressed as eGFR (Cockroft-Gault) or folic acid levels were observed.  
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In our study neither VB12, HoloTc nor %AB12 differed between T2DM patients regardless of 
metformin treatment. Median VB12 and HoloTc levels were within the normal range in both 
groups. Therefore, the primary hypothesis that VB12 levels would differ while HoloTc levels would 
be indifferent between T2DM patients with or without metformin treatment had to be rejected. 
Metformin treatment alone did not explain the altered VB12 metabolism as reflected by VB12 and 
HoloTc serum levels in all T2DM patients, as suggested by the literature [129, 201]. Nevertheless, 
the proportion of patients in the DMMet+ group with low VB12, low HoloTc, or high Hcy was higher 
compared to DMMet- group (not significant). Additionally, metformin dosage did negatively 
correlate with VB12 and HoloTc levels. These findings suggest that metformin may contribute to 
VB12 deficiency.  
Further analysis focused on VB12-deficient subgroups and included non-diabetic patients. In this 
sample (B), a significant difference of the %AB12 was observed and confirmed by multiple 
regression analysis. However, the model explained only 9.2% of the variance observed. These 
results suggest that VB12 metabolism is affected by diabetes itself as well as by other factors, 
which were not included in the model. It has been proposed that duration of VB12 deficiency and 
causes of VB12 deficiency play a major role in the VB12/HoloTc ratio [204], such as liver diseases 
[205] and in particular alcoholism [206]. In this study, patients with liver diseases and/or alcoholism 
were excluded. Duration of a VB12 deficiency can hardly be assessed in an observational study; 
therefore, interventional studies might be favorable to continue research on VB12 metabolism. 
Multiple regression analysis showed that T2DM in general had an impact on %AB12. Further 
observations regarding the impact of metformin in T2DM patients with low VB12 had a high 
variance (data not shown) due to the relatively small sample (17 T2DM patients; 11 DMMet+ and 
6 DMMet) and therefore were not taken into account. Thus, larger studies may be necessary to 
differ whether the altered VB12 metabolism is attributable to diabetes in general or specifically to 
metformin use.  
 
HoloTc has been proposed as a better marker to detect VB12 deficiency compared to serum VB12 
[207, 208] in an aged population [209]. We found significant inverse correlations of VB12 and 
HoloTc with Hcy, a functional marker of VB12 deficiency. Although, the effect was stronger 
between VB12 and Hcy compared to HoloTc and Hcy, stepwise multiple regression analysis 
included HoloTc as independent variable to explain variance in Hcy levels and not VB12. Thus, 
HoloTc seems favorable compared to VB12 to predict hyperhomocysteinemia caused by VB12 
deficiency in T2DM patients. Therefore, our results support the finding that HoloTc might be a 
better marker than VB12 to detect VB12 deficiency. Furthermore, regression analysis showed that 
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in our sample, elevated Hcy was also explained by age, folate deficiency or renal insufficiency, 
thus compromising its value as an independent reference for VB12 deficiency. Other studies found 
inverse correlations between GFR and Hcy within patients with normal renal function also [210, 
211]. Metabolism of methylmalonic acid, another functional biomarker of VB12 deficiency, is not 
affected by vitamin B6 or folic acid. Therefore, measurement of methylmalonic acid might be more 
sensitive in detecting VB12 deficiency than Hcy. However, methylmalonic acid levels may be 
compromised in patients with reduced GFR, too [212].  
Results from a previous study questioned whether low VB12 in metformin-treated patients with 
diabetes causes a true or functionally irrelevant cobalamin deficiency [129]. Interestingly, in our 
study significant inverse correlations of Hcy with VB12 and HoloTc were exclusively found in 
DMMet+ patients. Meaning that even though VB12 levels were comparable within all DM patients, 
low VB12 and HoloTc levels did cause functional deficiency in DMMet+ but not in DMMet-. An 
explanation for this finding might be that no true VB12 deficient DMMet- patients were included in 
our study, supported by the fact that no HoloTc below 37pmol/L was found in DMMet- group. 
Furthermore, our data suggest that metformin induces VB12 deficiency in a dose dependent 
manner. Other studies also found associations between metformin dose and VB12 levels [210, 
213]. Thus, it is reasonable to screen patients treated with metformin for VB12 deficiency, as 
proposed [214]. In a future study, inclusion of anemic patients might help to clarify whether the 
elevation of functional markers results from of VB12 deficiency or from impaired GFR and whether 
low VB12 and/or HoloTc coincide with anemia.  
VB12, HoloTc or Hcy levels did not differ in patients with mild, moderate or severe symptoms of 
neuropathy assessed with the NSS and NDS, while, well-established risk factors such as age and 
duration of diabetes differed between groups. While some studies showed associations between 
neuropathy, VB12 associated biomarkers, and metformin use [190, 215], others failed to find such 
correlations [216-218], making results controversial, overall. 
Controversy might exist because a range of different assessments for neuropathy and differences 
in study designs exist. The observed incidence of a VB12 deficiency in this study was high (34%). 
Irreversible neurologic damage caused by VB12 deficiency is preventable through treatment [130, 
190], at relatively low costs, and has few side effects. Therefore, screening for VB12 deficiency 
independently from diabetic neuropathy seems reasonable.  
 
We acknowledge some limitations. First, our sample size calculation was based on bigger 
difference in VB12 levels between T2DM patients with and without metformin. However, the 
prevalence of patients having VB12 deficiency defined as VB12 below 200pmol/L (34% (DMMet+ 
(39.3%) and 6 DMMet- (28.6%)) we observed is comparable to what is described for elderly users 
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[219, 220]. Therefore, differences in VB12 associated biomarkers may also be observed within all 
DM patients when more patients were included. Second, the assessment if HoloTc or VB12 might 
be better to detect VB12 deficiency was only based on a laboratory marker (Hcy levels). In this 
study non-anemic patients were included and therefore clinical symptoms where not taken into 
account. Further studies should include anemic patients and assess methylmalonic acid.  
 
Conclusion 
The clinical biochemistry of VB12 in T2DM patients with scarce VB12 supply is modified in 
comparison to nondiabetic patients. This results in higher %AB12 due to reduced VB12 levels. It 
needs to be clarified whether this effect is due to diabetes itself, metformin treatment, and/ or a 
combination of other heath related situations. Assessment of HoloTc seems favorable compared 
to VB12 to predict hyperhomocysteinemia caused by VB12 deficiency in T2DM patients. This may 
be a direct consequence of the modified %AB12 in T2DM patients, which strengthens the 
recommendation to assess VB12 supply in clinical practice by measuring HoloTc. VB12, HoloTc, 
and Hcy did not differ in patients with mild, moderate or severe symptoms of neuropathy.  
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Treatment of vitamin B12 (VB12) deficiency can be performed with oral high-dose substitution of 
VB12 or by intramuscular (i.m.) injection. Whenever alternative routes of administration exist, 
patient preferences should be given consideration when choosing the treatment. We aimed at 
assessing outpatient preferences towards oral or i.m. VB12 substitution and confirming non-
inferiority of early biomarker response in the oral treatment of a typical primary care population. 
  
Methods 
Prospective randomized unblinded parallel group trial. Patients were recruited by their general 
practitioner and randomly assigned to oral or i.m. treatment. Group O-oral was given 28 tablets of 
1000 µg cyanocobalamin in a monthly punch card fitted with an electronic monitoring system. 
Group I-i.m. received 4 weekly injections of 1000 µg hydroxocobalamine. Blood samples were 
drawn before the first administration, after one, two and four weeks of treatment and analyzed for 
VB12, holotranscobalamine (HoloTc), homocysteine (Hcy) and methylmalonic acid (MMA). For 
group O-oral, taking adherence and percentage of days with ≥ 2 dosing events were calculated. 
Before and after 28 days of treatment, patients were asked to fill in a questionnaire about their 
preference to the therapy options and associated factors.  
 
Results 
Between November 2013 and December 2015, 37 patients (age: 49.5 ± 18.5 years; women: 
60.5%) were recruited for oral (19) or i.m. (18) treatment. Baseline values with 95% confidence 
interval for serum VB12, HoloTc, Hcy and MMA were 158pmol/L [145-172], 49.0pmol/L [40.4-
57.5], 14.8μmol/L [12.0-17.7] and 304nmol/L [219-390], in group O-oral and 164pmol/L [154-174], 
50.1pmol/L [38.7-61.6], 13.0μmol/L [11.0-15.1] and 321nmol/L [215-427], group I-i.m, respectively 
(p=ns). After one month of treatment, levels of VB12 and HoloTc showed a significant increase 
compared to baseline (group O-oral: VB12: 354pmol/L [298-410] and HoloTc: 156pmol/L [116-
196]; group I-i.m.: VB12: 2796pmol/L [1277-4314] and HoloTc: 1269pmol/L [103-2435]). Further, 
Hcy and MMA levels showed a significant decrease compared to baseline (group O-oral: Hcy: 
13.8μmol/L [10.7-16.8] and MMA: 168nmol/L [134-202]; group I-i.m: Hcy: 8.5μmol/L [7.1-9.8] and 
MMA: 156nmol/L [121-190]). HoloTc and MMA levels were normalized by all patients at V28, 
whereas normalization of VB12 and Hcy was reached only by all patients in group I-i.m. Response 
in VB12, HoloTc and Hcy was more pronounced in group I-i.m. (p<0.01) and the primary 
hypothesis that oral VB12 treatment would be non-inferior to i.m. treatment had to be rejected. 
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Average taking adherence was 99.6 ± 1.1% and days with ≥2 dosing events reached 5.6%. Before 
randomization, preference was in favor of oral treatment (45.9%, n=17) compared to i.m. 
administration (21.6%, n=8). Twelve patients (32.4%) had no preference. Nine (24.3%) patients 
changed their preference after treatment. Patients who obtained their preferred route of 
administration maintained their preference in case of oral treatment and changed their preference 
after i.m. treatment.  
 
Conclusions 
Differences in VB12 levels between groups were higher than expected. Therefore, non-inferiority 
of oral treatment had to be rejected. However, normalization of HoloTc and MMA was reached by 
all patients after a one-month treatment. The clinical benefit of exaggerated biomarker response 
after i.m. treatment within a typical primary care population is questionable. Therapeutic schemes 
should be chosen with the consideration of mid-term biomarker effects and patient preferences. 
Initial rating in favor of either i.m. or oral therapy can change over time and justifies repeated re-
evaluation of patient preferences. (ClinicalTrials.gov ID NCT01832129) 
 
Keywords: vitamin B12 supplementation, vitamin B12 oral, oral versus intramuscular, cobalamin 
supplementation, patient preferences 
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Depending on the used definition, prevalence of vitamin B12 (VB12) deficiency is between 8-16% 
and 5-40%, among adults (26-64 years) [221] and in elderly [219], respectively. However, the true 
prevalence of VB12 deficiency in the general population is still uncertain but is known to rise with 
age, probably because of an impaired absorption [121, 222].  
 
Causes for VB12 deficiency can be divided into nutritional [223, 224], malabsorption syndromes, 
and other gastrointestinal causes [223]. Pernicious anemia typically presents with hematological 
signs and is associated with antibodies to intrinsic factor and/or parietal cells, but accounts for 
only a small proportion of the observed cases of VB12 deficiency [225]. Furthermore, defective 
transport mechanisms due to genetic factors account for a very small proportion of the disease 
[119]. Long-term treatment with acid-lowering agents [226, 227] and metformin [199] may also 
play a role in the development of VB12 deficiency.  
 
Clinical symptoms of VB12 deficiency are numerous. Besides nonspecific symptoms such as 
tiredness and a loss of appetite, manifestation of hematologic (megaloblastic anemia), neurologic 
(e.g. polyneuropathy, ataxia), as well as symptoms of a psychiatric nature (e.g. depression) are 
possible [119, 130]. Additionally, cardiovascular manifestations which come along with 
hyperhomocysteinemia are mentioned [186-189]. Because VB12 deficiency is a reversible cause 
of demyelinating nervous system disease and bone marrow failure, its early detection and 
treatment are important [130]. 
 
Indications for VB12 supplementation is VB12 deficiency with various causes (e.g. pernicious 
anemia, gastrectomy, dietary deficiency). [130] In addition, preventive treatment should be 
initiated in pure vegetarians, pregnant women on Mediterranean diet, patients with gastric surgery 
and Nitrous oxide exposure[122]. However, there are no official threshold concentrations when to 
initiate treatment. Biochemically, VB12 deficiency is characterized by subnormal to borderline 
serum VB12 levels. Holotranscobalamine (HoloTc) is the bioactive form of VB12 and has been 
discussed controversially as a more specific and sensitive marker of VB12 deficiency [124-126]. 
Functional VB12 deficiency is characterized by an increase of methylmalonic acid (MMA) and/or 
homocysteine (Hcy). Functional testing is recommended when VB12 deficiency is highly 
expected, levels of serum VB12 are moderately low (148 to 221 pmol/L), in patients with 
unexplained macrocytosis or other unexplained neurologic issues and when VB12 deficiency is  
highly suspected to be the reason for a treatable cause of dementia[122]. Further laboratory                       
finding and  
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findings are hematological abnormalities such as macrocytosis, pancytopenia and 
hypersegmented neutrophils. Hematological changes can be found in the more severe cases, 
while biochemical findings go in parallel with less specific clinical manifestations of VB12 
deficiency. However, no clear-cut limits exist for the prediction of symptoms [130]. Subclinical 
VB12 deficiency occurs and is found in up to 10-25% of the aged population. Treatment of these 
patients is common, even though the long-term benefits of such treatment are unclear [122].  
 
The treatment of VB12 deficiency consists of VB12 supplementation which can be performed 
either orally or by intramuscular (i.m.) injections. Patients with severe VB12 deficiency should 
receive injections of 1000 μg VB12 at least several times per week for 1 to 2 weeks, then weekly 
until clear improvement is shown, followed by monthly injections [122, 130]. Initial oral treatment 
with high dose VB12 can be considered in patients with mild malabsorption or dietary deficiency 
[130] Given the unpredictable absorption of oral treatment, in severe cases, the oral route should 
only be used after serum VB12 level has been normalized with parenteral treatment or when the 
response to the treatment is monitored frequently with measurement of serum VB12 and MMA 
[122] Routine parameters to monitor response to treatment after VB12 substitution are vitamin B12 
itself , its active fraction HoloTc and either Hcy or MMA as a functional marker (in case of a mild 
form without hematologic manifestations), and potassium levels, iron status, lactate 
dehydrogenase and bilirubin (in case of vitamin B12 -associated anemia). 
 
In Switzerland, VB12 supplementation is predominantly performed with i.m. injections of VB12 
[131], which are usually painful. No high-dose VB12 oral mono-preparation is currently available, 
despite evidence of its effectiveness [228-230]. Good response to oral supplementation has been 
observed even in the presence of gastrointestinal diseases that are commonly associated with 
VB12 deficiency. One study showed that VB12 deficiency could even be reversed in patients who 
had undergone gastrectomy [231]. However, evidence for the effectiveness of oral high dose VB12 
substitution coming from randomized trials comparing oral and i.m. substitution is limited [232]. 
 
Oral treatment with VB12 may be superior to i.m. injections in terms of patient acceptance and 
cost-effectiveness [132]. Patient preferences in treatment-related decisions should be elicited and 
taken into account, because patients who felt less empowered with regard to treatment decisions 
reported lower rates of adherence [107]. Finally, a better understanding of patient preferences and 
values for making choices is fundamental to achieve shared decision making and ultimately 
improve adherence. 
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We aimed at assessing outpatient preferences towards VB12 supplementation by oral or i.m. 
route, and confirming non-inferiority of early biomarker response in the oral treatment in a typical 
primary care population with biochemically defined VB12 deficiency. 
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Material and Methods 
This prospective, randomized, unblinded parallel-group trial was approved by the ethics 
committee of the canton Aargau and Solothurn, Switzerland, and has been registered at 
ClinicalTrials.gov ID NCT01832129. The study was conducted in accordance with the Declaration 
of Helsinki and follows the International Conference on Harmonization-Good Clinical Practice 
(ICH-GCP) guidelines. The primary hypothesis was that oral VB12 treatment would be non-inferior 
to i.m. treatment in terms of serum VB12 response after one month treatment. Patients were 
expected to prefer oral treatment over i.m. injections before and after a one month treatment. 
 
Participants 
Recruitment was initiated at 3 general practitioners (GPs) practices in the area of Olten, 
Switzerland. Eligible patients had a VB12 serum concentration <200 pmol/l, an indication for VB12 
supplementation according to the GP’s estimation, were ≥18 years old, and able to give written 
informed consent. Exclusion criteria were the concurrent intake of vitamin preparations containing 
VB12, a previously diagnosed dementia, known hereditary transcobolamin transportation defects, 
or lack of written and/or oral understanding of German, French, Italian, or English languages. 
 
Recruitment 
A letter with the patient information and written informed consent form was given to patients whose 
physician had ordered a laboratory test for the biochemical confirmation of VB12 deficiency. 
Patients were asked to bring along the informed consent form to their next scheduled visit with 
their GP during which the results of the lab test would be discussed. Eligible patients were asked 
by their GP to participate in the study. Patients who gave written informed consent were randomly 
assigned to group O-oral daily treatment or to group I-i.m. conventional weekly treatment.. Blocks 
of 4 were generated from computer software. Each GP practice received two blocks (four O-oral 
group and four I-im-group) each packed in sealed and unlabeled envelopes. Once a patient had 
consented, the GP or his staff opened one envelope to reveal what group of the study the patient 
had been randomised to. Upon request, further blocks were available. 
 
Interventions 
Patients of group O-oral were instructed to ingest daily one tablet of 1000 µg cyanocobalamine 
(B12 “Ankermann”; Wörwag Pharma GmbH & Co, Böblingen, Germany) for 28 consecutive days 
supplied in a 7x4 punch card with electronic adherence monitoring. Polymedication electronic 
monitoring system (POEMS) technology [33] was used to assess adherence to the oral VB12 
intake.  
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POEMS consist of a film with imprinted electronic components that measure the electrical 
resistance and record the time of its changes when a loop is broken, i.e. when a cavity is emptied. 
A first punch card fitted with POEMS was handed out for 14 days. A second identical punch card 
was handed out for a further two weeks at the third visit two weeks later. Patients were instructed 
to return the punch cards for pill count and for the extraction of the electronic adherence data. 
Patients of the group I-i.m. received conventional supplementation with weekly injections of 1000 
µg hydroxocobalamine (Vitarubin® Depot 1000 µg / 1ml; Streuli Pharma AG, Uznach, Switzerland, 
mixed with Lidocaine 1% 1 ml before injection). The treatment options were not blinded.  
 
Adherence outcomes 
For a given patient of the group O-oral, we calculated two adherence rates: taking adherence with 
pill count as the percentage of days with performed intakes divided by the days with prescribed 
intakes, and dosing irregularities as the percentage of days with ≥2 dosing events from the 
POEMS data.  
 
Biomarker assessment 
Venous blood samples were drawn before the first administration (V0), and after one (V7), two 
(V14), and 4 weeks of treatment (V28). Blood samples were analysed by immunological assays 
on a Beckman Coulter DxC 860i (VB12), Roche cobas® 6000 (homocysteine, folic acid), and 
Abbott Architect i2000SR (holotranscobalamine). Methylmalonic acid was measured by liquid 
chromatography mass spectrometry (LC-MS/MS) on a Thermo Scientific UltiMate 3000 Rapid 
Separation LC coupled to an AB Sciex 5500 TripleQuad MS. Blood cell count was determined on 
a Beckman Coulter DxH 800. Normalization of VB12 associated biomarkers was defined as a 
serum VB12 >258 pmol/l, HoloTc >37 pmol/l, Hcy <15 µmol/l, and MMA <270 nmol/L. Folate 
deficiency was defined as a serum value <9.1 nmol/l. GPs were informed about biomarker levels 
after V28.  
 
Patient preferences 
Preferences were inquired before block randomization (V0) and after 4 weeks of treatment (V28) 
with a scenario-based approach. Patients were asked to select treatment by ticking tablets, 
syringes, or no preference in a questionnaire, knowing that oral and i.m. substitution was equally 
effective. The questionnaire consisted of 9 items focusing on factors influencing preference: pain, 
disgust, side effects, effectiveness, inconvenience, difficulties, time consumption, costs, and non-
adherence to treatment schedule. Each item was to be answered twice for each therapy option 
(oral and i.m. treatment). Answers could be given on a 10-point Likert Scale.  
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Sample size estimation was based on assumptions regarding outcomes after 4 weeks. Patients 
were expected to display baseline VB12 concentrations of 100–150 pmol/l. Based on published 
data, patients reach levels of approximately 600 pmol/l with an estimated standard deviation of 
120 pmol/l after treatment. A difference of ≤100 pmol/l between levels after intramuscular or oral 
supplementation was estimated acceptable for non-inferiority, presuming this difference to be 
clinically meaningless.  
With the hypothesis that there is no difference between the groups, 50 patients are required to 
show with 90% confidence that the lower limit of a one-sided 95% confidence interval will be above 
the non-inferiority limit of 100 pmol/l. 
 
Statistical analysis  
Values are given as mean ± SD, median with quartiles and percentages where appropriate. 
Frequencies were analyzed using Chi‐square tests or Fishers test. Mann‐Whitney test was used 
to compare numerical variables between two groups and Kruskal-Wallis test was used between 
three groups. Spearman’s r was calculated to assess correlations between numerical variables 
and interpreted with the criteria 0-0.25 = little or no correlation; 0.26-0.50 = small correlation; 0.51-
0.75 = moderate to good correlation, and greater than 0.75 = very good to excellent correlation. A 
p-value ≤0.05 was considered significant.  
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Between November 2013 and December 2015, 37 patients (age: 49.5 ± 18.5 years; women: 
60.5%) were recruited for oral (n=19) or i.m. (n=18) treatment. No patient reported on harms or 
side effects during the study period. Recruitment was terminated after an anticipated analysis 
showing sufficient biomarker response for both treatment options and enormous difference 
between groups in mean VB12 values at V28 (2’442pmol/L) leading to the rejection of the primary 
non-inferiority hypothesis for oral treatment. Post-hoc sample size estimation was based on VB12 
outcomes at V28. Patients in group O-oral and group I-i.m. had VB12 levels of approximately 
350pmol/L with a standard deviation of 120pmol/l and 2’700pmol/L with a standard deviation of 
2’700pmol/L, respectively. With the hypothesis that there is a difference between the groups, a 
total of 28 patients are required to ensure that the 90% confidence interval includes the true 
difference between groups with an α of 5%. 
The baseline characteristics were equally distributed between the two treatment groups (Table 1). 
The study population contained patients with the following diagnosis or risk factors associated 
with VB12 deficiency: pernicious anemia (n=2), metformin intake (n=2), use of acid lowering drugs 
(n=4), vegetarian or low dietary intake of VB12 containing food (n= 18), diagnosed alcohol abuse 
or daily intake of alcohol (n=4), and gastric stabling (n=1). No established risk factor for VB12 
deficiency was identified in 6 patients. Distribution of risk factors was balanced between the groups 
(data not shown).  
 
A total of 38 electronic punch cards containing oral treatment were delivered, from which one was 
not returned (excluded from analysis) and 13 detected only partially the removals due to technical 
problems. From the 518 expected events, 356 were recorded (31.3% missed data). Days with ≥ 
2 dosing event occurred in 5.6% of all recordings. Average taking adherence by pill count was 
99.6% ± 1.1%.   
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Table 1: Baseline characteristics in patients receiving oral or i.m. VB12 substitution (n=37). Data are given 
as percentages, mean ±SD and median with quartiles. 
 Normal values Group O-oral (n=19) Group I-i.m. (n=18) p-value 
Women (n)  68.4% (n=13) 55.6% (n=10) 0.508 
Age (years)  47.3 ± 17.8 51.5 ± 19.6 0.543 
Body mass index(kg/m2)  27.3 ± 7.00 25.6 ± 4.20 0.715 
Vitamin B12 (pmol/L) 
       Mean (SD) 
       Median (quartiles) 
>258 
 
158 ± 27.4 
164 (135/177) 
 






       Mean (SD) 
















       Mean (SD) 
       Median (quartiles) 
< 15 
 
14.8 ± 5.80 
13.2 (10.9/16.7) 
 





Methylmalonic Acid (nmol/L) 
       Mean (SD) 
       Median (quartiles) 
< 270 
 
304 ± 172 
284 (160/379) 
 





Hemoglobin (g/L)  
       Mean (SD) 




138 ± 13.1 
136 (127/145) 
 





Mean cell volume (fL) 
       Mean (SD) 
       Median (quartiles) 
85-101 
 
91.7 ± 6.40 
91 (89/96) 
 





Mean corpuscular hemoglobin (pg) 
       Mean (SD) 
       Median (quartiles) 
28-33 
 
30.7 ± 2.10 
31 (30/32) 
 





Folic acid (nmol/L) 
       Mean (SD) 
       Median (quartiles) 
9.1 - 42.4 
 
16.2 ± 5.80 
16.6 (11.8/18.4) 
 






       Mean (SD) 
       Median (quartiles) 
136-145 
 
140 ± 1.9 
140 (139/141) 
 






       Mean (SD) 
       Median (quartiles) 
3.5-5.1 
 
4.6 ± 1.0 
4.2 (4.1/4.5) 
 






       Mean (SD) 




74 ± 14.1 
72 (64/83) 
 





Alanine amino transaminase (U/L) 
      Mean (SD) 
       Median (quartiles) 
<55 
 
8.0 ± 8.6 
8.0 (0/11) 
 





Aspart amino transferase (U/L) 
       Mean (SD) 
       Median (quartiles) 
5-34 
 
25.9 ± 5.9 
24 (21/32) 
 





Gamma-glutamyl transferase (U/L) 
       Mean (SD) 
       Median (quartiles) 
9-46 
 
39.2 ± 53.2 
15 (10/46) 
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Levels of VB12, HoloTc, Hcy, MMA, Folic acid (Fol), blood count, sodium, potassium, creatinine 
and liver enzymes did not differ at baseline (V0) between groups (Table 1). Levels of VB12 and 
HoloTc were significantly increased at V7, V14 and V28 compared to baseline for both groups 
(p<0.01) (Table 2). For group I-i.m. at each assessment point, VB12 and HoloTc response was 
significantly higher (p<0.01, Figure 1) and the level of Hcy was significantly more reduced (p<0.01) 
compared to group O-oral. Reduction of Hcy levels was significant at V7 for group I-i.m. and at 
V28 for both groups compared to baseline (group O-oral p<0.05; group I-i.m. <0.01). MMA levels 
were significantly decreased at V7 for both groups compared to baseline (p<0.01) and did not 
differ between groups (Figure 1). Blood count and Fol levels did not change significantly between 
V0 and V28 in both groups (data not shown). 
 
 
Figure 1: Biomarker levels at baseline (Visit 0), Visit 7, Visit 14 and Visit 28 for group O-oral treatment (●) 
and group I-i.m. treatment (►). Grey surfaces indicate sub therapeutic levels, dotted lines indicate 
threshold values for biomarker normalizaiton. A) Mean serum VB12 levels, dotted line at 258 pmol/L; B) 
Mean HoloTc levels, dotted line at 37 pmol/L; C) Mean Hcy levels, dotted line at 15 µmol/L; D) Mean MMA 
levels, dotted line at 270 nmol/L. 
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Table 2: Mean serum VB12, HoloTc, Hcy and MMA levels with 95% Confidence Interval at V0, V7, V14 
and V28 in Group O-oral and Group I-i.m. 
 
  Mean concentration (95% confidence interval) 
 Group V0 V7 V14 V28 
VB12 (pmol/l) O-oral 158 (145-172) 304 (250-357) 319 (284-355) 354 (298-410) 
I-i.m. 164 (154-174) 1088 (934-1236) 1897 (1219-2574) 2796 (1277-4314) 
p-value 0.58 <0.001 <0.001 <0.001 
HoloTc 
(pmol/l) 
O-oral 49.0 (40.4-57.5) 148 (109-187) 144 (115-173) 156 (116-196) 
I-i.m. 50.1 (38.7-61.6) 244 (200-288) 495 (373-617) 1269 (103-2435) 
p-value 0.94 <0.01 <0.001 <0.001 
Hcy (µmol/l) O-oral 14.8 (12.0-17.7) 14.6 (11.7-17.3) 14.3 (11.4-17.3) 13.8 (10.7–16.8) 
I-i.m. 13.0 (11.0-15.1) 9.5 (8.2 – 11.0) 9.0 (7.4-10.7) 8.5 (7.1-9.8) 
p-value 0.41 <0.001 <0.001 <0.001 
MMA (nmol/l) O-oral 304 (219-390) 188 (148-227) 187 (151-223) 168 (134-202) 
I-i.m. 321 (215-427) 172 (135-208) 161 (127-197) 156 (121-190) 
p-value 0.76 0.53 0.16 0.51 
Hcy= homocystein; HoloTc= holotranscobalamine; MMA= methylmalonic acid; VB12=vitamin B12 
 
After 28 days of treatment for group O-oral, normalized VB12 levels were reached by 16 (84.2%) 
patients, normal Hcy levels by 14 (73.9%) patients and normal HoloTc and MMA levels by 19 
(100%) patients (Figure 2). After 28 days of treatment for group I-i.m., all 18 patients (100%) had 
normal VB12, HoloTc, Hcy, and MMA levels. Percentage of patients with a normalization of all 
biomarkers at V28 was significantly higher in group I-i.m. compared to group O-oral (100% vs 
63.2%, p<0.05).  
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Figure 2: Rate of patients with normalized VB12 associated biomarkers after 28 days of treatment 
administered by oral (n=19; white bar) or i.m. route (n=18; grey bar), star (*) indicates significant 
difference = p< 0.05. 
 
At V0, VB12 or HoloTc did not correlate with Hcy or MMA within the study population. Within group 
O–oral a non-significant small correlation between Hcy levels and VB12 was found at V7 (r-
=0.369; p=0.12), V14 (r=-0.388; p=0.10) and V28 (r=-0.341; p=0.15) and between Hcy and HoloTc 
at V14 (r=-0.397; p=0.10) and V28 (r=-0.392; p=0.10). Levels of VB12 or HoloTc did not correlate 
with MMA. Within group I-i.m. a moderate correlation was found for VB12 and Hcy levels at V7 
(r=-0.725; p<0.001), V14 (r=-0.507; p<0.05) and a small non-significant correlation at V28 (r=-
0.254; p=0.38). Levels of HoloTc and Hcy did not correlate nor did levels of MMA correlate with 
VB12 or HoloTc levels. Correlation between Hcy and creatinine levels was moderate for the whole 
study population at V0 (r=0.522; p<0.001) and for the group O-oral at V28 (r=0.491; p<0.05). A 
high correlation was observed for group I-i.m. at V28 (r=0.713, p<0.001).Before randomization 17 
patients preferred oral treatment (45.9%), and eight patients preferred i.m. treatment 
(21.6%).Twelve patients (32.4%) had no preference. Concerns were compared between patients 
grouped by preference. For the patients who preferred tablets, a therapy with syringes would raise 
more concerns about the pain (p=0.001), disgust (p=0.004), side effects (p=0.017), inconvenience 
(p=0.001), difficulties (p=0.001) and time-consumption (p=0.001). Patients preferring i.m. 
treatment indicated their concerns about forgetting to regularly take the medicine (addressed as 
non-adherence to treatment schedule) (p=0.018), inconvenience (p=0.024) or higher time 
consumption when taking tablets (p=0.001) (Table 3).  
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Table 3: Patients answers to 9 items known to influence preference before randomization. Answers are 
sorted according to the first question “Which treatment do you prefer?” tablets/ syringes/ no preference. 
Each item was to be answered twice for therapy with a) syringes and with b) tablets. The higher the score 
the higher the anticipated effect of the corresponding item on a Likert scale 1-10. Data are given as mean 
±SD. P-value <0.05 indicates a significant difference between the group with the highest values versus the 












a) Syringes   
b) Tablets 
 
5.7 ± 2.0 
1.0 ± 0.0 
 
3.1 ± 1.6 
2.1 ± 2.2 
 
2.6 ± 1.2 





a) Syringes   
b) Tablets 
 
5.9 ± 2.4 
3.1 ± 1.7 
 
3.1 ± 2.2 
4.6 ± 2.3 
 
3.2 ± 2.4 




Side effects  
a) Syringes   
b) Tablets 
 
4.2 ± 2.6 
2.4 ± 1.3 
 
2.1 ± 1.8 
2.8 ± 2.5 
 
2.3 ± 1.5 




Effectiveness of the treatment  
a) Syringes   
b) Tablets 
 
8.4 ± 1.5 
7.8 ± 2.2 
 
9.0 ± 1.1 
6.9 ± 2.3 
 
8.8 ± 1.3 





a) Syringes   
b) Tablets 
 
6.8 ± 1.8 
2.7 ± 1.5 
 
2.6 ± 1.4 
4.9 ± 2.4 
 
2.3 ± 1.2 





a) Syringes   
b) Tablets 
 
4.7 ± 2.7 
1.7 ± 1.7 
 
1.8 ± 1.8 
1.9 ± 1.6 
 
1.4 ± 0.7 




Time consumption  
a) Syringes   
b) Tablets 
 
7.0 ± 2.6 
1.2 ± 0.5 
 
4.1 ± 2.8 
2.6 ± 0.9 
 
2.4 ± 1.0 





a) Syringes   
b) Tablets 
 
4.5 ± 2.6 
2.8 ± 1.7 
 
3.9 ± 3.1 
2.6 ± 1.8 
 
3.5 ± 2.7 




Non-adherence to treatment 
schedule 
a) Syringes   
b) Tablets 
 
3.3 ± 2.6 
2.4 ± 2.6 
 
3.8 ± 2.8 
4.3 ± 1.7 
 
2.6 ± 2.6 
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Nine patients (24.3%) changed their preference after treatment. When patients were allocated to 
the non-preferred administration group, twenty percent of them changed their mind independent 
of whether they were exposed to p.o. or i.m. treatment: Patients who received oral treatment 
changed their mind in favor of oral treatment (100%) and patients receiving i.m. treatment changed 
their mind toward different directions at V28. Patients who preferred oral treatment and were 
assigned to group O-oral maintained their preference (100% congruence). Patients who preferred 
i.m. treatment and obtained parenteral treatment changed their preference at V 28 (0% 




Figure 3: Patients preferences before and after 28 days of treatment administered by oral (n=19) or i.m. route (n=18). 
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In our study, levels of VB12 and HoloTc were significantly increased and levels of Hcy and MMA 
significantly decreased after 28 days of treatment with high-dose VB12 administered either by oral 
or i.m. route. These findings are in line with other trials, of which two trials assessed the effect of 
oral high-dose VB12 substitution (1000 µg cyanocobalamin) vs. placebo [230, 233], while three 
other randomized, controlled trials compared cyanocobalamin therapy administered by oral (1000-
2000 µg) or parenteral route (1000 µg cyanocobalamin) [228, 229, 234].  
Contrary to prior studies, we observed an exaggerated response after i.m. administration and 
therefore the hypothesis for non-inferiority of oral in comparison to i.m. treatment had to be 
rejected. Because we used electronic punch cards and monitored an almost perfect intake of 
tablets (99.6% taking adherence), non-adherence can be ruled out as a contributor to the less 
pronounced response in VB12, HoloTc and Hcy in patients following oral administration. Thus, the 
enormous difference must have chemical or physiological reasons. One reason might be the use 
of hydroxocobalamine, a physiological intermediate form which shows a greater availability to cells 
than other cobalamin forms [235]. In children with VB12 deficiency, one single injection of 400µg 
hydroxocobalamine resulted in improvement in motor function and cobalamin repletion [236]. 
Additionally, hydroxocobalamine is longer retained in plasma compared to equivalent doses of 
cyanocobalamin, which allows less frequent dosing. However, due to its low stability, 
hydroxocobalamine is less suited for oral supplementation, whereas cyanocobalamin is best 
suited for oral supplementation due to a more stable and inexpensive form [115]. Surprisingly, 
sustainability of biomarker response after i.m. hydroxocobalamine administration has poorly been 
described. In one study among 8 patients with VB12 levels below 80pg/mL (59.4 pmol/L), VB12 
levels between 300 and 1100 pg/L (221-812 pmol/L) were obtained 10 days after the injection of 
1000 µg hydroxocobalamine. The levels fell below 200 pg/L (148 pmol/L) between 4 and 10 weeks 
later [237]. In our study, wide inter-individual variation in VB12 and HoloTc responses was 
observed within the i.m. group, which corresponds to wide inter-individual variations in 
hydroxocobalamine pharmacokinetics as reported by others [238, 239]. 
To our knowledge, there are no reports of similarly high levels of VB12 and HoloTc with daily oral 
VB12 substitution over a longer treatment period, similar to what we observed after i.m. treatment. 
In one study with high-dose oral substitution of VB12 for 3 months, patients with initially low levels 
of VB12 (186±56 pmol/L) reached higher VB12 levels (mean 477 pmol/L) than we observed after 
28 days of treatment, albeit levels of HoloTc (183 pmol/L), Hcy (13.4 µmol/L) and MMA (0.23 µmol/ 
230 nmol/L) were comparable with the levels we observed after 7 days (HoloTc and MMA) and 
after 28 days (Hcy) of oral treatment [233]. Continuation of treatment up to 6 months did not result 
in additional significant changes in VB12, HoloTc, Hcy, and MMA [233].  
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A further study observed a plateau in serum VB12 levels with a mean of 1164 pg/mL (858 pmol/L) 
after 3 months when patients received a loading dose with 1000 µg hydroxocobalamine and a 
subsequent 18-month treatment with 1000 µg oral cyanocobalamin [240]. These findings suggest 
that continuous oral treatment with high dose VB12 reaches saturation in serum VB12 levels after 
3 months of treatment. In our study, three patients did not reach normal levels of VB12 after oral 
treatment. However, two out of those three patients had VB12 levels above normal range at V14, 
which slightly decreased afterwards.  In the absence of any rational explanations (e.g. patients did 
not stop prematurely treatment) , results indicate that time to VB12 saturation after therapy and 
the level of saturation may vary between patients. The other patient responded slowly to oral 
substitution, probably due to the underlying cause of VB12 deficiency, which was gastric stabling 
(VB12 levels at V0 and V28: 108pmol/l and 182pmol/L). Furthermore, the active part of vitamin 
B12, HoloTc, was normalized by all patients at V28. Pernicious anemia could be another 
explanation for non-response in the O-oral group. However, because all patients had some kind 
of response or a physiological rational for slower response (i.e. gastric stabling), this explanation 
is very unlikely. 
 
Five patients in the oral group did not reach normalized Hcy levels at V28. However, there is no 
agreement on normal ranges for VB12 associated biomarkers yet [241]. Hcy lacks specificity and 
response may be confounded by folic acid and vitamin B6 deficiency, as well as by 
renalinsufficiency , liver insufficiency and genetic abnormalities. Additionally, Hcy levels are 
influenced by, lifestyle, such as consumption of coffee, alcohol, and tobacco [242]. The incomplete 
normalization of Hcy levels in our cohort could be explained in two patients with folic acid 
deficiency or diagnosed renal insufficiency, respectively. Additionally, renal function might have 
affected normalization in other patients as well, indicated by correlation of Hcy and creatinine. 
Compared to i.m. treatment, decrease in Hcy levels was slower with oral treatment. Other studies 
also found Hcy levels to respond slowly to oral treatment [230], with a trend to further decrease 
over a period of 18 months [240].A negative concentration-effect relationship was observed for 
Hcy and VB12 in the group I-i.m.. A trend towards similar correlation between low Hcy levels and 
high VB12 levels was observed for group O-oral. A stronger concentration-effect relationship may 
be observed in patients with a more pronounced deficiency of VB12-associated biomarkers. 
Before drawing conclusions on concentration-effect relationship between VB12 and Hcy, results 
should be verified in a bigger sample of anemic patients with consideration of further factors such 
as renal function and lifestyle. 
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Interestingly, the functional biomarkers MMA and Hcy did not respond consistently in both groups. 
Patients in both groups reached normalized MMA levels at V7. Hcy levels in the I-i.m.-group were  
decreased at V7 too, whereas levels in O-oral-group were decreased at V28, and significantly 
higher at each assessment point compared to I-i.m. group. The different enzyme systems 
converting Hcy and MMA in the human body might also explain the observed difference in 
functional biomarker response between groups. In vitro studies showed that hydroxocobalamine 
induces the activation of one of these enzyme systems (methionine synthase) stronger and faster 
than cyanocobalamine [243]. 
 
In summary, supra-therapeutic levels were observed for VB12 and HoloTc after the i.m. treatment 
with hydroxocobalamine, which might never be reached through oral substitution. Additionally, 
normalization of all biomarkers was significantly higher in group I-i.m. compared to group O-oral 
(100% vs 63.2%, p<0.05). However, incomplete response in group O-oral was limited on VB12 
and Hcy. Therefore, the benefit of such an exaggerated response after i.m. injection seems limited 
to a practical advantage in the form of fewer administrations i.e. longer treatment intervals and in 
case of symptomatic patients needing a rapid normalization of VB12 associated biomarkers. A 
large prospective randomized controlled trial comparing high dose oral vs intramuscular 
cyanocobalamin in elderly patients is currently being performed (PMID: 22650964, NCTNCT 
01476007). This study is expected to report on long term oral and i.m. VB12 substitution (8, 26 
and 52 weeks). However, no reports on short term biomarker response or patient preferences are 
expected. Further studies are required to assess the effects of different cobalamin forms on 
biomarker response and on clinical outcomes. Accordingly, observed differences between 
cobalamin forms should be incorporated in guidelines for treatment of VB12 deficiency.  
 
As expected, patients preferred oral treatment to i.m. treatment, before the assignation to 
treatment as well as after its completion. Our findings are in line with reports from two studies on 
patient preferences on oral VB12 treatment [240, 244]. In a study in primary care, 83% of patients 
preferred over i.m. treatment [240]. In another study, from the patients receiving VB12 as injection 
and willing to try oral administration, the majority was satisfied with the switch and wished to 
remain permanently on oral therapy. Important factors for switching to oral therapy were the 
disadvantage of injections and their association with the many accompanying visits to their 
respective health care providers, higher costs, and the convenience of oral treatment [244]. We 
also found time consumption and inconvenience of i.m. treatment as important factors in favor of 
oral treatment.  
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There was a slight change in patient preferences after receiving oral therapy (n=2, 10.5%), whilst 
changes occurred only in favor of oral treatment. This may indicate that patients became 
appreciative of the route of administration after experiencing oral treatment at first hand. After 
experiencing i.m. treatment, 11 patients (38.9%) changed their preference in various directions. 
This is interesting in view of the pretreatment attitudes towards important factors associated with 
patient preferences, regarding a therapy with syringes (n=6) and regarding a therapy with tablets 
(n=3). These findings suggest that patients may have more prejudice regarding syringes, which 
may explain the numerous and various changes after experiencing i.m. treatment. 
Given the exaggerated response after i.m. treatment, the required frequency of injections with 
hydroxocobalamine in clinical practice may be lower, in patients with mild VB12 deficiency, which 
may augment the preference of an i.m. administration. Additional research with validated methods 
is needed to gain an insight into the patient preferences, especially when therapeutic options with 
comparable efficacy and safety are available.  
 
Limitations arrived from the fact that we included patients mostly without hematological symptoms 
and not necessarily abnormal functional biomarkers. Therefore, patients in our study were less 
likely to respond to VB12 substitution, what affects our ability to generalize our results to a 
symptomatic, anemic, VB12-deficient population. Second, the questionnaire we used to assess 
patients preferences, consisted of re-used questions from several assessment tools but was not 
validated completely as an entity. Nevertheless, the single questions can be judged valid to 
retrieve patient preferences. Additionally, we did not assess patient preferences for maintenance 
therapy and therefore cannot evaluate whether preference would change in this long-term 
situation. However, it seems justified to reevaluate treatment one month after initiation irrespective 
of treatment schedule as received treatment is highly suspected to influence attitudes and 
ultimately patient preferences. Third, we had a high proportion of technical issues leading to a loss 
of 1/3 of the electronically gained adherence data, therefore days with more dosing events might 
occurred more frequently as suggested by our calculations. However, this technical drawback had 
no impact on the calculation of taking adherence with conventional pill count method. Last, we 
stopped prematurely the study after an anticipated analysis and thus obtained a small sample 
size. However, the reached normalized levels in both groups did not justify to continue the study 
since the hypothesis was rejected with the small number of patients.  
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Differences in VB12, HoloTc and Hcy levels between groups were higher than expected. 
Therefore, the hypothesis of non-inferiority of oral treatment had to be rejected. However, 
normalization of HoloTc and MMA was reached by all patients and normalization of VB12 and Hcy 
by the majority of patients within group O-oral after a one-month treatment. The clinical benefit of 
exaggerated biomarker response after i.m. treatment within a typical primary care population is 
questionable. Therapeutic schemes should be chosen with the consideration of mid-term 
biomarker effects and patient preferences. Initial rating in favor of either i.m. or oral therapy can 
change over time and justifies repeated re-evaluation of patient preferences. However, the 
majority of patients preferred oral treatment before and after the study pointing out the need for a 
high dose oral VB12 preparation in Switzerland. Further research may help to evaluate which 
route of administration, oral vs i.m., of long-term VB12 treatment, will be appropriate to yield 
sustained biomarker response. 
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Background and objective 
Many drugs can be applied either by oral or parenteral therapy. The preferred route of 
administration is often predetermined by the indication, the required dose and the therapeutic 
setting. Substitution of vitamin B12 in deficient outpatients is one example where the equivalent 
efficacy of oral and intramuscular application offers both treatment opportunities. Whenever 
alternative routes of administration exist, the patient preference should represent a considerable 
criterion to choose between the treatment options. Our objective was to review current knowledge 
regarding the patients’ preferred route of administration. 
 
Setting and Method 
We conducted a literature research in the Pubmed, EMBASE and Web of Science databases 
using the terms “patient preference” OR “patients’ preference” OR “patient perspective” AND “oral 
treatment” AND “inject*”. Our search was limited to original research articles that have been 
published after 1980, were accessible online and included intravenous, intramuscular or 
subcutaneous as parenteral therapy options. Cross-references were also included for analysis. 
The research articles were classified by setting, indication and treatment, number of studied 
patients and mode of assessment, and patient preference. 
 
Outcome measures  
Main outcome was the number of studies with preference for oral treatment. Secondary outcomes 
included the methods used to assess patient preferences and identified factors with a presumed 
influence on preference. 
 
Results 
Our search strategy delivered 74 articles, of which 62 were excluded (Figure 1). Additionally, one 
article was included by cross-referencing. Of the gained 13 articles, there were 5 articles on cancer 
treatment, 3 on antibiotic therapies, 2 on vitamin deficiency, 1 on prophylaxis of thrombosis, 1 on 
osteoporosis, and 1 on migraine therapy.  
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Figure 1: Search methodology and retrieved articles 
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Eleven out of 13 articles reported preference for the oral administration (84.6%). Associated 
factors for the preferred routes of administration varied between the studies. Most articles reported 
convenience as an important factor to influence preference, either in favour of the oral or the 
parenteral therapy (Figure 2). 
 
 
Figure 2: Important factors with a presumed influence on preference 
*= injection associated side effects: no infections, hämatoma, problems with veins 
*= associated side effects of tablets: no swallowing difficulties, stomach problems 




no route specific side effects*
given as a tablet/injection
more freedom












one additional pill/injection does not matter
avoidance of injection/ talbets
savings to the health care system
no privacy if injection is made by the doctor
financial
experiences showed better efficacy
Proportion of studies (%)factor in favour for oral therapy
factor in favour for parenteral          
therapy
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A variety of different questionnaires and study designs were used to assess patient preferences. 
Two studies used already validated questionnaires to estimate patient preferences (Figure 3). 
These were an adapted version of the BMQ, the PSQ and one survey based on other studies for 
which we had not access. All surveys used 5-item Likert scales and one gave 14 options for 
patients preference. The remaining 11 studies especially designed questions and/or an interview 
for the study to assess patient preference. Likert-scales (5-10 items) were used 6 times, as often 
as multiple answer options that were given for factors which influenced patient preference. Three 
studies either used open questions or only two answer options. Three times scenario-based 
interviews were carried out either by telephone or in person. 
 
 
Figure 3: Type of assessment used to measure patient preference [%] 
 
Conclusions 
A variety of different questionnaires and study designs were used to assess patient preference. 
There is a lack of a standardized method, and knowledge about patient preference is still scarce. 
Unsurprisingly, patient preference for therapy options with identical active ingredient and different 
ways of application such as oral and parenteral administration (i.e. vitamin B12 deficiency, iron 
supplementation) is not investigated.  
In the retrieved studies, a majority of patients preferred oral treatment. The factor which mostly 
influenced patient preference was convenience. Dependent on the disease, oral or parenteral 
therapy was preferred. Given this and the availability of bioequivalent treatments for both therapy 
regimes, the incorporation of patient preferences may substantially add to treatment optimisation. 
Patient and physician should take a shared decision concerning the optional therapy regimens in 
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Rationale, aims and objectives 
To translate in German the 8-item Morisky Medication Adherence Scale (MMAS-8D). To validate 




A standard forward-backward procedure was used to translate the MMAS-8 into German. 
Validation took place on a convenient sample of ambulatory patients on chronic antiplatelet 
therapy between June 2010 and June 2011. Objective adherence was obtained from electronically 
monitored multidrug punch cards. Internal consistency was assessed using Cronbach’s alpha 
coefficient, construct validity using exploratory factor analyses and correlations between MMAS-
8D and related measures. Convergent validity was assessed with a subjective questionnaire about 
beliefs about medicines (BMQ Specific, 2 subscales).  
 
Results 
A total of 70 patients were included (mean age 65.7 ± 9.9 years; 31.4 % women). The mean score 
of the MMAS-8D was 7.5 (SD 0.8; range 4.5-8). Moderate internal consistency (alpha = 0.31) was 
observed, due to multidimensionality of the scale. Factor analysis yielded four components that 
accounted for 71.7% of the total variance. Convergent validity was supported by significant 
correlations with BMQ Necessity (r= 0.31; p<0.01), BMQ Concerns (r= -0.16, p<0.05) and with 
electronic adherence reports (U-values 44 and 471, p<0.05). Platelet aggregation values were 
within therapeutic range for 80% of the patients. Blood values of the antiplatelet agent within 
therapeutic range were associated with a higher MMAS-8D score (U-value 125, p<0.05). 
 
Conclusion 
The German MMAS-8 appears to be a reliable instrument to catch medication adherence in 
cardiovascular patients. It may be useful in patients with chronic therapy for detecting 
nonadherence. 
 
Keywords: adherence, questionnaire, German version, validation 
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The assessment of medication adherence in patients is crucial as non conformity with prescribed 
drug regimen poses a substantial risk for therapeutic failure, regardless of the underlying disease 
[245]. Various adherence assessment methods have been used over the past decades, either 
direct (i.e., with detection of the substance in a biological fluid, thus proving that a dose of a drug 
was ingested) or indirect (i.e., which do not demonstrate drug ingestion). From the indirect 
measures (such as self- reporting, medication diaries, residual pill counting, pharmacy records, 
clinician opinion, electronic devices with remote control), questionnaires remain the most 
commonly used type because of major advantages (mainly they are simple, practical, cheap, non-
invasive, unobtrusive) [246], while electronic monitoring represents the most objective measure 
[247]. 
 
Among self-reported questionnaires, the 8-item Morisky Medication Adherence Scale (MMAS-8) 
[24] is one of the most widely used scale to measure self-reported adherence, mainly because of 
the simplicity of its administration and scoring. It consists of seven yes/no questions and one 5-
point Likert scale. The scale has demonstrated high internal consistency and good sensitivity and 
specificity; it was shown to be valid and reliable [24]. The questionnaire was shown to be an 
effective screening tool in clinical practice to identify non-adherent patients at risk of uncontrolled 
blood pressure [248]. The MMAS-8 has been translated into more than 50 languages, e.g. French, 
Malay, Portuguese and Thai [29, 249-251] and used in long-term medical conditions, across 
different settings and various cultural contexts. The scale has also translated into Chinese and 
analyzed with hypertensive and myocardial infarction patients [252, 253].  
 
Numerous adherence studies have been conducted in a German speaking setting, most of them 
with self developped questionaires [254] or scales [255]. Parts of the MMAS-8 have been 
translated in German and used in specific investigations [256] or larger trials [257] but the German 
scale was never validated. Consequently, one can assume that several German versions of the 
psychometric instrument are available, rending comparison of results questionable. Further, the 
lack of validation might lead to biased results. Adherence to antiplatelet therapy has been 
estimated in many studies and appears to be high. Of 2,640 patients surveyed in the German 
Stroke Data Base, 96% reported to be still on any antiplatelet therapy (mostly aspirin) for 
prevention one year after their stroke [258]. In a retrospective analysis using administrative claims 
data of 9,635 US veterans with established cardiovascular disease, 84% had sufficient antiplatelet 
medicine dispensed over 5 years to cover 80-120% of the treatment duration [259]. Considering 
that interventions aimed at optimizing adherence will be more effective if they are tailored to a 
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patient´s needs, health professionals will need on one hand overall adherence measurement 
tools, on the other hand single items assessing pre-existing behaviours and habits. Because of 
the foreseeable use of the MMAS-8 as an adherence measurement and assessment tool in 
German speaking countries including Switzerland, we were interested in establishing a German 
version of the MMAS-8, the MMAS-8D (Deutsch).  
The validity of electronic devices (i.e. systems that record date and time of each dispensing of 
medication) in measuring adherence was demonstrated in many studies, either for container caps 
with single drug [260] or for weekly pill boxes with polypharmacy [261]. Recently, electronic 
monitoring was recommended as method of choice in research on adherence [262]. A meta-
analysis demonstrated a high to moderate correlation between self-reported questionnaires and 
medication adherence measured using monitoring devices [263]. Thus, we performed a validation 
against electronic measures of adherence and the Beliefs about Medicines Questionnaire [264], 
a validated subjective questionnaire which showed a significant relationship with adherence to 
medication in substantial different social, cultural, economic and healthcare system contexts [247]. 
Further, the association did not differ if objective or subjective adherence measures were used. 
This article reports the validation of the German MMAS-8 against objective and subjective 
measures of adherence in ambulatory patients with antiplatelet therapy. 
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Participants and setting 
A convenient sample of 19 general practitioners in Solothurn, Switzerland, invited patients with 
chronic antiplatelet treatment to participate in a cross-sectional study on drug resistance between 
June 2010 and June 2011. The study is described elsewhere [265]. In brief, 82 outpatients older 
than 18 years with on-going prescriptions for aspirin and/or clopidogrel accepted participation. 
They obtained their entire oral solid medication (polypharmacy) for seven days in a punch card 
equipped with electronic adherence monitoring. Blood samples were collected after adherence 
monitoring to measure platelet aggregation and to determine polymorphism of the CYP2C19 
gene. The patients were aware of the purpose and function of the electronic system prior to study. 
They were advised to take their medicine at the time they were normally used to, by just pushing 
out all the pills contained in one cavity. Filling of the questionnaires was performed at the study 
center, questions were answered on site by the study investigator. This observational cross-
sectional study obtained ethical approval from the Swiss local ethics committee of Aargau and 
has been registered at ClinicalTrials.gov ID NCT01039480. All patients provided written informed 
consent before participation.  
 
Translation of the instrument 
Translation in German was done according to the “Principles of Good Practice” for the translation 
and cultural adaptation process for patient-reported outcomes (PRO) measures [266]. The back 
translation technique was performed by two translators, one conducting the forward translation 
and the other one conducting the back translation. Equality of sense rather than equality of word 
was favoured. The source language versions were compared and discrepancies lead to 
modifications in the target language version until both translators were satisfied with semantic and 
conceptual equivalence between source and target languages. The developer of the MMAS-8 
approved the German version. The corrected target language version was validated with 3 
monolingual subjects for comprehensiveness, appropriateness, acceptability, and feasibility.  
 
Subjective adherence measure 
The MMAS-8 [24] consists of seven yes/no questions and one 5-point Likert scale. Patients 
answering “no” to all questions but ‘‘yes’’ to item 5 (reverse coding) and “Never/rarely” to item 8 
obtain the maximal 8 points and are classified as “high adherence”. Patients answering differently 
obtain a lower score that indicates lower adherence and are classified as “medium” (6-<8) or “low” 
(<6) adherence. The questionnaire takes about 5 minutes to complete. The term “[health concern]” 
medication was not specified in our questionnaire in order to steer for polypharmacy. 
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Beliefs about medicines 
The Beliefs about Medicines Questionnaire (BMQ) [264] is an instrument that assesses the 
cognitive representation of medication and consists of two sections (BMQ-Specific and BMQ-
General). Many studies demonstrated a high correlation between BMQ scales and self-reported 
adherence in several chronic diseases, including asthma [267], hypertension [268], HIV [269], and 
diabetes [270]. We selected this questionnaire since it targets beliefs about medicine in general, 
i.e. polypharmacy, and not a single drug. The German version has been validated in chronically 
ill patients and showed good internal consistency (Cronbach’s alpha 0.79–0.83).[271] We used 
the BMQ-Specific that assesses patients’ beliefs about the particular medication prescribed for 
them and consists of a 5-item Necessity scale (necessity of taking medications for maintaining 
present and future health) and a 5-item Concerns scale (concerns about the potential adverse 
consequences of taking medicine). Responses are given on a 5-point Likert scale ranging from 
strongly agree (scored 5) to strongly disagree (scored 1). Scores are summed and range from 5 
to 25 for each subscale, with high scores indicating strong beliefs in the concept. The Necessity-
Concerns differential is calculated by subtracting concerns scores from necessity scores (scores 
range from -20 to 20). This score represents a crude indicator of the way a person rates his/her 
perceived need for the treatment relative to his/her concerns about following it. If the differential is 
positive, the person notes that the benefits of medication outweigh the costs. Contrarily, if 
negative, the person perceives heavier cost than benefit [264].  
Objective adherence measures 
Polypharmacy electronic monitoring system (POEMS) technology [246] was used to asses 
adherence to the reference medication. In brief, POEMS consists of a polymer film with imprinted 
electronic components that measure the electrical resistance and record the time of its changes 
when a loop is broken i.e., when a cavity is emptied. The patient’s entire oral solid medication is 
filled in a disposable multidrug punch card with 7x4 cavities, equipped with the film on its backside. 
For a given patient, we calculated two established adherence rates to the antiplatelet agent i.e., 
to the drug of interest within the prescribed polypharmacy: taking adherence (number of days with 
performed intakes divided by number of days with prescribed intakes) and timing adherence with 
the strictest grace interval of 25%[272] (number of doses taken at 24 ± 6 hours for a once-daily 
regimen or 12 ± 3 hours for a twice daily regimen). In addition, we calculated for each patient the 
mean drug intake time of the antiplatelet agent. The timing variability in drug intake was defined 
as variance of the mean drug intake time[273] and indicates the timeliness of the intakes. 
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Platelet aggregation was measured in venous blood samples and is described elsewhere [265]. 
In brief, values below the cut-off of 30 arbitrary units (AU) for the ASPItest (Aspirin) and 53 AU for 
the ADPtest (clopidogrel) were considered as in the therapeutic range and consequently, the 
patient as fully adherent. Pharmacogenetic analysis of the CYP2C19 gene was performed for 
clopidogrel values outside therapeutic range. Polymorphism (CYP2C19*2, 2C19*4, 2C19*17) is 
associated with insufficient platelet inhibition in clopidogrel-treated persons [274]. Laboratory 
signs of inflammation were defined by C-reactive protein >5 mg/l and is associated with resistance 
to Aspirin [275]. 
 
Statistical analysis 
Where appropriate, mean and standard deviations, median and interquartile ranges are 
presented. Internal consistency or reliability of the MMAS-8D was assessed using Cronbach’s 
coefficient alpha which indicates whether each item of a scale is appropriate for assessing the 
underlying concept of its scale. Values for Cronbach’s alpha range between 0 and 1; the closer 
they are to 0, the less the items are related to one another. Values above 0.7 are generally 
considered to indicate satisfactory internal consistency [276]. However, opinions differ regarding 
acceptable cut-offs [277]. 
Construct validity i.e., the degree to which an instrument reflects the underlying construct that it 
was designed to assess, was performed with exploratory factor analysis (principal component 
analysis extraction method, PCA), followed by varimax rotation. Factors with Kaiser’s eigenvalues 
of >1 were selected i.e., factors that accounted for more of the total variance than any single 
original item. Factor loadings greater than 0.4 were used for defining items associated with a given 
factor. Results are given in terms of percentage of variance in the score explained by the principal 
factor. 
Convergent validity i.e., the degree to which an instrument is related to measures of similar 
constructs, was performed with the non-parametric Spearman’s rho test since self-reported values 
(MMAS-8D and BMQ-Specific) and objective measure (electronic punch cards) were skewed 
toward high scores. Differences in adherence rates were compared using the Mann–Whitney U 
test for continuous variables, comparison of categorical variables was performed with Chi-Square 
test. Correlations were interpreted with the criteria 0-0.25 = little or no correlation; 0.26-0.50 = 
small correlation; 0.51-0.75 = moderate to good correlation, and greater than 0.75 = very good to 
excellent correlation. Data were entered and analyzed using SPSS statistical package version 
21.0 (SPSS Inc, Chicago, Illinois, USA) and p-values <0.05 were considered significant. 
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From 82 enrolled patients, 12 were excluded because of missing data due to deficiency in the 
recording technology. Of the remaining 70 patients (mean age 65.7 ± 9.9 years; 31.4% women, 
mean age 67.9 ± 9.7 years and 68.6% men, mean age 64.7 ± 9.9 years; n.s.) full sets of data were 
available. The study sample consisted of patients with a prescription of antiplatelet agents for 
primary (42.9%) or secondary prevention (57.1%). Mean number of prescribed drugs per patient 
was 5.2 ± 2.3 (range 1-13) that were to be taken once daily (37.1%; all but one in the morning), 
twice daily (48.7%, all but four in the morning and the evening), thrice daily (11.5%) or fourth daily 
(2.9%). With one exception, all antiplatelet agents were lodged with the morning medication 
(98.6%). All doses of the antiplatelet agents were taken (100% taking adherence) and all but 4 
patients had intake times within the grace interval of ± 3 hours (91.4% timing adherence). A stricter 
grace interval of ± 1.5 hours was observed in 39 patients. The variance of the mean intake times 
averaged 1.4 h2 ± 4.3 h2, with a median of 0.5 h2 and an interquartile range IQR of 0.8 (25th 
percentile of 0.2 h2; 75th percentile of 1.0 h2). The variance was not associated with the number of 
drugs (r= 0.19; p=0.06; n.s.) nor with the number of intake times (r= 0.17; p=0.08; n.s.). Platelet 
aggregation values were within therapeutic range for 74% of the patients taking aspirin, 75% of 
those with clopidogrel and 95% of those on dual therapy, yielding to total 56 patients (80%) with 
optimal platelet aggregation. For further 7 patients (10%), genetic mutation (3 patients with 
clopidogrel) or underlying inflammation factors (4 patients with Aspirin) were detected. 
 
Responses of the MMAS-8D were coded analogue to the English version. With the recommended 
scoring method, the mean score of the MMAS-8D was 7.5 (SD 0.8; range 4.5 - 8), with a median 
of 8 and an interquartile range IQR of 1 (25th percentile of 7; 75th percentile of 8). With the 
recommended cut-offs, the majority of patients were in the high adherence group (64.3%), while 
30.1% and 5.7% were in the medium and low adherence groups, respectively. Only 2 patients 
indicated that they did not take their medication the day before (item 5) while 9 patients (12.9%) 
declared to forget sometimes to take their medication (item 1). The mean BMQ scores were 19.7 
(SD 4.1; range 6 – 25; median 20) for the Necessity scale and 9.5 (SD 3.9; range 5 – 20; median 
9) for the Concerns scale. With a Necessity-Concerns differential of 10.1 (SD 5.6; range -2 – +20), 
participants noted that the benefits of medication outweigh the costs. 
 
   
8 Project C: Adherence assessment methods 
    
125 
 
Internal consistency / Reliability 
Cronbach’s alpha was 0.31 for the eight items of the German version MMAS-8D and slightly higher 
when item 1 was not used for computation (0.40). Overall standardized Cronbach’s alpha was 
0.41. The item-to-total correlations ranged from -0.015 to +0.530 (Table 1). 
 
Table 1: Reliability test (n=70) 
 Corrected item-
total correlation 
Cronbach’s alpha if item 
deleted 
Item 1 -0.015 0.401 
Item 2 0.287 0.161 
Item 3 0.127 0.282 
Item 4 0.064 0.309 
Item 5 0.009 0.328 
Item 6 0.038 0.317 
Item 7 0.247 0.219 
Item 8 0.530 0.202 
 
Construct validity 
The principal component analysis (PCA) was used to show the dimensionality of the scale. On the 
basis of eigenvalues greater than 1, four components were retained, which explained 71.7% of 
the total variance. The items that contributed to the first component involved forgetfulness and 
remembering (items 1, 2, 8) and explained 24.4% of the variance. The items that contributed to 
the second component (17.3% of the variance) concerned stopping medication when one feels 
better and feeling hassled about one’s treatment plan (items 6, 7). The items that contributed to 
the third component concerned stopping medication when one feels worse and taking the 
medication the day before (items 3, 5). Item 4 concerning travelling situation contributed to the 
fourth component (13.5%). Table 2 shows the moderate to strong loading (>0.4) of all items, after 
varimax rotation with Kaiser normalization. 
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Table 2: Items, patients’ answers and maximal value of factor loading of the MMAS-8D in German (n=70) 
Item nb. Patients’ response to be 
considered adherent 
Number (%) Factor 
loading 
(component)* 
1 No 61 (87.1%) 0.692 (1) 
2 No 64 (91.4%) 0.179 (1) 
3 No 64 (91.4%) 0.748 (3) 
4 No 67 (95.7%) 0.875 (4) 
5 Yes 69 (98.6%) 0.795 (3) 
6 No 68 (97.1%) 0.782 (2) 
7 No 67 (95.7%) 0.824 (2) 
8 Never/rarely; Once in a 
while; Sometimes; Usually; 
All the time 
Never: 62 (88.6%) 
Once: 7 (10%) 
Sometime: 1 (1.4%) 
0.773 (1) 
 * first, second, third or fourth component obtained with principal component analysis (PCA) after varimax 
rotation with Kaiser normalization 
 
Convergent validity 
Convergent validity of the MMAS-8D was demonstrated through correlations with objective and 
subjective measures (Table 3). Patients with intake times within a grace interval of ± 3 or 1.5 hours 
had a significant higher MMAS-8D score (U-values 44 and 471, p<0.05). Adherence measured as 
timeliness of the intakes correlated moderately with MMAS-8D scores (r= -0.15) and in the 
expected direction, without reaching statistical significance (p=0.11; n.s.). There was a statistically 
significant relationship between items 6 and 7 and the recorded intake times (Chi-Square value 
34 and 22, p<0.01), with patients not stopping their medicine when they feel like their health is 
under control (item 6) and not feeling hassled about sticking to their treatment plan (item 7) taking 
their medication more often within the 3 hours grace period. The MMAS-8D scores were 
significantly correlated with the Necessity (r= 0.31; p<0.01) and the Concerns subscores of the 
BMQ questionnaire (r= -0.16, p<0.05). The correlations were small to moderate and in the 
expected directions i.e., patient who self reported higher adherence to their medication with the 
MMAS-8D had significantly higher sense of necessity of medication and lower concerns about it. 
After exclusion of the 7 patients with inflammation or genetic polymorphism, blood values of the 
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antiplatelet agent within therapeutic range correlated highly with MMAS-8D score (U-value 125, 
p<0.05). A subgroup analysis was performed according to indication of antiplatelet therapy. 
Patients with an antiplatelet agent for secondary prevention showed a statistically significant 
higher MMAS-8D score than patients in the primary prevention group (median 8 vs 7; U-value 
407, p<0.01). 
 
Table 3: Convergent validity: Spearman correlations and Mann-Whitney-U values of the MMAS-8D with 
objective adherence measures (electronic monitoring and blood values of antiplatelet agent) and beliefs 
about medicine scores 
 MMAS-8D 
Measures [numbers of patients] Correlatio
n  
U-value p-value 
BMQ necessity [70] 0.31  <0.01 
BMQ concerns [70] -0.16  <0.05 
Adherence as timeliness of intake [70] -0.15  0.11 (n.s.) 
Adherence as variability ± 3 hrs [70]  44 <0.05 
Adherence as variability ± 1.5 hrs [70]  471 <0.05 
Platelet aggregation in the range [63]  125 <0.05 
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In the present study with electronic adherence monitoring as reference standard, we examined 
the reliability and validity of the 8-item German version of the Morisky Medication Adherence 
Scale. The high adherence scores obtained electronically even with the strictest grace interval for 
medication intake were indicative of a highly adherent sample of patients. Direct measure of 
adherence by laboratory tests like platelet aggregation confirmed drug intake for 80% of patients, 
while reasons for reduced antiplatelet effect like genetic polymorphism or inflammation were 
observed for further 10% of the patients. Estimates of adherence obtained with the translated 
scale were in concordance to all rates calculated from electronic records.  
We found for the German version of the MMAS-8D low psychometric properties compared with 
the original English MMAS-8, especially for internal consistency (Cronbach’s alpha 0.31 vs. 
0.83.[24]) The small to moderate reliability we observed is similar to that of three other studies that 
validated the French [251], Malaysian [29] and Thai [250] versions of the MMAS-8. Since 
Cronbach’s alpha measures whether each item of a scale is appropriate for assessing the concept 
of the scale, the internal consistency of the entire scale will be high if all items measure the same 
phenomenon. In our case, we retained 4 components after varimax rotation that explained 71.7% 
of the variance (24.4% for the first component), indicating that the scale is four-dimensional. This 
is in contradiction with the original English scale that was declared one-dimensiona l[24], but in 
strong concordance with the results of the French and the Thai scales that attributed 55.2% and 
57.4% of the variance, respectively, to three components [250, 251]. Consequently, the 
unacceptable low Cronbach’s alpha in our study may indicate the multidimensionality of the scale 
rather than its inconsistency [277]. Further, the MMAS-8 contains items aimed at identifying 
reasons for non adherence that can be classified as causal indicators rather than effect indicators 
[278]. Because causal indicators by definition may not be highly intercorrelated, statistics with 
Cronbach’s alpha are inappropriate for these indicators, since high internal consistency depends 
on high inter-item correlation [278]. In this sense, some authors urge to indicate supplementary 
information to evaluate multiple-item measures of a scale [277] since Cronbach’s alpha seems to 
be an inadequate index to describe the internal consistency of a scale. 
Although subjective and objective measures of adherence have different strengths, the MMAS-
8D demonstrated convergent validity with electronic measures of adherence and with laboratory 
values. Since subjective measures are subject to potential inaccuracy because of patients’ 
memory or reluctancy to report deviant behaviour, and may thus overestimate adherence [279], 
objective measures with electronic systems were valued as more accurate. However, the 
correlation between self-related questionnaires and electronic records of adherence was shown 
to be small to moderate [263], predominantly because different sets of information are collected 
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with different approaches and perspectives. Notwithstanding, the correlation with electronic 
records, blood values and the significant association with BMQ subscores support the validity of 
the MMAS-8D. The latter is in accordance with findings from a study with women newly treated 
against osteoporosis with daily or weekly oral bisphosphonates, where the Necessity subscore of 
the BMQ showed a significant association with the 8-item Morisky scale [280]. 
The subgroup analysis showed that patients with antiplatelet therapy for secondary prevention 
self-reported a higher adherence than patients in primary prevention. This is in line with a recent 
meta-analysis with 376,162 patients, where 2/3 of the patients with a history of cardiovascular 
disease (and thus with a prescribed drug to prevent secondary disease progression) were 
adherent, compared to 1/2 of the patients with a drug to prevent a first event (primary prevention) 
[281].  
The authors acknowledge some limitations of the study. First, the sample could be prone to 
selection bias. Motivated patients might have been more likely to accept participation and thereby 
be more adherent than the general population of outpatients with antiplatet therapy. In a similar 
perspective, the sample could be prone to social-desirability response bias i.e., patients tending 
to present themselves in the most favorable manner. This is suggested by the overrepresentation 
of the maximal MMAS-8D scores, with almost 2/3 of the patients allocated to the high adherence 
group. This substantial ceiling effect is common in questionnaires [282]. Similar high results were 
observed in the French validation study (median score of 7; 44% of patients in the high adherence 
group.[251]) Second, the modest sample size may have biased our results, since small sample 
sizes can affect the result of the internal consistency. However, our sample size was greater than 
the study validating the Swedish version of the MMAS-8 (60 respondents in 1998, 53 respondents 
in 2002[283]) and than the first study validating a rating scale against electronic monitoring (61 
patients with electronic medication’s caps [284]). Third, the relatively brief monitoring period may 
be criticized because insufficient to estimate overall adherence to therapy. However, given that 
firstly intake of an antiplatelet agent over seven days is sufficient to influence platelet aggregation 
and to be detected in blood, and that secondly MMAS questions span the past 2 weeks, the short 
study period was estimated satisfactorily in our validation setting and able to deliver the required 
values of intake pattern. It should be further mentioned that the validity of the MMAS-8D scale 
might be somewhat compromised when the single medication for the health condition is not 
specified in the scale item. However, this health concern specified item is not compatible with 
polypharmacy and consequently, we generalized the items to target polypharmacy and not a 
single drug. By doing so, we made the items agree with the electronic monitoring. Finally, any 
electronic monitoring device can act as intake reminder and temporarily enhance adherence, 
especially when participants are aware of the purpose of the electronic system as in our study. 
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especially when participants are aware of the purpose of the electronic system as in our study. 
However, a recent randomised controlled trial with 226 diabetes patients investigated the reactive 
effect of electronic monitoring over 8 weeks [262]. The authors concluded that using an electronic 
device may lead to a small increase in adherence compared to standard packaging, however 
without reaching significance and without changing over time. As a consequence, a slightly higher 
adherence is inevitable in a patient’s population equipped with any reminder packaging. 
 
Because the German language is the official language in Germany, Switzerland and Austria, with 
identical grammar and orthography, our questionnaire can be used in the 3 German speaking 
countries without further adaptation. We could not find any negative comments in the literature 
when a questionnaire in German is used in several German speaking countries. A recent survey 
was developed in Switzerland in German language and was sent simultaneously to nurses in 
Switzerland, Germany and Austria through their respective societies [285]. The authors did not 
mention any comment on the language of the questionnaire. Much more, an international 
multicentre validation of a newly translated questionnaire in German was approved by ethic 
committees in Switzerland, Germany and Austria and was a strength for the recruitment of patients 
in primary care [286]. Cultural differences between the German speaking countries may concern 
the health system, which however is not a topic in the MMAS. 
To conclude, the German MMAS-8D was able to categorise 94.4% of the patients as good 
adherer, which was confirmed by established measures of adherence obtained from electronic 
data. It appears to be a reliable instrument to catch medication adherence in cardiovascular 
patients, despite a low internal consistency. Further, it is endowed with simplicity and quickness 
of administration and scoring, which facilitates its use in several pathologies.  
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8.2 Medication possession ratio may detect half of the self-declared non-adherent 
patients to direct oral anticoagulation treatment – A pilot study [C-2] 
 
Metaxas C, Hersberger KE, Arnet I 
Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, 




Adapted from the Poster presented at the 10th Pharmaceutical Care Network Europe (PCNE) Working 
conference: Build- Lead- Engage- Disseminate Bled, Slovenia, 1-4 February 2017.    
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Poor adherence to direct oral anticoagulants (DOAC) treatment in practice has been reported 
[287]. Because of non-forgiving characteristics, DOACs require strict intake intervals that translate 
into very high adherence rates. Identifying deviant behavior is needed to initiate adherence 
counselling. Indirect measures can be used to detect non-adherence such as self-report 
(subjective) or pharmacy refills (objective). The Polymedication Check (PMC) is a reimbursed 
intermediate medication review in Switzerland that focuses on adherence and medicines use in 
outpatients. The PMC consists of a semi-structured interview covering one closed-end question 
on adherence (subjective measure). In Switzerland, dispensed packages, daily prescribed doses 
and dates of refills are usually recorded in the pharmacy database. The Medication Possession 
Ratio (MPR, objective measure) is a method for calculating adherence rate from refill data with 
the following formula: days’ supply divided by the days of the interval of interest. 
 
Purpose of the Study  
We aimed at assessing whether the affirmative answer to the PMC question “Do you sometimes 
forget to take your medication?” coincides with a Medication Possession Ratio (MPR) <90% (non-
adherence) in DOAC treated patients. 
 
Method  
Fifth-year pharmacy students recorded one PMC with an anticoagulated patient during internship 
in community pharmacies between November 2014 and March 2015. Patient’s refills of the past 
12 months were used to calculate a MPR if at least two refills were available. Assumptions for the 
calculation of the MPR were taken from literature [288].  
 
Results  
The 69 PMCs concerned DOACs for 30 (43.5%) patients (52% women, 73.0 ± 12.2 years old, 9.9 
± 4.9 medications). The most often prescribed DOAC was rivaroxaban (93.3%), apixaban and 
dabigatran were marginally prescribed (3.3% each). Five cases were excluded due to less than 
two refills. All 25 remaining patients were treated with rivaroxaban.  
Refills (mean of 2.9±0.8 per patient) were available for a mean of 128±62 days. MPR ranged from 
50.2 - 182.7%. MPR below 90% was observed in 4 patients (16%) (Figure 1), out of them two self-
reported to sometimes forget to take the DOAC. Other two patients reported non-adherence but 
showed a MPR >90%. Oversupply up to 110% was observed for 7 patients, and excessive 
oversupply for 6 patients (MPR: 114-183%). 
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Figure 1: MPR of 25 included patients. MPR bars of patients who self-reported non-adherence are indicated 
in red.    
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Objective and subjective measures of non-adherence coincided poorly. One reason might be that 
the expression «Forget sometimes» might not mean skipping a dose and thus, might not translate 
into a reduced MPR value. To «Forget sometimes» may be interpreted as a simple delayed intake. 
We question the wording of the question that might be equivocal, and further the appropriateness 
of objective measures such as the MPR as single trigger to adherence counselling. Composite 
adherence measures may help to establish a more precise picture of adherence. In future, 
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9.1 Impact of a tailored and stepwise educational program on adherence to rivaroxaban 
therapy in Switzerland – adaptable to other European countries such as Germany or 
France [D] 
 
Study proposal, unpublished 
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Impact of a tailored and stepwise educational 
program on adherence to rivaroxaban therapy 
in Switzerland  
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1. Project description 
 
Scientific domain: Pharmaceutical Care / Anticoagulation therapy 
 
Key words: rivaroxaban, community pharmacies, educational program, adherence 
monitoring, pharmaceutical care 
 
Ethics committee approval: required 
 
2. Administrative information 
 
Coordinating center: Basel 
 
Project sites: community pharmacies and cardiologists in the region of Basel, Switzerland 
 
Duration of project: 9 months   
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Published evidence suggests that non‐adherence to anticoagulation in general and to rivaroxaban 
in particular is common. Previous work by our group showed that electronic monitoring of 
adherence to polypharmacy along with feedbacks allows improving intake patterns. A community 
2-arm project is proposed where patients with a first prescription of rivaroxaban are allocated to  
A) usual care in control community pharmacies, B) educational intervention in trained pharmacies. 
Randomization will occur at pharmacy level. All community pharmacies located in the North‐West 
German‐speaking part of Switzerland (Basel Stadt and Land, Aargau, Solothurn; approx. 300) will 
be invited to participate and to recruit patients. In parallel, cardiologists will recruit patients, 
suggest the participation in an educational project and direct them to a pharmacy of their choice 
(interventions and control).  
Eligible will be patients aged 18 or older with a first prescription of rivaroxaban for atrial fibrillation. 
Patients accepting to participate (gave Informed Consent) will obtain A) either rivaroxaban in 
original packages equipped with smart recorder cards (4DD® cards) or B) their oral medicines in 
smart weekly dispensers (in Switzerland: Pharmis® punch cards equipped with electronic wires 
POEMS; in other European countries: currently used weekly pillbox equipped with smart recorder 
cards). Patients will be asked to bring back used packages (original and repackaged) for 
downloading data. The project duration will be 9 months. The educational program (intervention) 
will focus on knowledge and adherence of the entire medicine schedule (polypharmacy). Patients 
will be proposed several educational units according to their current needs and problems (tailored 
and stepwise), followed by 3 months with intensified pharmaceutical care including additional 
feedback on their electronically monitored intake pattern. Outcomes to be monitored include: 
adherence (self‐reported, taking, timing, clusters), drug‐related problems, quality of life, and 
satisfaction. Data collection points comprise baseline (Tfirst), and at every smart refill (every 2‐4 
weeks for the whole project duration of 9 months (Tlast). 
The intervention starts with the patients’ screening questionnaire and the educational program for 
patients. Community pharmacists providing the interventions will be trained on how to provide 
feedback with individual electronic adherence data. Continuing coaching will be provided. Data 
analysis will be divided into intervention pharmacies and control pharmacies. Between‐group 
(bivariate) and multivariate analysis will enable to identify factors that may explain different levels 
of success of the educational intervention and of the intensified pharmaceutical care on patients 
outcomes. For all tests, a confidence interval of 95% will be considered. 
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ACTS  Anti‐Clot Treatment Satisfaction questionnaire  
AF  Atrial fibrillation 
A14  Adherence scale 14 
DVT  Deep vein thrombosis 
DOAC  New oral anticoagulants 
OAC  Oral anticoagulants 
PE  Pulmonary embolism 
PMC  Polymedication check 
POEMS Polypharmacy electronic monitoring system 
SF‐12  Short form 12 
S‐TOFHLA Test of functional health literacy in adults  
VKA   Vitamin K antagonists 
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5.1 Atrial fibrillation 
Atrial fibrillation (AF) is the most common form of sustained arrhythmia. The prevalence of AF in 
the general population is 1% and estimates suggest its prevalence is increasing  [289, 290]. AF is 
commonly associated with other diseases such as hypertension, heart failure, heart disease and 
diabetes. If AF is left untreated, patients are on significant risk for stroke and other morbidities. 
The aim of treatment is to prevent complications, particularly stroke, and to reduce symptoms. 
Drug treatments include anticoagulants to reduce the risk of stroke and antiarrhythmic drugs to 
restore or maintain the normal heart rhythm or to slow the heart rate in people who remain in AF. 
In June 2014, the National Institute for Health and Care Excellence (NICE) - guidelines for the 
management of AF have been revised and introduced major changes to stroke risk assessment 
in patients. Assessment of CHA2 DS2-VASc risk should be undertaken for all patients with 
paroxysmal, persistent or permanent AF, those with atrial flutter and those who have converted 
back to sinus rhythm but are at risk of arrhythmia recurrence. Oral anticoagulation should be 
considered in men with a CHA2DS2-VASc score of 1 and offered in all patients with a CHA2DS2-
VASc score of 2 or above, taking bleeding risk into account [291]. Thus, rate for oral 
anticoagulation use will increase in the next years. 
 
5.2 Oral anticoagulation therapy 
After 30 years of vitamin K antagonists (VKA) use, new oral anticoagulants were developed and 
become more popular. Rivaroxaban, a direct factor Xa inhibitor, is approved and indicated in the 
treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and the prophylaxis of DVT 
after hip or knee replacement surgery, the prophylaxis of stroke and systemic embolism in non‐
valvular atrial fibrillation (AF), and after acute coronary syndromes. Maintaining appropriate 
anticoagulation with VKA is challenging. Therefore switching patients with poor control to 
rivaroxaban may improve therapeutic outcome due to rivaroxaban’s favorable pharmacokinetics. 
Additionally, doses do not change and no monitoring is necessary making treatment with 
rivaroxaban more convenient for patients than therapy with VKA. On one hand, rivaroxaban 
therapy has relevant advantages for patients. On the other hand, rivaroxaban has a short half‐life 
and therefore an increased risk of thrombosis after the omission of one dose [145]. Thus, the once 
daily intake regimen requires a strict timing adherence to ensure appropriate therapeutic 
coverage. Finally, consultations for controlling blood values in patients taking VKA will not be 
necessary anymore, and the opportunity to discuss aspects of adherence during such encounters 
will not be possible. 
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5.3 Adherence to oral anticoagulants 
Adherence is defined as “the extent to which a person's behavior ‐ taking medicine, following a 
diet, and/or executing lifestyle changes ‐ corresponds with agreed recommendations from a health 
care provider”  [1]. The level of adherence to medicine varies greatly and is related to treatment, 
patient, and /or health care provider [2]. Intentional non‐adherence reflects the active decision of 
the patient not to take his medicine as prescribed. This is a rational process where patients beliefs 
and concerns are important factors influencing the motivation to take the medicine. Unintentional 
non‐adherence can be considered as an accidental process. The patient does not take the 
medicine as prescribed due to forgetfulness or not knowing how to use his medicines or other 
barriers. 
Non‐adherence in patients with AF or in patients treated with OAC for other reasons is a common 
problem. Non‐adherence rates were observed in up to 32 % patients treated with warfarin [146] 
and only 52% of patients with AF are adherent to a once daily drug regimen 18 months after 
treatment initiation. [292] Data from patients maintained on short‐term thromboprophylaxis with 
rivaroxaban suggest low non‐adherence rates (4%) but these patients are at a considerably 
increased risk for complications(e.g. pulmonary embolism) [293]. In general, medicine adherence 
for patients treated with new oral anticoagulation for chronic conditions has been poorly documented. 
Rodriguez et al., stated that rates of premature discontinuation with DOACs in registration trials range 
from 2.3-37%, in which 11% (range 3-14.3%) no apparent reason for discontinuation is available [147]. 
A recent project observed adherence rates, given as proportion of days covered, of 0.86 (SD: 0.19) in 
patients treated with rivaroxaban [294]. 
 
5.4 Interventions to enhance adherence to oral anticoagulants 
Simplifying treatment regimen for anticoagulation and other conditions may improve medicine 
adherence, which can potentially prevent therapy failure and adverse events. The addition of a 
reminder system was shown to increase adherence (pill counts) by 4.1 – 4.3% in HIV patients [295] 
and reminder systems combined with dose simplification were shown to decrease rate of non-
adherence by 24-26% [147]. A recent Cochrane review [44] found that current methods of improving 
medicine adherence for general chronic diseases are mostly complex and not effective. Another 
review showed that patient education about disease and medicine knowledge is not sufficient for 
addressing non‐adherence while self‐ efficacy is an important factor [50]. Controversially, two 
studies showed that enhancement of patient knowledge about OACs and the underlying disease 
were associated with improve long‐term adherence or better therapeutic outcome [81, 82]. 
Another review on patient education and OAC therapy [61] stated that the process of patient 
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education is influenced by literacy/language barriers, cost‐effectiveness of the programs, and 
accountability in educational outcomes. Therefore, improving anticoagulation outcomes needs first 
the prioritization of the educational content for the development of meaningful long‐term 
interventions. Additionally, there is a need for validated instruments measuring outcomes after 
patient education, for objective adherence measures and for sufficient project power enabling 
the detection of improvements in adherence and clinical outcomes. Because usually the OAC 
therapy represents just one element of a medicine regimen, polypharmacy needs to be 
considered. One can assume that DOACs ‐ in contrast to VKAs ‐ are perceived as ordinary oral 
medicine due to the absence of specific monitoring and dose adjustment. Therefore, adherence 
interventions need to consider the patient‘s current polypharmacy. Unlike a currently performed 
project on education program for Eliquis® (AEGEAN, ClinicalTrials.gov: NCT01884350), we will 
address all medicine in the educational program and measure adherence to all medicine. 
 
5.5 Pharmacy‐led counseling in Switzerland 
5.5.1 Polymedikation check (PMC) 
Since 2010, community pharmacists in Switzerland can offer a medicine use review, the so called 
Polymedikation check (PMC), to patients on ≥ 4 prescribed drugs taken over ≥ 3 months. The PMC 
is based on the Medicines Use Review (MUR) from the United Kingdom [41]. This type of 
pharmacist-led medicine review services are available in several other countries such as the 
United States of America, Australia, Canada, and New Zealand [37-40]. The PMC focuses on 
drug‐related problems, adherence issues, and the need for suppling of the medicine in a weekly 
pill organizer. This service is well implemented in Switzerland and remunerated as a cognitive 
service (Annex A). A recent evaluation of the PMC showed a consistent trend for improved 
adherence rates in patients treated with antiaggregation drugs after receiving a PMC, however 
without reaching significant level [296]. 
 
5.5.2 Weekly pill organizer 
A recent project showed that during a PMC in patients treated with OAC, pharmacist offered in 
72.5% of the cases the use of a dose dispensing aid such as a weekly pill organizer. Dose 
dispensing aids (e.g. Dosett®, Pharmis®) are frequently supplied to older patients with complex 
medicine use in Switzerland and Australia and other European countries such as Holland, Spain, 
France and the UK [297]. In Switzerland, the delivery of a weekly pill organizer is reimbursed by 
the health care system. In its function as drug reminder systems, dose dispensing aids allow to 
improve non-intentional non-adherence. The impact of these drug reminder systems has been 
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evaluated in a systematic review: positive effects on adherence and clinical outcomes were clearly 
demonstrated [298]. 
 
5.6 Adherence assessment methods 
Adherence can be measured directly or indirectly. The quality of different adherence 
measurements was assessed in a recent review [20]. In brief, the authors concluded that 
composite measures are important to establish a detailed picture of adherence. From all available 
indirect adherence assessment methods, the electronic monitoring represents the most objective 
measure and is recommended as the method of choice in research on adherence [30]. Up to now, 
electronic monitoring of one medicine was feasible using devices such as the MEMS® caps 
(Medicine Event Monitoring System). In several studies using these electronic caps, discussing the 
adherence profiles with the patients had a significant impact on patient outcome, mainly through a 
shared decision of the follow‐up strategy [32]. However, only one single medicine was monitored 
and the derived intervention focused on that specific medicine. 
Recently, our group developed a monitoring system for polypharmacy named POEMS 
(Polypharmacy Electronic Monitoring System; see Figure 1) [33]. It consists of a paper foil with 
imprinted electronic components that measure the electrical resistance and record the time of its 
changes when a loop is broken, i.e. when a cavity is emptied. The patient’s entire oral solid 
medicine is filled in a disposable multidrug punch card with 7x4 cavities (Figure 1), equipped with 
the foil on its backside [33]. In a previous project [299], we combined biomarker measurements 
with this new method of electronic adherence monitoring of solid oral drugs. The use of POEMS 
allowed to rule out non‐adherence and therefore to assess drug‐drug interactions, whereas 
pharmacogenetic tests and biomarker assessments allowed the identification of contributing factors 
when the lack of biomarker response persisted. 
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Figure 1: A) Front side of a commercially available multidose punch card (Pharmis GmBH, Beinwil am See, 
Switzerland) with 4 x 7 cavities pre-filled with a patient’s individualized medication regimen. B) Rear side 
covered with an electronic film of conductive tracks, a battery and an antenna, and a microchip housing 
(ConferenceClinique S.A. Lausanne, Switzerland).  
 
The recorder card 4DD® was developed by the company Adherence innovations (based in The 
Netherlands; www.adherence-innovations.com) to help patients remember the intake of 
medicines through an alarm flashing (light) and beeping (sound; see Figure 2). With a clip system, 
the card can be affixed to original packages or weekly pill organizers. The development of a smart 
version will enable to obtain electronic monitoring data. Patients will press the red button at the 
time of the intake, and register the intake event with exact date and time. For both systems 
(POEMS and 4DD® card), the data are transferred to a web-based database, 
either via a wireless communication device (NFC for POEMS) or a plug cable 




Figure 2: Reminder card 4DD® (Adherence innovations, The Netherlands). Up to four intake times can be 
programmed either by the pharmacist or the patient himself. Pressing the red button will register the intake 
with date and time. 
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6. Plan and methods 
 
6.1 Overall goals 
A) To develop a stepwise educational program on anticoagulation in general and on rivaroxaban in 
particular and to evaluate its impact in ambulatory patients under polypharmacy. The research 
question is: “Can a pharmacy‐based educational program contribute to ameliorate the adherence 
to first‐time rivaroxaban in ambulatory patients under polypharmacy?” The educational program 
should be easy to implement in daily practice. 
 
B) To develop a stepwise educational program on adherence using feedback from electronic monitoring. 
The research question is: “Can a pharmacy‐based educational program followed by 
ind iv idua l ized feedback from electronic monitoring (= intensified pharmaceutical care) 
contribute to enhance timing-adherence to rivaroxaban in ambulatory patients under 
polypharmacy?” 
 
6.2 Specific aims 
The aims are a) to investigate the impact of the intervention on subjective (questionnaire based) 
and objective (electronically monitored) adherence; b) to assess patient satisfaction with an 
educational tailored and stepwise program on anticoagulation therapy. 
 
6.3 Project hypothesis 
I. Patients in the educational intervention group will have higher taking adherence than patients 
in the control group. 
II. Patients in the intervention group will have a better knowledge of anticoagulation and 
rivaroxaban at the end of the project (after 9 months) than patients in the control group. 
III. Patients in the intervention group will declare satisfaction with the educational program, 
independently of the electronic monitoring system. 
IV. Patients in the intensified intervention group will have higher timing adherence after additional 
feedback on intake pattern at the end of the project (V10, after 9 months) compared to V8 
(after 7 months). 
 
6.4 Project design  
This is a prospective project with 2 groups, with cluster randomization at the pharmacy level 
(intervention pharmacy or control pharmacy; Figure 3). Patients fulfilling all inclusion criteria and 
no exclusion criteria will be served by one of the two pharmacies: 
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1A) Intervention pharmacy (I-Apo) for Switzerland: All oral medicines will be dispensed in 
Pharmis® multidrug punch cards equipped with the electronic monitoring system POEMS, 
medicines will be reviewed (PMC), at least 2 educational sessions will be dispensed, after 7 
months (V8) additional individualized feedback based on the individual intake profile will be 
provided. 
 
1B) Intervention pharmacy (I-Apo) for other European countries: All oral medicines will be 
dispensed in locally available multicompartment weekly organizers (e.g. www.medi-7.de) 
equipped with the smart recorder cards, medicines will be reviewed (according to locally current 
practice), at least 2 educational sessions will be dispensed, after 7 months (V8) additional 
individualized feedback based on the individual intake profile will be provided. 
 
2) Control pharmacy (C-Apo): Rivaroxaban original package will be equipped with smart recorder 
cards, medicines will be reviewed (in Switzerland: with PMC; in other European countries: 
according to locally current practice), routine care will be dispensed, no specific education and no 
feedback to individual intake profile. 
 
6.5 Interventions 
There will be two types of interventions provided by the intervention pharmacies (1) the 
educational program and (2) the intensified pharmaceutical care program with feedback. Both need 
to be developed and tested. The following elements represent key elements of the interventions: 
 
The educational program consists of (a) one main session at the first contact, (b) one 
consolidation session at the second contact, and (c, d, e) further 3‐7 deepening sessions at the 
remaining contacts until V7. The main session will start with a medicines review (PMC). A 
questionnaire will allow detecting further individual patient needs (beliefs and concerns, perceived 
barriers, motivation, environment, and competencies). 
 
The intensified pharmaceutical care program starts after 7 months and will be provided only at 
sessions V8-V10. It consists of visualizing the past intake pattern obtained with the electronic 
monitoring, providing feedback based on the individual patient profile and stressing the need of 
time adherence, or adapting the treatment plan in collaboration with the physician. Reasons for 
delayed and/or premature intakes will be investigated, and according practical solutions will be 
proposed.  
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6.6 Recruiting centers  
Community pharmacies accepting to participate (see Tasks 7.5) and dedicated cardiologists in the 
region of Basel, Switzerland. The intervention will solely be provided in the community pharmacies. 
 
6.7 Population and sample 
Inclusion criteria: 
 patients with AF newly prescribed rivaroxaban 
 taking at least 2 additional oral solid drugs 
 aged 18 years or older 
 self‐managing their medicine 
 capable to give informed consent in German language 
Exclusion criteria: 
 patients with a diagnosis of declared dementia 
 patients who are supported in their drug management through a home care organization 
 patients using a weekly medicine aid system (control and educational group; daily 
medicine aid is not an exclusion criteria) 
Sample:  
To detect an expected absolute difference (effect size) of 11% between the taking adherence 
rates of the control group (76% according to Di Matteo 2004 in cardiovascular diseases [5]) and 
the educational intervention group (87%; 20% absolute difference (effect size) would be possible 
according to Lee 2006 in combination with a reminder system after 6 months of intervention [300]), 
we need a sample size of 67 patients per group and a minimum of 20 recruiting pharmacies per 
group, based on the assumptions that participating pharmacies will recruit a mean of 7 patients 
[296] and of a fairly small clustering effect of 0.05 (0.026 would be possible according to Sturt J.A. 
in a cluster randomized trial on diabetes education in primary care [301]). 
 with a level of significance set at 5% (one-sided) 
 with a power of the project set at 80% 
 with a standard deviation in the population set at 30% and 20%, for the control and the 
educational intervention group, respectively 
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An additional sample of 50 patients and 15 recruiting pharmacies (educational group) is needed 
to detect an expected absolute difference (effect size) of additional 10% between the taking 
adherence rates of the educational (87%) and the adherence enhancing program (97%) after 9 
months of project duration, based on the assumption that participating pharmacies will recruit a 
mean of 7 patients and a fairly small clustering effect of 0.05. 
 with a level of significance set at 5% (one-sided) 
 with a power of the project set at 80% 
 with a standard deviation in the population set at 20% in both groups (educational and 
educational plus intervention) 
 (calculated with http://sampsize.sourceforge.net/iface/s2.html#means).  
 
In total, we need a sample of 216 patients with an anticipated drop‐out rate of 32 patients (17%) 
[296]. Cardiologists will recruit patients, suggest the use of electronic punch cards to manage 
medicine, and direct patients to the pharmacy of their choice (interventions and control). In parallel, 
project pharmacies will be instructed to recruit patients. The project will be terminated when 216 
patients will be recruited. Randomization will occur at the pharmacy level. The project duration will 
be 9 months after inclusion. 
 
Follow‐up: Patients who want to continue obtaining their polypharmacy in punch cards after 
completion of the project will be served accordingly by the community pharmacy but the electronic 
monitoring will be removed. 
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Figure 3: Project flow chart. 
 
6.8 Drug‐related problems 
Given the type of intervention, we cannot think of any adverse events that will be directly related to 
the trial. We will ask pharmacists to record drug‐related problems with a specific classification tool 
[302]. We will develop an open questionnaire where patients will be invited to name any drug‐
related problem in daily life they may have experienced from the intervention. 
 
6.9 Informed consent  
Patients participating in this trial will all have to provide written informed consent for participation in 
the trial. 
 
6.10 Method of masking  
This is an open intervention project. Pharmacists and patients will not be blinded to the intervention. 
Patients in the educational intervention group and in the control group will not be blinded to the 
compliance monitoring (POEMS or smart recorder card). Patients will be instructed to bring their 
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rivaroxaban original package every month back for downloading data. Responsible clinicians will be 
informed monthly about pharmacist-led interventions and at the end of the project about results 
from the electronic monitoring. 
 
6.11 Process measures 
An overview of data which will be assessed is given in Table 1. 
I. Subjective non‐adherence will be assessed using the A14 adherence questionnaire [303] 
in its German version. This is a 14‐item questionnaire with 5‐point Likert scale ranging from 
“never” (4 points) to “very often” (0 point). It takes about 7 minutes to complete. Patients 
with a total score of 50‐56 points are classified as “adherent”, those with a lower score as 
“non‐adherent”. We obtained the right to use the questionnaire. 
II. Objective non‐adherence will be assessed electronically (with POEMS and smart recorder 
card in Switzerland; with smart recorder card in other European countries). 
III. Health Literacy will be assessed using the short version of the Test of Functional Health 
Literacy in Adults (S‐TOFHLA) [304]. Health literacy represents the cognitive and social 
skills of individuals and determines the motivation and ability to gain access to, understand, 
and use information in ways which promote and maintain good health. Health Literacy 
means more than being able to read information and successfully make appointments and 
additionally addresses the environmental, political, and social factors that determine health 
[50]. The S‐TOFHLA contains 4 numeracy tests and 2 prose passages and takes a 
maximum of 12 minutes for answering. The S‐TOFHLA is a practical measure and can be 
used to identify individuals who require special assistance to achieve learning goals. It has 
been translated into German and was shown to be reliable and valid. [305] 
IV. Patient satisfaction with anticoagulation therapy will be assessed with the Anti‐Clot 
Treatment Satisfaction questionnaire (ACTS), a specific treatment satisfaction 
questionnaire. This 15‐item self‐report questionnaire includes 3 questions concerning 
benefits and 12 questions concerning burden of anticoagulation therapy. Patients will be 
asked to report their  experience with anticoagulant treatment during the last 4 weeks on a 
5‐point Likert scale (1= not at all, 2= a little, 3= moderately, 4 quite a bit, 5= extremely). 
The ACTS has been translated into German. The ACTS burdens and ACTS benefits scales 
consistently satisfied traditional reliability and validity criteria, confirming its clinical 
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usefulness as a self‐reported instrument of patient satisfaction with anticoagulant treatment 
in clinical trials. [306] 
V. Quality of life will be assessed using the SF‐12, a short version of the SF‐36. This self‐report 
questionnaire measures functional health and well‐being with 12 items from the patient's 
point of view. It is a practical, reliable and valid measure of physical and mental health that 
can be completed in five to ten minutes [307]. The SF‐12 has been translated into German 
and validated in patients with coronary heart disease. The summary measures replicate 
well the SF‐36 summary measures and showed similar responsiveness to change. [308]  
VI. Knowledge on anticoagulation, rivaroxaban. 
VII. Needs of patients (screening tool for the intervention group) and patient reports in the 
control group. 
VIII. Drug related problems and corresponding interventions will be assessed with the 
classification system “pharmDISC” during the medicine review PMC and at each refill visit 
the intervention groups (education and education-plus groups). This system was developed 
and validated by our research group for the classification of drug‐related problems and 
pharmaceutical interventionsin community pharmacies [302]. 
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Table 1: Overview of data collection (I-Apo = Intervention pharmacy; C-Apo = control pharmacy); (X) = 
facultative, according to local practice 
 Patient 
characteristics, 




















 I-Apo C-Apo I-Apo C-Apo I-Apo C-Apo I-Apo C-Apo I-Apo C-Apo 
V1 X X X X X X X X   
V2   X (X) X X X X X X 
V3   X (X)     X X 
V4   X (X)     X X 
V5   X (X)     X X 
V6   X (X)     X X 
V7   X (X)     X X 
V8   X (X) X X X X X X 
V9   X (X)     X X 
V10 X X X X X X X X X X 
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‐ subjective: self‐report using A14 at baseline (V1), at V2, V8 and at last visit for all groups. 
‐ objective: values obtained from electronic intake data: 





Timing adherence  %	 	 	 	 	 	 	 	  
= 
	 	 	 	 	 	 	
	 	 	
	 
Time variability in drug intake	
∑ | |
	 	 	 	 	 	 	
 
 
Days without dosing = 
	 	 	 	 	
	 	 	 	
 
 
Percentage of too short (overdosing) or too long (underdosing) intervals 
 
Clustering methods will be used to identify pattern of adherence and different clusters will be 
compared to a variety of patient characteristics. [309] 
 
Health literacy will be assessed at baseline (V1) and last visit (V10) for all groups. 
Patient satisfaction with anticoagulation treatment will be assessed at baseline (V1), V2, V8 and 
at the final visit for all groups. 
Knowledge of anticoagulation and treatment will be assessed at baseline (V1), V2, V8 and last 
visit for all groups. 
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Bivariate analysis will include a) between‐group analyses (Chi‐squared test for categorical 
variables, Students t‐test or Mann‐Whitney test for continuous variables). These analyses will be 
performed at baseline and at the end of the project to evaluate the impact of the interventions. The 
effect over time b) will be assessed using within‐group analyses of the intervention group (Wilcoxon 
test for continuous variables in several time points). Multivariate analysis will include c) factor 
analysis to detect factors associated with successful interventions.  
 
6.14 Data generation, data entry, blinding 
Patient data will be generated at the community pharmacies and entered into their local software 
as part of their routine. A checklist will describe the content of each visit. Thus, it will guide 
pharmacists through each visit. All data from the questionnaires will be sent together with the CRF 
to the clinical project center by post mail or e‐mail. Electronic monitoring data from the POEMS will 
be sent electronically by the pharmacist during medicine refill to the server of the pharmacy project 
center. The pharmacy project center will be responsible for coordinating, checking, and exporting 
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7.1 Development of tools and their scores 
7.1.1. Main educational session (V1) 
This session will deal with basic information on AF, anticoagulation in general, and therapy with 
rivaroxaban in particular. All educational topics according to the review of Wofford et al, appropriate for 
rivaroxaban therapy will be included [61]. As much information and material (booklets) as possible will 
be taken from the European Heart Rhythm Association (EHRA) practical guide [310]. 
Complementary information about the co‐medicine will be given (purpose, expected effects). All 
given information will agree with the Swiss Summaries of Product Characteristics [133]. Self‐
management with punch cards will be explained and electronic monitoring will be disclosed. 
 
7.1.2. Consolidation session (V2)  
This session will check which information the patient could retain from the basic information 
dispensed at the first session. Elements missing for whatever reason will be repeated. Individual 
patient needs will be checked and prioritized. Current problems with medicine management (e.g. 
side effects, persistence with treatment) will be assessed. Solutions will be proposed and shared 
decision of the follow‐up strategy will be made. 
 
7.1.3. Deepening educational sessions (V3-V8)  
They will focus on individual needs for deepened knowledge and recurrent problems will be 
assessed. Solutions will be proposed and shared decision of the follow‐up strategy will be made. 
 
7.1.4. Screening for needs at first visit (V1)  
Evidence on barriers and facilitators were taken from the literature and compiled in a self‐
administered questionnaire.  
 
7.1.5. Knowledge Questionnaire (V1, V2, V8, V10)  
Existing questions from the literature were compiled and evaluated by an expert panel. The final 
self‐administered questionnaire contains 15 questions and will be tested for readability, 
acceptability and comprehension in a convenience sample. It will be validated in a sample of 
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7.1.6. Pilot testing of the screening tool  
The tool for the screening of patient needs will be pilot tested in a convenience sample for 
acceptability, comprehension and readability.  
 
7.2 Request of existing tools 
Existing validated tools in German (S‐TOFHLA, ACTS and SF‐12) will be requested from their owners. 
 
7.3 Case report form (CRF) 
CRFs for intervention and control pharmacies and for recruiting cardiologists will be developed. They will 
contain the responses of the patients to the questionnaires, baseline data, notes and minutes, and 
adherence data. 
Data collected through electronic system will be accessible through pseudonymization (i.e. keeping 
patients privacy and date confidentiality but allowing access for authorized persons). Data collected on 
paper sheets will be anonymized with patient identification codes. 
 
7.4 Ethic committee approval 
The project will be submitted to the Ethical Committee Nordwest Schweiz for approval. 
 
7.5 Recruitment of the pharmacies 
For the recruitment of educational plus intervention pharmacies addresses of the community pharmacies 
offering punch cards in the North‐West German‐ speaking part of Switzerland (Basel‐ Stadt and Land, 
Aargau, Solothurn) will be provided by Pharmis AG. This company is the leading provider of software and 
support for repacking medicines into blister punch cards (www.pharmis.ch). For the recruitment of 
educational and control pharmacies all community pharmacies of the cantons Basel Stadt and Basel 
Land pharmacies will be invited to participate by an invitation letter.  
 
7.6 Recruitment of cardiologists 
Contact has been made with several cardiologists and the discussion about their participation is ongoing. 
 
7.7 Education of pharmacists 
Previous research from our group has identified that the training of pharmacists in view of performing a 
clinical project is best conducted in 2 steps.  
During an initial meeting at the university general information on the project will be given to the participating 
pharmacists. Medication knowledge will be updated giving information about rivaroxaban / AF treatment 
including handouts (DOAC leaflet by Bayer®, EHRA guide). 
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The different aspects and the importance of adherence will be pointed out and tools (questionnaires, 
screening tool, and documentation of interventions) and data collection will be introduced. Stepwise 
patient education as described above will be shown. Teaching adherence measurement methods like 
electronic data monitoring (POEMS) will also be part of the education program. Possible difficulties should 
be uncovered and solved. A training video with a pseudo-patient will be produced to show important steps 
of the interventions and handling of the CRF, the video will be online available during the study. 
The second meeting will take place at the community pharmacies. During a visit, a researcher will run a 
fictitious case to check all elements (questionnaires, data gathering tools, and web application). The 
correct application of data gathering tools is essential for this project. 
 
7.8 Coaching of the pharmacists 
All training elements (power points slides, training videos, documents, and checklists) will be available 
online on PCRG website (www.pharmacare.unibas.ch). Experience from a previous project in our group 
showed that project pharmacists are repeatedly viewing online information intended for them. A hotline 
will be implemented to help pharmacists e.g., when they encounter a problem while they are in contact 
with a patient. Other information will be delivered via phone call or video conference (skype). 
 
7.9 Electronic monitoring 
POEMS technology and smart recorder cards will be disseminated to the project pharmacies (POEMS 
films, electronic devices, data reader, and login for the web application). Pharmacists will be able to 
allocate an electronic punch card or smart recorder cards to a specific patient, to read the returned punch 
card, and to visualize the intake pattern with the patient. They will not have access to the database. The 
responsible investigator will have administrator access to the entire database. 
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8. Significance of the planned work 
We see several impacts of the planned work on national and international levels. 
First in Switzerland, our results may contribute to implement a specialized cognitive service in 
addition to the generic Polymedikation Check. It could be added to the “Leistungs Orientierte 
Abgabe (LOA)” contract between community pharmacy and health care insurance. The new 
“educational anticoagulation service” will provide support for patients with a new prescription of 
rivaroxaban for long-term conditions and will ensure safe medicine use and improve medicine 
adherence.  
Second on international level where medicines review services are already known (UK, NL, 
United States of America, Australia, Canada, and New Zealand [37-41]), the extension of the 
medicines review with an educational anticoagulation part could be realized. In countries without 
medicines review services, the educational anticoagulation service could be proposed to the local 
health care system. 
Third, our results may help stakeholders to evaluate the benefits of electronic drug reminder 
packaging. The use of such reminder blisters is increasing, equally in countries without 
reimbursement such as Germany [312]. Our results could serve local health care systems.  
Finally, our results may support the positive impact of education and knowledge on adherence in 
general, and on adherence to rivaroxaban in particular. 
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10 General discussion and conclusions 
 
This thesis contributes to a better understanding of patient knowledge and preferences. The goal 
was to assess patient knowledge of anticoagulation, patient preferences for VB12 therapy, and to 
develop an educational program on adherence for outpatients with rivaroxaban therapy (adaptable 
to all DOACs). Further, assessment instruments for knowledge, preferences and adherence in 
German were created. Because underlying concepts are complex, this goal was approached in 
four distinct projects. Consequently, in this thesis various methodologies were applied such as 
focus group discussions, semi-structured interviews, evaluation of biomarker levels, applied 
observational studies as well as randomized parallel group designs.  
 
Patient knowledge about oral anticoagulation therapy  
Project A consisted of two studies. First, we aimed at screening for knowledge gaps about OAC 
in outpatients treated with VKAs or DOACs. We therefore amended the basic PMC with specific 
questions on OAC and assessed its impact on knowledge in an observational study (Study A-1). 
Because no specific DOAC knowledge assessment questionnaire was psychometrically validated 
and published, we developed and validated a questionnaire to self-assess knowledge about 
DOAC (Study A-2). The KODOA-test can be used in clinical trials to determine associations 
between knowledge of DOAC and adherence or clinical outcomes.  
 
Screening for knowledge gaps about OAC in outpatients was achieved with the basic PMC which 
was amended with specific questions about OAC. These questions were derived from a French 
publication about the evaluation of a pharmaceutical interview in an anticoagulation clinic [151]. 
Questions were translated into German, formulated as open-ended questions and placed at the 
very end of a basic PMC in form of a semi-structured interview. In the observational study A-1, 
patients on VKAs or DOACs received the amended PMC. The study demonstrated that the 
majority of patients had knowledge gaps concerning OAC and that half of the patients did not 
know how to proceed in case of a missed dose. Our findings are in agreement with other studies 
that observed that a majority of patients treated with OAC had poor or inadequate knowledge of 
the treatment [152-154]. We further found a trend that patients with DOAC therapy were more 
likely to have knowledge gaps compared to patients on VKAs. A recent survey of the European 
Heart Rhythm Association (EHRA) showed also that there is room for improvement regarding 
education of patients taking OACs [313]. A lack of knowledge of OAC sets patients at risk for 
medication errors, induces low self-care behavior and causes poor health outcomes [49]. We 
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observed high prevalence of  knowledge gaps regarding OAC therapy, predominately in patients 
on DOAC. This observation served as a rationale for further projects on knowledge about DOAC. 
In particular the development and validation of a specific questionnaire to self-assess knowledge 
of DOACs in clinical trials and the development of a study protocol for a cluster-randomized 
controlled trial that investigates associations between enhanced DOAC knowledge and improved 
adherence (Studies A-2 and D). 
 
We further observed that identification of knowledge gaps led pharmacists to provide educational 
counselling spontaneously. Although unstructured, the provision of this targeted and tailored 
counselling increased patients’ knowledge of OAC. The increase of patient knowledge of OAC 
following an educational counselling was previously shown [181-184]. Education in these studies 
was based on educational content. We could conclude that even a simple screening with open-
ended questions enables community pharmacists to easily counsel OAC patients.  
 
The semi-structured interview we used consisted of eight questions which do not cover all 
educational domains important for OAC according to Wofford [61]. Because our study was not 
specific to VKA, topics such as blood-testing and food-drug interactions were omitted on purpose. 
Further, the presence of students as observer of a counselling with the amended PMC could have 
triggered community pharmacists to engage more in counselling practice than usual (also known 
as the Hawthorne effect [160]). In further studies, different sets of questions for either DOAC or 
VKA might be adequate and long-term sustainability of the increased knowledge of OAC and 
subsequent influence on behavior e.g., adherence and save use of medicines, need to be 
addressed in randomized controlled trials. Finally, the length of a counselling session with the 
amended PMC was rather long. Therefore, it may be reasonable to amend the PMC with specific 
questions only for high-risk medication such as OAC. We therefore suggest to further adapt the 
amended PMC to an “anticoagulation PMC”, similar to the medicines use review in UK which was 
also adapted for specific target groups [159].  
 
Research aiming to further develop medication review services in Swiss community pharmacy is 
ongoing. A current project concerns the development of the PMC to become a specific medication 
review for patients at hospital discharge [314]. Because the basic PMC is poorly implemented in 
daily practice, major adaptions are planned within this project. Likewise, the “anticoagulation PMC” 
could be improved with similar adaptions of the basic PMC protocol. Recently, a Swiss e-learning 
tool on oral anticoagulants was developed and is currently tested with pharmacy students [315].  
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The aim of this project is to prepare community pharmacists for patient education. To educate 
community pharmacists or other HPC might improve counselling quality, allow patient centered 
communication and decrease length of a counselling session.  
 
In the Study A-2, we followed an evidence-based approach to select relevant items for patient 
knowledge of DOAC. After literature review, completeness of retrieved items were exhaustively 
verified and supplemented with the Swiss summaries of Product Characteristics (SPCs), the 
Update EHRA Practical Guide on the use of non-vitamin K antagonist anticoagulants [113], and 
the patient guide for taking DOAC from the cardiology patient page [170]. Twelve anticoagulation 
experts across different professions participated in the questionnaire development process to 
ensure content validity and the selection of relevant items. The developed Knowledge Of Direct  
Oral Anticoagulants (KODOA) test was validated in patients on DOAC and pharmacists. The 
KODOA-test confirmed to be feasible, comprehensive, reliable and valid to self-assess patient 
knowledge of DOAC. Construct validity was supported by significant differences in scores between 
patients and pharmacists. Finally, the KODOA-test was responsive to educational counselling 
about DOAC which supports construct validity. 
 
We observed an internal consistency slightly lower than other knowledge assessment 
questionnaires. The obtained Cronbach’s alpha value is likely to result from the multi-factorial 
nature of the KODOA-test because it consists of items derived from several education topics. The 
KODOA-test includes very easy items and very difficult items. Despite the fact that such grade of 
difficulty tends to decrease the internal consistency of the scale [175], we need basic questions 
on the medication that patient uses such as “Dosing frequency”. Finally, a low Cronbach’s alpha 
might be explained by the shortness of the KODOA-test with solely 15 questions, since internal 
consistency increases as test length increases [176]. With these considerations, an alpha of 0.67 
seems acceptable. Stability over time was confirmed by test-retest correlation above the threshold 
of 0.7, which indicates adequate reliability [177]. Mean time between test and re-test was 12 days. 
Recommendations for interval between two identical tests vary between 2 days [175] and three 
months [178]. We selected a short time interval based on ethical consideration because patients 
with deficient knowledge should be corrected as soon as possible in order to avoid life threatening 
situations. Knowledge scores remained high after approximately two more weeks demonstrating 
the sustainability of the educational counselling. In addition, patients agreed uniformly that their 
knowledge had increased. Nevertheless, further follow-ups could be useful to maintain high level 
of knowledge. 
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A recent study investigating knowledge in OAC patients included patients with DOAC, but 
knowledge assessment method was not developed for patients on DOAC therapy [181]. Thus, an 
accurate measurement of patient knowledge of DOAC is still lacking. The KODOA-test could serve 
as reliable and valid knowledge assessment questionnaire for clinical trials. Whether the KODOA-
test is applicable in other languages needs confirmation by further research.  
 
The need to give special attention to patients on OAC has been recognized on an international 
level, i.e. the International Pharmacists for Anticoagulation Care Taskforce (iPACT) aims at 
providing high-quality care for patients receiving oral anticoagulation medication all around the 
world through high-quality training and counselling for pharmacists and healthcare practitioners 
[316]. Studies A-1 and A2 might contribute with important findings from Switzerland to the existing 
evidence and current investigations about patient knowledge on OAC on international level. 
Project A provides simple screening questions for the identification of knowledge gaps (A-1), a 
validated knowledge assessment questionnaire about DOAC and a standardized educational 
manual for counselling (A-2) for practice and research. How to best perform educational 
counselling e.g. spontaneous and unstructured counseling, counselling according to an education 
manual or another technique needs to be addressed in further studies. Additionally, studies are 
needed to proof efficacy, appropriateness and economics of an intervention with educational 
counselling. 
 
Patient preferences and vitamin B12 deficiency 
Project B consisted of three studies. The aim of the first study (B-1) was the assessment of the 
impact of type 2 diabetes (T2DM) and metformin use on VB12 associated biomarkers and their 
suitability to reflect VB12 supply. In a randomized controlled parallel group trial, we further aimed 
to compare early biomarker response and patient preferences to high dose oral and i.m. VB12 
treatment with consideration of adherence issues (B-2). The last study (B-3) aimed to assess 
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In Study B-1, differences of VB12, holotranscobalamine (HoloTc), the biologically active fraction 
%AB12=HoloTc/VB12*100 and homocystein (Hcy) were analysed i) among diabetic outpatients 
with (T2DMMet+) and without metformin use (T2DMMet-) and ii) in comparison to an external non-
diabetic reference group with low levels of VB12 (<200pmol/L). We found that metformin treatment 
alone did not explain the altered VB12 metabolism as reflected by VB12 and HoloTc serum levels 
in all T2DM patients, as suggested by the literature [129, 201]. Nevertheless, proportion of patients 
in the DMMet+ group with low VB12, low HoloTc, or high Hcy was higher compared to DMMet- 
group (not significant). Additionally, metformin dosage did negatively correlate with VB12 and 
HoloTc levels. These findings suggest that metformin does influence VB12 metabolism. Further 
analysis focused on VB12-deficient subgroups and included non-diabetic patients. In this sample, 
a significant difference of the %AB12 was observed and confirmed by multiple regression analysis. 
However, the model explained only 9.2% of the variance observed. These results suggest that 
VB12 metabolism is affected by diabetes itself as well as by other factors, which were not included 
in the model. Thus, the reported data are not able to draw definitive conclusion about the impact 
of metformin use on VB12 associated biomarkers. We therefore suggest to assess the impact of 
T2DM, metformin use and other factors (e.g. age, duration of VB12 deficiency) on VB12 associated 
biomarkers in further studies.  
 
HoloTc has been proposed as a better marker to detect VB12 deficiency compared to serum VB12 
[207, 208] in an aged population [209]. We found significant inverse correlations of VB12 and 
HoloTc with Hcy, a functional marker of VB12 deficiency. Although the effect was stronger 
between VB12 and Hcy, compared to HoloTc and Hcy, stepwise multiple regression analysis 
included HoloTc as independent variable to explain variance in Hcy levels and not VB12. Thus, 
HoloTc seems more favorable than VB12 to predict hyperhomocysteinemia caused by VB12 
deficiency in T2DM patients. Therefore, our results support the finding that HoloTc might be a       
better marker than VB12 to detect VB12 deficiency. Before recommending a change of current 
practice, further studies should include anemic patients and assess methylmalonic acid (MMA) 
levels to investigate the suitability of VB12 and HoloTc to represent VB12 supply in T2DM patients.  
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Study B-2 was a prospective randomized unblinded parallel group trial. Patients were recruited 
by their general practitioner and randomly assigned to oral or i.m. VB12 treatment. Group O-oral 
received oral daily 1000 µg cyanocobalamine for 28 days and group I-i.m. received 4 weekly 
injections of 1000 µg hydroxocobalamine. Blood samples were analyzed for VB12, HoloTc, Hcy 
and MMA. Before and after treatment, patients were asked to fill in a questionnaire about their 
preferences. After 28 days of treatment with high-dose VB12 administered either by oral or i.m. 
route, median levels of VB12-associated biomarkers were normalized. The majority of patients 
preferred oral treatment before and after the study.  
 
Our findings are in line with other trials, of which two trials assessed the effect of oral high-dose 
VB12 substitution (1000 µg cyanocobalamin) vs. placebo [230, 233], while three other 
randomized, controlled trials compared cyanocobalamin therapy administered by oral (1000-2000 
µg) or parenteral route (1000 µg cyanocobalamin) [228, 229, 234]. Contrary to prior studies, we 
observed an exaggerated response after i.m. administration and therefore the hypothesis for non-
inferiority of oral in comparison to i.m. treatment had to be rejected. Because we used electronic 
punch cards and monitored an almost perfect intake of tablets (99.6% taking adherence), non-
adherence could be ruled out as a contributor to the less pronounced response in VB12, HoloTc 
and Hcy in patients with oral administration. Thus, the enormous difference must have chemical 
or physiological reasons. One reason might be the use of hydroxocobalamine while other trials 
used cyanocobalamine for i.m. treatment. Hydroxocobalamine is a physiological intermediate form 
which shows a greater availability to cells than other cobalamin forms [235]. Thus, injection 
intervals for hydroxocobalamine and cyanocobalamine may differ. 
 
Findings about biomarker levels after oral and i.m. treatment might add evidence to current 
practice of VB12 substitution. Current guidelines do not consider different cobalamine forms for 
the substitution of VB12 [122, 317]. The challenge is that cobalamine is recommended, but two 
different substances are available for parenteral application: “Cyano- and hydroxocobalamine”. 
Moreover, in some publications, both forms are falsely described equivalent (see Stabler SP, 2013 
[130]: “There are many recommended schedules for injections of vitamin B12 (called 
cyanocobalamin in the United States and hydroxocobalamin in Europe”). Oral versus parenteral 
VB12 substitution is still under investigation by others: A large prospective randomized controlled 
trial comparing high dose oral vs intramuscular cyanocobalamin in elderly patients is currently 
being performed (PMID: 22650964, NCTNCT 01476007). This highlights the importance of the 
research field.  
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As expected, patients preferred oral treatment to i.m. treatment before the assignation to treatment 
as well as after its completion. Our findings are in line with reports from two studies on patient 
preferences on oral and parenteral VB12 treatment [240, 244] where the majority of patients 
preferred the oral route. 
 
Although our study and others showed that patient majorly prefer oral substitution, no high-dose 
VB12 oral mono-preparation is currently available in Switzerland. Further, a discussion has 
emerged if the coenzyme forms methylcobalamine and adenosylcobalamine might be superior to 
cyano- and hydroxocobalamine [318]. It is unclear if an adequate oral VB12 formulation will soon 
be available for VB12 deficient patients in Switzerland. An alternative is offered by the import of 
VB12 containing mono-preparations from other countries such as Germany. In this case, 
insurance would not pay treatment what is likely to influence preferences. Therefore, adequate 
patient information is essential to come up with a final shared decision.  
 
Limitations of Studies B-1 and B-2 arrived from the fact that we included patients mostly without 
hematological symptoms and not necessarily abnormal functional biomarkers, what affects our 
ability to generalize our results to a symptomatic, anemic population.  
 
The literature review (Study B3) across different diseases yielded similar results: A majority of 
patients preferred oral treatment. Out of the 13 articles retrieved, five concerned cancer therapy, 
three antibiotic therapies, two vitamin deficiency and three other indications. Depending on the 
disease, oral or parenteral therapy was preferred. Given this and the availability of bioequivalent 
treatments for both therapy regimes, the evaluation of patient preferences may substantially add 
to treatment optimisation. Patients and physicians should take a shared decision for optional 
therapy regimens in order to promote individualized therapy and thus, have a major impact on 
cost-effectiveness. 
 
Adherence assessment methods 
In Study C-1, we aimed to validate the German version of the MMAS-8 in cardiovascular patients. 
We further aimed in Study C-2 to evaluate whether one subjective question “Do you sometimes 
forget to take your medication?” that is contained in the PMC coincides with an objective 
adherence measure, the MPR.  
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The MMAS-8 [24] consists of seven yes/no questions and one 5-point Likert scale. The scale has 
demonstrated high internal consistency and good sensitivity and specificity, it is valid and reliable 
[24]. In Study C-1, the German version of the MMAS showed low psychometric properties 
compared with the original English MMAS-8, especially for internal consistency (Cronbach’s alpha 
0.31 vs. 0.83 [24]). The small to moderate reliability we observed is similar to that of three other 
studies that validated the French [251], Malaysian [29] and Thai [250] versions of the MMAS-8. 
Since Cronbach’s alpha measures whether each item of a scale is appropriate for assessing the 
concept of the scale, the internal consistency of the entire scale will be high if all items measure 
the same phenomenon. In our case, we retained four components after varimax rotation that 
explained 71.7% of the variance (24.4% for the first component), indicating that the scale is four-
dimensional. This is in contradiction with the original English scale that was declared one-
dimensional [24], but in strong concordance with the results of the French and the Thai scales that 
attributed 55.2% and 57.4% of the variance, respectively, to three components [250, 251]. 
Consequently, the unacceptable low Cronbach’s alpha in our study may indicate the 
multidimensionality of the scale rather than its inconsistency [277]. The MMAS-8D demonstrated 
convergent validity with electronic measures of adherence and with laboratory values. The 
correlation with electronic records, blood values and the significant association with BMQ 
subscores support the validity of the MMAS-8D. The latter is in accordance with findings from a 
study with women newly treated against osteoporosis with daily or weekly oral bisphosphonates, 
where the necessity subscore of the BMQ showed a significant association with the 8-item Morisky 
scale [280]. Study C-1 provides as a by-product a validated adherence assessment questionnaire 
in German, the MMAS-8D.  
 
After publication of Study C-1, the MMAS-8 had been translated in Polish [319] and was used in 
several international studies, such as one with patients with cystic fibrosis [320] or asthma [321]. 
These results suggest that the MMAS-8 is still widely used for adherence assessment. To date, 
studies using the German version of the MMAS-8 are ongoing [322] and are therefore expected 
to be published soon. However, due to copyright issues, we decided not to use the MMAS-8D in 
further projects. For subjective adherence assessment in Project D, we decided to use the “A14” 
adherence questionnaire [303] in its German version for which we obtained the rights.  
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A recent study [323] compared the MMAS-8, as a subjective adherence measure, and the MPR 
derived from pharmacy refill index, as an objective adherence measure, and observed poor 
accuracy of the MMAS-8 to identify objective medication non-adherence. In the pilot study of 
Study C-2, we compared the MPR from pharmacy refill data with one single objective question of 
the PMC. In line with the mentioned observations, congruence between subjective and objective 
assessment of adherence was poor, indicating that subjective measures and objective adherence 
assessment may capture different aspects of non-adherence.  
 
Study proposal in anticoagulation 
Finally, Project D aimed to develop a tailored and stepwise educational program on adherence 
to DOAC therapy in Switzerland. The development of the study proposal will speed up the study 
start in future. Other than in the previous projects on knowledge about OAC (Project A), 
educational counselling was planned to be offered repetitively according to patient needs. 
Additionally, visualizing of intake pattern obtained with the electronic monitoring should be 
employed for providing feedback and stressing the need of time adherence, or adapting the 
treatment plan in collaboration with the physician. The study realization and evaluation will be 
executed beyond of this thesis.     
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Limitations specific to individual studies were discussed in previous sections. Overall limitations 
of this thesis were: 
 Sample sizes of our studies were relatively small. Small sample sizes may limit the ability 
to generalize findings to all affected patients. Further, samples could be prone to selection 
bias. Motivated patients might have been more likely to accept participation and thereby 
patients were included who are more likely to be adherent and are probably better informed 
about treatment than the general population of outpatients. In particular, validation studies 
may have been affected by modest sample size, since small sample sizes can affect the 
result of the internal consistency. 
 Patients enrolled in our studies were exclusively recruited in Switzerland, what may limit 
the applicability of our results to other countries and languages. 
 The compiled questions used to assess patient preferences and the questions that were 
used to screen for knowledge gaps consisted of re-used questions from other assessment 
tools but were not validated completely as an entity.  
 The observation periods included follow-up intervals from to 2 to 4 weeks to assess patient 
knowledge and preferences. We therefore cannot evaluate how knowledge or preference 
would change in long-term situation. The relatively brief adherence-monitoring period in 
Studies B-2 and C-1 may be criticized because it is insufficient to estimate overall 
adherence. 
 Observer bias might have occurred leading to a bias in favor of the research hypotheses 
because one researcher was involved in development of study designs, collection of data, 
analysis and interpretation.  
 Finally, our literature searches about patient preferences across different settings and 
knowledge about anticoagulation were made in 2013 and 2015, respectively. Because 
both research areas are highly debated topics, a greater number of articles might be 
available in the meantime. However, basic rules about knowledge and preferences will not 
change.   
   
10 General discussion and conclusions 





This thesis adds findings on the existing evidence of patient knowledge about OAC in outpatients, 
of patient preferences for VB12 therapy and of detection and treatment of VB12-deficient 
outpatients. Further, this thesis validated two questionnaires that can be used in future research 
or practice: the KODOA-test to self-assess patient knowledge of DOAC and the MMAS-8 in 
German to assess adherence. 
The following conclusions could be drawn:  
Patient knowledge about oral anticoagulation therapy 
 A majority of outpatients show knowledge gaps concerning their therapy with OAC.  
 Specific screening questions allow community pharmacists to detect deficient knowledge 
in short time and to provide spontaneous unstructured educational counselling when 
needed.  
 The newly developed and validated KODOA-test showed good psychometric properties in 
Swiss elderly outpatients taking DOAC. Thus, the KODOA-test is a reliable and valid 
questionnaire to assess patient knowledge of DOAC. 
 To our knowledge, the KODOA-test is the first validated questionnaire specific for patients 
taking DOAC and sensitive to change. Therefore, the KODOA-test could be used in clinical 
trials where associations between knowledge of DOAC and adherence or clinical 
outcomes are of interest. 
 Patient knowledge increases after having received educational counselling either provided 
in an unstructured manner with the help of the amended PMC or in a structured and tailored 
manner after testing with the KODOA-test. Thus, the detection of knowledge gaps enable 
the provision of tailored patient counselling.  
 Patients show high acceptance and state to be more confident about how to take their 
anticoagulant agent either after having received educational counselling provided 
spontaneously, in an unstructured manner with the help of the amended PMC or after 
educational counselling in a structured manner after testing with the KODOA-test. We 
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Patient preferences and vitamin B12 deficiency 
 The clinical biochemistry of VB12 in T2DM patients with scarce VB12 supply is modified 
in comparison to nondiabetic patients. This results in higher %AB12 due to reduced VB12 
levels. It needs to be clarified in future research whether this effect is due to diabetes itself, 
metformin treatment and/ or a combination of other heath related situations.  
 Assessment of HoloTc seems more favorable than VB12 to predict hyperhomocysteinemia 
caused by VB12 deficiency in T2DM patients. This may be a direct consequence of the 
modified %AB12 in T2DM patients which strengthens the recommendation to assess VB12 
supply in clinical practice by measuring HoloTc.  
 After oral and i.m. substitution with VB12, differences in VB12, HoloTc and Hcy levels 
between groups were higher than expected. Therefore, the hypothesis of non-inferiority of 
oral treatment had to be rejected. However, normalization of HoloTc and MMA was 
reached by all patients and normalization of VB12 and Hcy by the majority of patients 
within group O-oral after a one-month treatment. The clinical benefit of exaggerated 
biomarker response after i.m. treatment within a typical primary care population is 
questionable. Therapeutic schemes should be chosen with the consideration of mid-term 
biomarker effects and patient preferences. 
 Initial rating in favor of either i.m. or oral therapy can change over time. However, the 
majority of patients preferred oral treatment before and after the study which highlights the 
need for a high dose oral VB12 preparation in Switzerland.  
 
Adherence assessment methods 
 The German MMAS-8D appears to be a reliable instrument to catch medication adherence 
in cardiovascular patients. Further, the MMAS-8D is endowed with simplicity and 
quickness of administration and scoring, which facilitates its use in several pathologies. It 
may be useful in patients with chronic therapy for detecting non-adherence. 
 Combination of subjective and objective adherence measures may help to establish a 
more precise picture of (non-)adherence. 
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According to the conclusions and findings of this thesis, recommendations for future research and 
practice are: 
Patient knowledge about oral anticoagulation therapy 
 The best way to counsel patients about OAC and association of increased patient 
knowledge about OAC with adherence and clinical outcomes should be assessed in further 
studies. Project D provides future researcher with a study proposal to investigate 
associations of increased patient knowledge about OAC and adherence.  
 Patient opinions on counselling about OAC and acquisition of more knowledge of barriers 
and facilitators for patient-centred counselling should be of interest in further studies in 
order to ameliorate educational counselling in primary care setting. 
 HCP in primary care should screen for deficient knowledge and provide educational 
counselling about OAC actively. The patient’s whole therapy and his daily experiences 
should be included in the counselling in order to achieve patient centred counselling. 
 In order to ensure continuous care in OAC patients, it may be helpful to provide different 
HCP with standardized screening questions and educational manuals about OAC 
counselling. Further, remuneration of counselling might increase implementation of such 
service in daily practice.  
 
Patient preferences and vitamin B12 deficiency 
 Assessment of HoloTc seems more favourable than VB12 to identify VB12-deficient 
patients. Whether these findings are restricted to T2DM patients should be assessed in 
further studies. 
 The impact of T2DM, metformin use and other factors (e.g. age, duration of VB12 
deficiency) on VB12 associated biomarkers should be investigated in further studies. 
 Optimal injection interval for i.m. hydroxocobalamine is still to be defined. Weekly 
administration according to guidelines lead to exaggerated biomarker response in non-
anemic patients. Consequently, lower injection frequency is very likely to be equivalent 
and thus makes treatment for patients more convenient and thereby influencing patient 
preferences. 
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 In practice, patient preferences should be assessed routinely before treatment initiation, 
across various diseases where equivalent treatment options exist. Repeated re-evaluation 
of patient preferences should be integrated while delivering continuous care because 
preferences might change over time.  
 
Adherence assessment methods 
 In practice, community pharmacists should screen for non-adherence by combining MPR 
from pharmacy refill data and subjective adherence assessment forms.  
 The collaboration with IT specialists to integrate non-adherence alerts from refill data from 
pharmacy software could support community pharmacists in screening for non-adherence 
in daily practice.  
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12 Appendix  
 
The following appendix is limited to the main documents used within the various 
projects. For further information including all measurement instruments or raw data, 
please send a request to the author. 
 
Study Title Page 
A-1/ C-2 Final ethical approval II 
A-1/ C-2 Case report form IV 
A-1/ C-2 Informed Consent VII 
A-1/ D PMC protocol VIII 
A-1 PMC amendment IX 
A-1 Follow-up questionnaire: knowledge gaps and satisfaction  XI 
A-1 Standardized documentation protocol XII 
A-2 Final ethical approval XIV 
A-2 Case report form XV 
A-2 Informed Consent XIX 
A-2 KODOA Version AF XXI 
A-2 KODOA Version TVT/LE XXV 
A-2 Manual for standardized educational counselling XXIX 
A-2 Feedback form: Feasibility XXXVI 
A-2 Patient questionnaire: Baseline Characteristics XXXVII 
A-2 Follow-up questionnaire: Patient satisfaction XXXIX 
B-1 Final ethical approval XLI 
B-1 Case report form XLIII 
B-1 Informed Consent XLVI 
B-1 Documentation for physical examinations incl. NDS XLVII 
B-1 Patient questionnaire incl. NSS XLIV
B-2 Final ethical and Swissmedic approval  LIII 
B-2 Case report form LV 
B-2 Informed Consent LX 
B-2 Patient questionnaire : Nutrition and demographics LXII 
B-2 Patient questionnaire : Preferences LXV 
B-2 Source documents for GP Practice Group i.m. LXIX 
B-2 Source documents for GP Practice Group oral LXXIV 
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